<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-11-10 09:18:02 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. G. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Network Boston, Nature Medicine</td>
          <td>82</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>131</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, Joan Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>51</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="Chronic graft-versus-host disease (cGVHD) frequently follows allogeneic hematopoietic stem cell transplantation and impacts the mucosa. This atlas study highlights the role of exhausted-like effector CD8+ T cells (TEXEF) in oral mucosal cGVHD pathogenesis. Biopsies from the oral mucosa were collected at oral cGVHD onset or at six months post-transplant and analyzed using single-cell RNA sequencing and other modalities. At cGVHD onset, in addition to changes in the myeloid compartment, two distinct populations of CD8+T cells with a TEXEF phenotype were prevalent: an inflammatory CD8T cell cluster (CD8T_4) expressing CCL4, CD69, and TNFSF9, and an exhausted CD8T cell cluster (CD8T_5) characterized by the expression of CXCL13, HIF1A, and HLA-DRA, both correlated with clinical disease severity. Pseudo-time analysis suggests a transition from the inflammatory pre-exhausted CD8T_4 cluster to the cytolytic, terminally exhausted CD8T_5 cluster. The CXCL9-CXCR3 interactions among CD8+ T cells, fibroblasts and myeloid cells are implicated in tissue damage. Onset of cGVHD despite frequent oral mucosal FOXP3⁺ regulatory CD4⁺T cells suggests potential impaired Treg function or CD8+T cell dysfunction. These findings highlight TEXEF cells as key contributors to oral cGVHD pathology and potential therapeutic targets for mitigating sustained tissue injury in cGVHD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d284cca909c27cba4b0530f9740be31da2b9880" target='_blank'>
              Exhausted-like effector CD8 T cells mediate immune-stromal interactions at mucosal Chronic Graft-versus-Host Disease onset
              </a>
            </td>
          <td>
            A. C. Costa-da-Silva, Rubina Sharma, M. Aure, D. Martin, Noemi Kedei, Damilola F. Killanin, A. Javaid, Francis A Boksa, Drashty P Mody, J. Nguyen, S. Ganesan, Joshua T. Dodge, Clara H. Kim, Marie Kao-Hsieh, David E. Kleiner, C. Kanakry, S. Pavletic, J. W. Mays
          </td>
          <td>2025-09-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>73</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/06b3a0cceb71229da8ceeee3a0b96b24a3ee5c07" target='_blank'>
              Common origin for effector and regulatory follicular and tissue-Adapted CD4+ T cells in Non-Small Cell Lung Cancer
              </a>
            </td>
          <td>
            J. Tosello Boari, W. Richer, Yoann Missolo-Koussou, Elisa Bonnin, Sébastien Lemoine, M. Pretti, Rodrigo Nalio Ramos, Jordan Denizeau, Sylvain Baulande, Mylène Bohec, S. Lameiras, Philippe Martin, Rafael Mena Osuna, Jeremy Mesple, Wenjie Sun, Marine Lefevre, A. Seguin-Givelet, C. Sedlik, Filipa Ramos, Saumya Kumar, Leïla Perié, Luís Graça, Olivier Lantz, E. Borcoman, Nicolas Girard, J. Waterfall, Eliane Piaggio
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db216fc3d5be7dbd3db4a74639b3258d970f9b5a" target='_blank'>
              Reinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade
              </a>
            </td>
          <td>
            Paulien Kaptein, Nadine Slingerland, A. M. van der Leun, Eline Runderkamp, Roos A. Wagensveld, S. Michael Chin, Janniek R. Mors, M. Machuca-Ostos, Timm M. Reissig, K. Moynihan, I. Djuretic, Y. A. Yeung, T. Schumacher, D. Thommen
          </td>
          <td>2025-09-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Metastatic lung carcinoma poses considerable treatment difficulties. It exhibits cellular characteristics that differ from those of early-stage cancer. Immunotherapy demonstrates enhanced hope for patients with advanced and metastatic lung cancer. Tumor-associated macrophages (TAMs) may be a contributing factor that diminishes the effectiveness of immunotherapy. Secreted phosphoprotein 1 (SPP1)+ TAMs are considered to possess immunosuppressive characteristics, as their interaction with CD8+ T lymphocytes results in the exhaustion of these cells. We analyzed single-cell RNA sequencing datasets of lung cancer metastases in order to examine the development of brain metastatic tumors. Furthermore, the cell–cell interactions between SPP1+ TAM cells and CD8+ T cells within primary and brain metastatic cancers were systematically compared. Additionally, we utilized a flow cytometer and immunofluorescence to demonstrate how SPP1 affects the function of CD8+ T cells. In vitro, we generated SPP1-overexpressing macrophages and performed qPCR, Western blot, and co-culture assays with or without anti-SPP1 or anti-A2AR treatment to evaluate immunosuppressive effects. The results demonstrated that the proportions of immune cells in metastatic brain tissues are lower, while the infiltration of macrophages is higher. SPP1+ TAMs contribute to immune suppression in lung cancer by limiting the activation of CD8+ T cells and cytokine production. Anti-SPP1 treatment positively impacts CD8+ T cell function, counteracting SPP1-induced dysfunction and facilitating the production of cytokines. SPP1 overexpression in macrophages enhanced their immunosuppressive phenotype by upregulating CD73 and cytokines such as IL-10 and TGF-β, leading to impaired CD8⁺ T cell function via A2AR signaling; notably, neutralization of SPP1 or A2AR successfully restored CD8⁺ T cell activity. Our findings characterize the immunological environment of both primary and metastatic lung cancer, highlighting SPP1-mediated immune suppression as a potential therapeutic target to restore T cell responses. Preclinical data demonstrate that Anti-SPP1 antibodies can reverse T cell exhaustion and enhance immune responses in lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/659292b315a12f27348d32dba8f9ec9a4a03cedd" target='_blank'>
              Single-cell transcriptomic analyses provide insights into SPP1+ TAM-mediated immune suppression and CD8+ T cell dysfunction in lung cancer
              </a>
            </td>
          <td>
            Rahma Taher Almgrami, Tengyue Zhang, Qitai Zhao, Mingming You, Jinyan Liu, Yi Zhang
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Background Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable responses in B-cell acute lymphoblastic leukemia (B-ALL). However, the contribution of the tumor microenvironment to the therapeutic response after CAR T-cell treatment remains incompletely understood. Methods We performed single-cell RNA sequencing and spectral flow cytometry-based analyses of bone marrow-resident immune cells from B-ALL patients before and after CAR T-cell treatment. Results We observed profound changes in the microenvironment in response to CAR T-cell-mediated inflammation, including an increase in myeloid cells. Significant induction of the interferon response, hypoxia, and TGF-β signaling was accompanied by expansion of myeloid-derived suppressor cells (MDSCs) and endogenous exhausted CD8+ T cells. PD-1 expression in endogenous T cells post-treatment was associated with a lack of durable response in the cohort of patients analyzed. Further, we revealed that HIF-1α, VEGF, and TGFBR2 are key players in the intercellular communication between CAR T cells and the immune niche, potentially driving widespread T-cell dysfunction. Infusion of anti-CD19 CAR T cells led to increased accumulation of human MDSCs, exacerbation of a hypoxic environment and T-cell exhaustion in hematopoietic stem/progenitor cell-humanized mice bearing a human tumor. Conclusions In conclusion, CAR T-cell-mediated myeloid activation is associated with pathways of immune dysregulation that may antagonize the effects of therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e17ba18b5c3d494ffd54cbb6fc378f9f236571c2" target='_blank'>
              Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance
              </a>
            </td>
          <td>
            Marianna Ponzo, Lorenzo Drufuca, C. Buracchi, Marco M. Sindoni, Silvia Nucera, C. Bugarin, Ramona Bason, G. Rossetti, R. Bonnal, Cristian Meli, B. Rambaldi, F. Lussana, Silvia Ferrari, Alex Moretti, G. Dastoli, Giulia Risca, C. Pellegrino, M. Manz, Stefania Galimberti, A. Rambaldi, G. Gaipa, A. Biondi, Massimiliano Pagani, Chiara F Magnani
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/150e482713115efc1b44d4529edb3279c0d13350" target='_blank'>
              Childhood brain tumours instruct cranial haematopoiesis and immunotolerance
              </a>
            </td>
          <td>
            Elizabeth Cooper, David A. Posner, C. Lee, Linda Hu, Sigourney Bonner, Jessica T. Taylor, Oscar Baldwin, Rocio Jimenez-Guerrero, Katherine E. Masih, Katherine Wickham Rahrmann, Jason Eigenbrood, Gina Ngo, Luca Porcu, Valar Nila Roamio Franklin, Clive S. D’Santos, Richard Mair, Thomas Santarius, Claudia Craven, I. Jalloh, Júlia Moreno Vicente, Timotheus Y. F. Halim, Li Wang, Arnold R. Kreigstien, F. Swartling, Javed Khan, M. Clatworthy, Richard J. Gilbertson
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/65799dca4a24e6fbcd774c66d4741d26a7a006c5" target='_blank'>
              Targeting a macrophage stemness factor to mitigate diseases post respiratory viral infection
              </a>
            </td>
          <td>
            Mohd Arish, A. Chaudhuri, Janli Tang, H. Narasimhan, An Fang, Jinyi Tang, Xiaoqin Wei, Chaofan Li, I. Cheon, Wei Qian, Farha Naz, Gislane Almeida-Santos, Samuel Young, T. Parimon, Y. Shim, Robert Vassallo, Peter Chen, Jie Sun
          </td>
          <td>2025-10-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitor (ICI) therapies present a pillar of modern cancer therapy but can cause neurological immune-related adverse events (n-irAEs), of which up to 35% are severe or even fatal. However, the detailed immunological mechanisms and risk factors underlying n-irAEs remain largely unknown. Here, we leveraged single-cell genomics to dissect immune cell type, state, and clonal heterogeneity associated with n-irAEs. Methods We performed coupled single-cell RNA sequencing and T cell receptor (TCR) profiling on peripheral blood cells of 17 patients with cancer receiving ICI therapy, including 8 patients with acute neurotoxicity. This approach enabled integrated analyses of immune cell states and T cell clonality linked to ICI-induced n-irAEs. Results We profiled 186 435 immune cells and conducted pseudotime analyses, revealing that patients with n-irAEs, compared with controls, present with clonally expanded CD4+ cytotoxic T lymphocytes (CD4+ CTLs) with an n-irAE-specific effector gene expression profile. These T cells predominantly belong to a select set of expanded clonal families and express genes linked to antigen-induced activation, cell lysis, and neuroinflammation. Moreover, they highly express CXCR3 (FC=2.03 compared with control CD4+ CTLs, with a false discovery rate=7.7×10⁻⁴), encoding the chemokine receptor of CXCL10, previously nominated as a biomarker for severe ICI therapy-induced n-irAEs with concomitant multiple organ system toxicity. Conclusions Overall, our study highlights the expansion and activation of CD4+ CTLs in ICI-induced neurotoxicity, proposing these cells as potential targets for developing new biomarkers and therapeutic strategies to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8a4f4e0b8916eaa4261cd264db53571afd725a2f" target='_blank'>
              Clonally expanded effector CD4+ cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy
              </a>
            </td>
          <td>
            Ambre Giguelay, Patrick Maschmeyer, L. Müller-Jensen, Christian Schinke, Smilla K. Maierhof, Natasha Nambiar, Manpreet Meyer, Petra Huehnchen, Wolfgang Boehmerle, Matthias Endres, Samuel Knauss, L. S. Ludwig
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1ff24f2e8ab0ac14f953e55e0ecee156943f456a" target='_blank'>
              Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma
              </a>
            </td>
          <td>
            M. Sandholzer, Clara Serger, Alessia G. Liner, Sarp Uzun, David König, H. Thut, R. Ritschard, Jonas D. Fürst, Andreas Zingg, N. Rodrigues Mantuano, B. Kasenda, K. Glatz, E. Kappos, Matthias Matter, A. Holbro, F. Stenner, J. Passweg, Nina Khanna, L. Jeker, Mascha Binder, A. Zippelius, Heinz Läubli
          </td>
          <td>2025-09-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Colorectal cancer (CRC) is a highly immunosuppressive malignancy characterized by limited therapeutic options and a poor prognosis. Within the CRC tumor immune microenvironment (TIME), tumor-associated macrophages (TAMs) represent the predominant immune cell population. This study aimed to characterize the specific macrophage subsets contributing to CRC progression and resistance to immunotherapy. Single-cell RNA sequencing (scRNA-seq) was used to identify the key macrophage marker genes. The clinical significance of death-associated protein kinase 1 (DAPK1), was evaluated in clinical CRC cohorts using immunohistochemistry, immunofluorescence, Kaplan-Meier plots and Cox Proportional Hazards Models. Cytometry by time-of-flight, RNA-seq, flow cytometry and an in vitro co-culture system were performed to explore the functional role of macrophage-derived DAPK1 in the TIME. Subcutaneous tumor models and splenic-liver metastasis models were constructed to assess the potential of DAPK1 inhibition to enhance immune checkpoint blockade (ICB) efficacy. scRNA-seq analysis revealed predominant DAPK1 expression in intratumoral macrophages of CRC TIME. Elevated macrophage-specific DAPK1 level was significantly associated with worse prognosis. DAPK1+TAMs exhibited immunosuppressive properties and inhibit CD8+T cells cytotoxicity. Pharmacological inhibition of DAPK1 enhanced the efficacy of anti-PD-1 therapy in murine models. DAPK1+TAMs infiltration was an independent risk factor for overall survival in patients with CRC. These DAPK1+TAMs exhibit an immunosuppressive phenotype and promote the establishment of the TIME with immune evasion. Targeting DAPK1 may represent a potential strategy for synergizing immunotherapy in CRC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d25841457c8b6bc5218514a8ce08f04c9f270986" target='_blank'>
              DAPK1-positve macrophages facilitate immunosuppressive microenvironment and determine immunotherapy efficacy in colorectal cancer
              </a>
            </td>
          <td>
            Jiang Chang, Yuxu Niu, Shizhao Zhou, Ziqi Zhang, Weiying Zhu, Junchang Zhu, Haoran Xiu, Ke Shang, Qingyang Feng, Ye Wei
          </td>
          <td>2025-11-04</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/952046f90f3d6fd3b65c4bc71397ef55777b1e4f" target='_blank'>
              Albumin-STING Nanoagonist Reprograms HSPCs to Antitumor Neutrophils Enhancing MHC I–Mediated CD8⁺ T Cell Immunity
              </a>
            </td>
          <td>
            Jinsong Tao, Hong-Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Wei Gao, Duxin Sun
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a872ad111f545dec2c3ad6375d1f4e56d1e106cf" target='_blank'>
              Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune Surveillance
              </a>
            </td>
          <td>
            Thomas Fabre, Eleanore Hendrickson, Katherine McGourty, Paola M. Marcovecchio, James McMahon, Sara Patti, KaiLi Cage, Stephen Searles, Christella Widjaja, Christopher Stairiker, Kathryn Bound, Roxanne Martino, Edward Pyszczynski, Ying Zhang, Graham Thomas, Samuel A. Stoner, Keith A. Ching, Fang Jin, Christopher P. Dillon, Thomas A. Wynn, Richard L. Gieseck, Alexander M. S. Barron
          </td>
          <td>2025-09-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background LKB1 (STK11)-deficient tumors exhibit an immunosuppressive microenvironment that limits the efficacy of immunotherapies such as anti-programmed cell death protein 1 (PD-1) antibodies. However, the underlying mechanisms driving immune evasion remain unclear. Dendritic cells (DCs), especially conventional DC 1 (cDC1), play a crucial role in antigen presentation and CD8+ T-cell activation, yet their dysfunction in LKB1-deficient tumors has not been well characterized. Methods Tumor-intrinsic LKB1 deficiency was modeled by subcutaneous inoculation of CRISPR/Cas9-engineered Stk11-knockout tumor cell lines into syngeneic mice. DC infiltration and function were assessed through a series of flow cytometry-based in vivo and in vitro assays, including analyses of infiltration, migration, antigen uptake, maturation, and CD8+ T-cell priming. Naïve CD8+ T-cell activation by cDC1s was evaluated via adoptive transfer of CD45.1+ OT-I T cells. Secretome proteomics and functional rescue experiments identified anterior gradient 2 (AGR2) as a key immunosuppressive mediator, and arginase 1 (ARG1) was validated as its functional interactor through liquid chromatography-tandem mass spectrometry (LC-MS/MS), co-immunoprecipitation, and imaging flow cytometry. Upstream regulation of AGR2 was investigated by AMPKα/FOXA1 silencing and chromatin immunoprecipitation (ChIP) quantitative PCR, revealing a tumor-intrinsic AMPKα–FOXA1–AGR2 axis driving DC dysfunction. Results LKB1-deficient tumors exhibited significantly reduced cDC1 infiltration, and cDC1s were functionally impaired in antigen uptake, migration, and naïve CD8+ T-cell priming. AGR2, a secreted protein transcriptionally upregulated via the tumor-intrinsic AMPKα–FOXA1 pathway, was identified as a key mediator of DC dysfunction. Mechanistically, AGR2 interacted with ARG1, stabilizing its expression and promoting ARG1 accumulation in DCs. Restoring DC infiltration and activity through FLT3L-driven expansion and tumor-antigen–specific DC supplementation significantly enhanced the efficacy of anti-PD-1 treatment in LKB1-deficient lung adenocarcinoma models. Conclusion Our study identifies profound DC dysfunction—characterized by impaired antigen uptake, migration, and naïve CD8+ T-cell priming—as a key mechanism of immune evasion in LKB1-deficient tumors. This dysfunction is driven by tumor-secreted AGR2, which stabilizes ARG1 in DCs and suppresses CD8+ T-cell activation. Targeting the AMPKα–FOXA1–AGR2–ARG1 axis or restoring DC competence offers a promising strategy to enhance immunotherapy efficacy in LKB1-deficient subtype.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e07849093d53dea4843df9f47992371aef80f74" target='_blank'>
              Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer
              </a>
            </td>
          <td>
            Yuxin Yao, Yuejun Luo, Zhanyu Wang, Enzhi Yin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoya Tang, Nan Sun, Jie He
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5941ecec7872e6e7a4fe85dc2f11895a3625725" target='_blank'>
              PD-1 signaling is essential for the early accumulation of HBV-specific CD8+ T cells during HBV infection
              </a>
            </td>
          <td>
            Xiaoqing Zeng, Wen Pan, Ziwei Li, Zhaoli Liu, Hongming Huang, Xuecheng Yang, K. Sutter, Mengji Lu, Ulf Dittmer, Gennadiy Zelinskyy, Xin Zheng, Dongliang Yang, P. Kennedy, Yanqin Du, Jia Liu
          </td>
          <td>2025-09-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Introduction A comprehensive characterization of immune cells within the tumor microenvironment (TME) of cervical squamous cell carcinoma (CSCC) is essential to advance understanding of tumor biology and guide immunotherapy development. Methods Using single-cell RNA sequencing, we analyzed 14,441 immune cells isolated from tumor tissues and paratumor tissues of three CSCC patients. By integrating data on tumor suppressors, oncogenic factors, cytokines, and chemokines, we performed differential gene expression analyses across immune populations. Results This analysis identified nine major immune cell subsets, including CD8+ T cells, regulatory T cells (Tregs), natural killer/T cells (NK/T cells), B cells, plasmacytoid dendritic cells (pDCs), and macrophages. Notably, elevated CCR7 expression in exhausted CD8+ T cells was associated with improved prognosis, suggesting it as a preliminary candidate for an immunoregulatory target that warrants further investigation. Additionally, CCL5 levels were elevated in Tregs, indicating a possible involvement in their recruitment to the tumor site that requires further validation. Furthermore, differential gene expression analysis identified candidate genes for further mechanistic investigation. Discussion This systematic comparison of the TME between tumor and paratumor tissues reveals dynamic changes in the immune landscape, providing insights and suggesting potential targets for further study to enhance understanding and treatment of CSCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37a843f84193a8f20739341bcfd74ef25632d521" target='_blank'>
              Profiling of immune cell subsets and functional characteristics of cervical cancer based on single cell RNA sequencing
              </a>
            </td>
          <td>
            Yue Yuan, Dejun Sun, Mingyue Yang, Ying Xia, Chunli Yuan, Xiaosong Wang
          </td>
          <td>2025-09-25</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b829e516ebd849b779eb9a27bfa0536b868f851" target='_blank'>
              Regulatory T cells inhibit CD8+ TRM-like cells during the early stages of tumor immune escape
              </a>
            </td>
          <td>
            Jason B. Williams, Shishir M. Pant, Alexander L. Kley, Bharat A. Rajmalani, Clarence Yapp, Jiang Zhang, Kyle Deans, E. Rotrosen, Angelika Sales, Peter K. Soger, Thomas S. Kupper
          </td>
          <td>2025-10-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb6cd3cc9c09de4de9afc685bf10e2503b30b407" target='_blank'>
              Identifying Distinct Molecular Response of CAR-T cells to Solid Tumors by Synthetic Single-Cell Transcriptomic Analyses
              </a>
            </td>
          <td>
            Yi Hui Luo, Elisabetta Forte, Yoshiaki Tanaka
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8bf2e04bf6e2797aba3ea1f4f0aeb768b1def37b" target='_blank'>
              Memory Regulatory T Cells Reprogram into Protective Tfh-like Effectors in Recurrent Malaria
              </a>
            </td>
          <td>
            Nana Appiah Essel Charles-Chess, A. Ruberto, Carson Bowers, N. Obeng-Adjei, M. R. Hansen, Disha Bangalore Renuka Prasad, B. Traore, K. Klonowski, Peter D. Crompton, S. P. Kurup
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="ABSTRACT Introduction IgG4-related disease (IgG4-RD) is a chronic immune-mediated fibroinflammatory disorder characterized by dense lymphoplasmacytic infiltration and storiform fibrosis, often resulting in organ dysfunction. Although glucocorticoids provide initial clinical improvement, relapse is common, underscoring the need for targeted therapies. B-cell depletion therapy has emerged as a promising approach, shedding light on the roles of plasmablasts and cytotoxic T lymphocytes in disease pathogenesis. Areas covered This review summarizes recent advances in immunological mechanisms of IgG4-RD, focusing on plasmablasts, activated B cells, cytotoxic T lymphocytes, T follicular helper (Tfh) cells, macrophages, dendritic cells, other immune cells, and fibroblasts. We highlight how single-cell RNA sequencing and highly multiplex immunofluorescence have uncovered novel immune subsets and their interactions. These technologies have identified previously unrecognized populations, including GZMK+ cytotoxic Tfh cells, MKI67+ B cells, and double-negative type 3 B cells, offering unprecedented resolution into disease mechanisms. Expert Opinion Single-cell technologies have revolutionized our understanding of IgG4-RD immunopathogenesis and potentially revealed disease heterogeneity across clinical phenotypes. These insights hold promise for biomarker development and precision therapeutic strategies. Future directions should include spatial transcriptomics and proteomics, improved animal models, and translational efforts to bridge mechanistic discoveries with targeted treatment for this complex multi-organ disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/27e4a21748b08b1e9d963014b8ee717521ebdabc" target='_blank'>
              Immunopathogenesis of IgG4-related disease in the era of single-cell RNA sequencing and highly multiplex immunofluorescence
              </a>
            </td>
          <td>
            Satoshi Hara
          </td>
          <td>2025-09-26</td>
          <td>Expert Review of Clinical Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="The immunosuppressive tumor microenvironment (TME) drives radioresistance, but the role of γδ T cells in regulating radiosensitivity remains incompletely understood. In this study, we found that γδ T cell infiltration in the TME substantially increased after radiotherapy and contributed to radioresistance. Depletion of γδ T cells enhanced radiosensitivity. Single-cell RNA sequencing revealed that γδ T cells in the post-radiotherapy TME were characterized by the expression of Zbtb16, Il23r, and Il17a, and served as the primary source of IL-17A. These γδ T cells promoted radioresistance by recruiting myeloid-derived suppressor cells and suppressing T cell activation. Mechanistically, radiotherapy-induced tumor cell-derived microparticles containing dsDNA activated the cGAS-STING/NF-κB signaling pathway in macrophages, upregulating the expression of the chemokine CCL20, which was critical for γδ T cell recruitment. Targeting γδ T cells and IL-17A enhanced radiosensitivity and improved the efficacy of radiotherapy combined with anti-PD-1 immunotherapy, providing potential therapeutic strategies to overcome radioresistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b1efdac109d7acd0476c2a995db227fa1bebc94" target='_blank'>
              IL-17-producing γδ T cells in the tumor microenvironment promote radioresistance in mice.
              </a>
            </td>
          <td>
            Yue Deng, Xixi Liu, Xiao Yang, Wenwen Wei, Jiacheng Wang, Zheng Yang, Yajie Sun, Yan Hu, Haibo Zhang, Yijun Wang, Zhanjie Zhang, Lu Wen, Fang Huang, Kunyu Yang, Chao Wan
          </td>
          <td>2025-10-07</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Neutrophils, a first-line defender, has a multifaceted presence in chronic inflammation, autoimmune pathology, and tumor progression. The microenvironmental cues facilitate functional plasticity and phenotypic heterogeneity to neutrophils that enable both their protective and pathogenic roles. Autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JIA) display the presence of dysregulated subsets of neutrophil, such as low-density granulocytes (LDGs) that promote proinflammation and contribute to tissue damage via NETosis and type I interferon-mediated signaling. In cancer, particularly tumors, they exhibit tumor-associated neutrophils (TANs) which may polarize either towards anti-tumorigenic ‘N1’ or pro-tumorigenic ‘N2’ phenotypes based on available modulators such as TGF-β and leucine-driven epigenetic modifications. The development in neutrophil biology has introduced several novel therapeutic strategies that allow NET targeting, inhibition of chemokine receptors like CXCR2, and exploration of neutrophil-derived biomarkers for diagnosis and disease monitoring. Such findings encourage the importance of neutrophils as both effectors and therapeutic targets in inflammatory and neoplastic conditions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/297b618276da8a976275300915cf5f9bf45c76b8" target='_blank'>
              Roles of Neutrophils in Autoimmune Diseases and Cancers
              </a>
            </td>
          <td>
            Anjali Bhargav, Vinay Kumar, N. Rai
          </td>
          <td>2025-09-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/95647d1154b817b57db9f1b613d8f1eb838999de" target='_blank'>
              DNMT3A-R882 mutations intrinsically drive dysfunctional neutropoiesis from human haematopoietic stem cells
              </a>
            </td>
          <td>
            Giovanna Mantica, Aditi Vedi, Amos Tuval, H. Encabo, Daniel Hayler, Aleksandra Krzywon, E. Mitchell, William G. Dunn, Tamir Biezuner, Hugo P Bastos, Kendig Sham, Antonella Santoro, Joe Lee, Nick Williams, A. Danin, Noa Chapal, Y. Moskovitz, Andrea Arruda, E. Fiorillo, V. Orrù, Michele Marongiu, Eoin McKinney, Francesco Cucca, Matthew Collin, Mark D. Minden, Peter J Campbell, George S. Vassiliou, M. Fabre, J. Nangalia, D. Bonnet, Liran Shlush, E. Laurenti
          </td>
          <td>2025-10-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b846de35114daacf2b8cb62d0ddc0dc54e1e9471" target='_blank'>
              Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy
              </a>
            </td>
          <td>
            Lior Goldberg, Eric R Haas, Jiaqi Wu, Bryan Garcia, Ryan Urak, Vibhuti Vyas, Ruby Espinosa, Tamara Munoz, Shirley Bierkatz, K. Pathak, Nathaniel P. Hansen, P. Pirrotte, Jyotsana Singhal, J. Figarola, Ricardo Zerda Noriega, Zhuo Li, Dasol Wi, Erin Tanaka, Ramon I. Klein Geltink, Min-Hsuan Chen, Xiwei Wu, J. Wagner, Jinny A Paul, Mary C. Clark, Dat Ngo, Ibrahim Aldoss, Stephen J. Forman, Xiuli Wang
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98a4e027d57002b46ccf88e1aa10930bce31da48" target='_blank'>
              Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma
              </a>
            </td>
          <td>
            Isabelle Bergiers, M. C. Köse, Sheri Skerget, Milan Malfait, N. Fourneau, Jenna-Claire Ellis, Greet Vanhoof, Tina Smets, Bie Verbist, Dries De Maeyer, Jeroen Van Houdt, Koen Van der Borght, Raluca Verona, Bradley Heidrich, William Kurth, Michel Delforge, Nathalie Meuleman, Jan Van Droogenbroeck, P. Vlummens, Christoph J Heuck, Yves Beguin, Nizar J. Bahlis, T. Casneuf, J. Caers
          </td>
          <td>2025-10-01</td>
          <td>PLOS Genetics</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="The maintenance of a basal immunoinflammatory signature in hematopoietic stem/progenitor cells (HSPCs) constitutes a fundamental regulatory axis governing hematopoietic competence and immune effector generation. While epigenetic repressors constrain this inflammatory phenotype, the molecular amplifiers that preserve this critical state remain undefined. Through integrated single-cell transcriptomic/epigenomic profiling and functional interrogation, we identify Setd2-mediated H3K36me3 as an indispensable epigenetic amplifier sustaining baseline inflammation in murine HSPCs. Setd2 ablation specifically eliminated interferon (IFN)-enriched HSPC subpopulations and attenuated inflammatory signaling cascades. Functionally, Setd2-deficient HSPCs exhibited impaired IFNγ responsiveness, compromised B-lymphopoiesis, and diminished reconstitution capacity due to Lin−c-Kit+Sca1high cell depletion. Paradoxically, Setd2 loss conferred resistance to IFNγ-induced HSPCs exhaustion, which may contribute to the maintenance of Setd2-deficient HSPCs in our myelodysplastic syndrome (MDS) model under the inflammatory milieu. Mechanistically, Setd2 sustained chromatin accessibility and enhancer (H3K27ac) activity at inflammatory gene loci. This work delineates a critical link between Setd2-mediated chromatin regulation, baseline inflammation, HSPC function, and immune competence, providing insights into inflammatory dysregulation in hematopoietic malignancies like MDS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bab10320fbd38970f800ebefeaf9e2ab497a6500" target='_blank'>
              Setd2 ensures the establishment of a precise basal inflammatory state within murine hematopoietic stem/progenitor cells
              </a>
            </td>
          <td>
            Hong Tao, Xinyue Luo, Jiachun Song, Fuhui Wang, Yinyin Xie, Rong Fan, Xiaojian Sun, Qiuhua Huang, Yuanliang Zhang
          </td>
          <td>2025-11-06</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/313fedd146b7503db4be885b70aaa8b04e759604" target='_blank'>
              A data-driven model of macrophage polarization states reveals an IFN macrophage signature in active Crohn’s disease
              </a>
            </td>
          <td>
            Sarina C. Lowe, Madelaine Leitman, Noah Yan, Alexander Hoffmann
          </td>
          <td>2025-09-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/652af720fe035d258a47aa0abc6ca14da634c448" target='_blank'>
              Cytotoxic Vδ2+ T cell subsets expand in response to malaria in human tonsil and spleen organoids
              </a>
            </td>
          <td>
            K. Press, Florian Bach, Elsa Sola, Kylie Camanag, Nicholas L Dooley, Anselma Ivanawati, Damian Oyong, Mayimuna Nalubega, Abel Kakuru, Sedrack Matsiko, Nankya Felistas Namirimu, Kenneth Musinguzi, Annet Nalwoga, Evelyn Nansubuga, Johnie Ategeka, Ebusu Charles, Odongo Bakar, Chloe Kashiwagi, Xuhuai Ji, Molly Miranda, Joselyn Tachiwa-Appiah, Kareena Sandhu, Lilit Kamalyan, K. van der Ploeg, Michelle J. Boyle, Lisa E. Wagar, Mark M Davis, P. Jagannathan
          </td>
          <td>2025-09-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="The immune ecosystem is central to maintaining effective defensive responses. However, it remains largely understudied how immune cells in the peripheral blood interact with circulating tumor cells (CTCs) in metastasis. Here, blood analysis of patients with advanced breast cancer revealed that over 75% of CTC-positive blood specimens contained heterotypic CTC clusters with CD45+ white blood cells (WBCs), which correlates with breast cancer subtypes, racial groups, and decreased survival. CTC-WBC clusters included overrepresented T cells and underrepresented neutrophils. Specifically, a rare subset of CD4 and CD8 double-positive T (DPT) cells was 140-fold enriched in CTC clusters versus their frequency in WBCs. DPT cells shared properties with CD4+ and CD8+ T cells but exhibited unique features of T cell exhaustion and immune suppression. Mechanistically, the integrin heterodimer α4β1, also named very late antigen 4 (VLA-4), in DPT cells and its ligand, VCAM1, in tumor cells are essential mediators of DPT-CTC clusters. Neoadjuvant administration of anti-VLA-4 neutralizing antibodies markedly blocked CTC–DPT clusters, inhibited metastasis, and extended mouse survival. These findings highlight a pivotal role of rare DPT cells in fostering cancer dissemination through CTC clustering. It lays a foundation for developing innovative biomarker-guided therapeutic strategies to prevent and target cancer metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4b3207b5d57cd5e8be09dffff60afa2174fc6551" target='_blank'>
              Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis
              </a>
            </td>
          <td>
            David Scholten, Lamiaa El-Shennawy, Yuzhi Jia, Youbin Zhang, Elizabeth Hyun, C. Reduzzi, Andrew D. Hoffmann, Hannah F Almubarak, Fangjia Tong, Nurmaa K Dashzeveg, Yuanfei Sun, Joshua R. Squires, Janice Lu, Leonidas C Platanias, C. Wasserfall, W. Gradishar, M. Cristofanilli, Deyu Fang, Huiping Liu
          </td>
          <td>2025-09-16</td>
          <td>The Journal of Clinical Investigation</td>
          <td>1</td>
          <td>15</td>
        </tr>

        <tr id="Massive immune cell infiltration and persistent inflammation in the central nervous system (CNS) are key hallmarks of multiple sclerosis. Here, we report a myeloid-derived suppressor cell (MDSC)–based therapeutic strategy, named CNS Immune Targeting Enabled by MDSCs (CITED), which uses surface-decorated MDSCs carrying rapamycin nanoparticles (NPs) for targeted multimodal immune reprogramming in CNS. We show that NP decoration enhances MDSC immunomodulatory function, facilitates their trafficking to inflamed CNS regions, and increases NP accumulation within CNS. In an experimental autoimmune encephalomyelitis model, CITED exhibited robust therapeutic efficacy, resulting in reduced disease progression, improved motor function, and diminished myelin damage. Mechanistic studies reveal that CITED exerts its therapeutic effects by targeted reprogramming of both innate and adaptive immune responses in CNS. Specifically, CITED inhibits immune cell infiltration, rebalances CD4 T cell phenotypes, and promotes the polarization of myeloid cells toward anti-inflammatory phenotypes. Collectively, CITED could provide a broadly effective approach for targeted immune restoration in multiple sclerosis and potentially other autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8f24c23e0ed496fd13e4cd70e0bb4daac42d668" target='_blank'>
              Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis
              </a>
            </td>
          <td>
            Endong Zhang, H. Algarni, Luyu Zhang, Chih-Jia Chao, Shan He, Aditi Upadhye, Qing Bao, Dahee Jung, Shubhi Srivastava, Edidiong Michael Udofa, Philana Phan, Dejan S. Nikolic, Steve Seung-Young Lee, Jalees Rehman, Zongmin Zhao
          </td>
          <td>2025-10-15</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) can switch between immune-activating and cancer-promoting states; yet, the stress pathways that lock them into procancerous states remain obscure. Here we defined the role of transcription factor NRF2 as a mediator of procancerous macrophages. Methods We combined spatial transcriptomics, single-cell RNA sequencing, three-dimensional (3D) cell culture and in vivo tumor models to explore how NRF2 activation status in tumor-associated macrophages modifies responses to immunotherapy. Results In MC38 colon tumors, repeated anti-CD40 or radiotherapy created necrosis that split TAMs into peripheral Cxcl9+ and peri-necrotic Spp1+ subsets. Spatial transcriptomics, single-cell RNA sequencing, and Keap1-deficient mice showed that the latter are NRF2-imprinted “stress-TAMs”, with immunosuppressive and tumor-promoting activity. The same NRF2 activation gradient separates pro-inflammatory CXCL9+ and anti-inflammatory SPP1+TAMs across diverse human cancers. NRF2-imprinted TAMs silence IFN-STAT1 programs, lose major histocompatibility complex-II and chemokine expression, fail to expand T cells, drive tumor cell invasion in 3D co-cultures, and foster metastasis. Constitutive hematopoietic NRF2 activation accelerated the growth of therapy-naïve MMTV-PyMT breast tumors and markedly impaired the efficacy of agonistic anti-CD40 antibody therapy in MC38 subcutaneous and lung-metastasis models. Conversely, macrophage-specific Nrf2 deletion restored immunogenic TAMs and potentiated anti-CD40 and anti-programmed cell death protein-1 treatments. Conclusions Our data pinpoint a previously underappreciated cytoprotective mechanism, which inadvertently sustains immunosuppressive macrophages and confers therapy resistance. These results define stress-induced TAMs as an untapped driver of macrophage-based immune evasion. Inhibiting NRF2 activity alongside standard immunotherapies could restore a pro-inflammatory macrophage–T-cell amplification loop, potentially improving patient responses to T-cell—and macrophage-directed immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3b564268f908e2668ba03acbe4a747ca42980a5" target='_blank'>
              Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy
              </a>
            </td>
          <td>
            Dominik J. Schaer, Nadja Schulthess-Lutz, Livio Baselgia, Kahrisan Kunasingam, R. Humar, K. Hansen, Melanie Eschment, Elena Duerst, F. Vallelian
          </td>
          <td>2025-10-31</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Pancreatic ductal adenocarcinoma (PDAC), the most common malignant type of pancreatic cancer, is characterized by a dense desmoplastic stroma, low neoantigen burden, and a highly immunosuppressive tumor microenvironment (TME), which severely limit cytotoxic T-cell infiltration and the efficacy of immune therapies. Here, we present a novel strategy harnessing acute transplant rejection mechanisms by employing a recombinant oncolytic rVMG vector engineered to express the murine H-2Kk MHC class I alloantigen (rVMG-H-2Kk), thereby inducing tumor-specific antigenic mismatch responses. In vitro, rVMG-H-2Kk exhibited strong replication and cytolytic activity while inducing cell surface expression of both H-2Kk and endogenous H-2Kb, in addition to upregulation of antigen presentation genes (β2-microglobulin, Tap1, and Tapbp). In two independent immunocompetent PDAC models, intratumoral and systemic delivery of rVMG-H-2Kk delayed tumor progression and prolonged survival. Multiplex immunohistochemistry and immunophenotyping revealed substantial TME remodeling, marked by increased effector T-cell infiltration, regulatory T-cell depletion, and reduced fibrosis. Spatial transcriptomics further showed compartment-specific immune activation and epithelial metabolic reprogramming, corroborating with enhanced tumor immunogenicity. Despite these effects, rVMG-H-2Kk also induced compensatory immunosuppressive pathways, including upregulation of antiviral response genes and immune checkpoint receptors such as PDL-2. Importantly, combination therapy with rVMG-H-2Kk and murine checkpoint blockade (anti-PD-1 and anti-CTLA-4) drastically improved survival than checkpoint blockade alone. Strikingly, surviving mice resisted tumor rechallenge, indicating the establishment of durable antitumor memory. Collectively, these findings establish rVMG-H-2Kk as a novel immunotherapeutic platform capable of converting immune-cold tumors into immune-hot, sensitizing tumors to immune checkpoint inhibitors, and establishing durable antitumor immunity in PDAC. One Sentence Summary Oncolytic virus-based delivery of an alloantigen improves antitumor immunity and synergizes with immune checkpoint inhibitors in pancreatic cancer. Significance statement Delivery of murine alloantigens via an engineered oncolytic vesiculovirus, combined with immune checkpoint blockade, overcomes immunosuppressive barriers and establishes durable antitumor immunity in PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/144175af3ddbf48d09d3cc3b2903ab4c80fcc958" target='_blank'>
              Pancreatic tumor microenvironment reprogramming via alloantigenexpressing virotherapy elicits tumor rejection and improves immunotherapy response
              </a>
            </td>
          <td>
            M. Tesfay, Aleksandra Cios, Zetao Cheng, K. U. Ferdous, Randal S. Shelton, Bahaa Mustafa, Natalie M. Elliott, Elizabeth A. Raupach, Camila C Simoes, I. Miousse, Alicja Urbaniak, Michael A. Bauer, Eric R. Siegel, Steven R Post, J. C. Chamcheu, Rang Govindarajan, V. Grdzelishvili, Martin J Cannon, M. Fernandez-Zapico, Alexei G. Basnakian, C. Chabu, Omeed Moaven, M. Borad, B. Nagalo
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Neutrophils are integral components of the bone marrow and stromal cell network. They express the immune checkpoint molecule PD-L1 and can induce T cell exhaustion, thereby promoting immunosuppression. In this study, we investigated whether tumor-derived Cldn7 deficiency could recruit polymorphonuclear neutrophils (PMNs), induce their metabolic reprogramming, and consequently drive their transition toward a pro-tumor phenotype, leading to the establishment of an immunosuppressive tumor microenvironment (TME). Using single-cell RNA sequencing, clinical sample validation, and both in vivo and in vitro experiments, we found that Cldn7 deficiency in colorectal cancer (CRC) results in a tumor microenvironment characterized by significantly increased infiltration of CD11b⁺ Ly6G⁺ neutrophils. This is accompanied by neutrophil metabolic reprogramming that facilitates their phenotypic shift toward a tumor-promoting state, which in turn suppresses the cytotoxic function of CD8⁺ T cells and contributes to the formation of an immunosuppressive TME, thereby accelerating CRC progression. Mechanistically, Cldn7 deficiency indirectly activates the NF-κB signaling pathway, leading to elevated secretion of chemokines such as CXCL1 that are responsible for PMN recruitment. Inhibition of the NF-κB/CXCL1 axis reduces PMN infiltration, decreases PD-L1 expression on neutrophils, suppresses neutrophil glycolysis and histone lactylation, reverses the exhausted phenotype of CD8⁺ T cells, thereby mitigating the immunosuppressive microenvironment. Furthermore, overexpression of Cldn7 enhances the efficacy of immune checkpoint blockade (ICB) therapy.Collectively, our findings indicate that Cldn7 deficiency not only contributes to immune evasion and malignant progression in CRC but also plays a critical role in immune modulation. Targeting PMN metabolic reprogramming and immunosuppressive function associated with Cldn7 loss may offer a promising strategy to improve the therapeutic efficacy of immunotherapy in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57fa7d965f4e46d2deb56381980d3616631c7424" target='_blank'>
              Claudin-7 deficiency induces metabolic reprogramming of neutrophils in the colorectal cancer microenvironment
              </a>
            </td>
          <td>
            Xiaoqing Liang, Dajin Yuan, Songyun Zhao, Jianbo Zhou, Kun Wang, Xiaoli Liu, Yin Liu, Huimin Li, Mengdi Hao, Wenbin Huang, Wenjie Li, Lei Ding
          </td>
          <td>2025-10-16</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85e162cf56bd63abf6599cc2250aa8c629f569ea" target='_blank'>
              PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model
              </a>
            </td>
          <td>
            Francesca Alvarez Calderon, R. Fleming, Marlana B Winschel, Lev Gorfinkel, Rebecca Sutherland, Katherine Michaelis, James Kaminski, Elisa Rojas Palato, Kayleigh Ingersoll, Lorenzo Cagnin, J. Lane, V. Tkachev, Leslie S Kean, Ulrike Gerdemann
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/739a87fd565af12d2e067e28eb04d43a769bbc0a" target='_blank'>
              Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis
              </a>
            </td>
          <td>
            Tomson Kosasih, Tatsuya Morishima, Sohyeon Lee, Jungyeon Yoon, Kanako Wakahashi, Pilhan Kim, Aiko Sada, Hitoshi Takizawa
          </td>
          <td>2025-10-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Bispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting tumor-specific antigens such as interleukin 13 receptor alpha 2 (IL13RA2) and epidermal growth factor receptor variant III (EGFRvIII) have been developed for glioblastoma (GBM). However, there is limited mechanistic understanding of the action of BTE since prior studies were mostly conducted in immunocompromised animal models. To close this gap, the function of BTEs was assessed in the immunosuppressive tumor microenvironment (TME) of orthotopic and genetically engineered mouse models (GEMM) with intact immune systems. Methods A BTE that bridges CD3 epsilon on murine T cells to IL13RA2-positive GBM cells was developed, and the therapeutic mechanism was investigated in immunocompetent mouse models of GBM. Multicolor flow cytometry, single-cell RNA sequencing (scRNA-seq), multiplex immunofluorescence, and multiparametric MRI across multiple preclinical models of GBM were used to evaluate the mechanism of action and response. Results BTE-mediated interactions between murine T cells and GBM cells triggered T cell activation and antigen-dependent killing of GBM cells. BTE treatment significantly extended the survival of mice bearing IL13RA2-expressing orthotopic glioma and de novo forming GBM in the GEMM. Quantified parametric MRI validated the survival data, showing a reduction in glioma volume and decreased glioma viability. Flow cytometric and scRNA-seq analyses of the TME revealed robust increases in activated and memory T cells and decreases in immunosuppressive myeloid cells within the brains of mice following BTE treatment. Conclusions Our data demonstrate that the survival benefits of BTEs in preclinical models of glioma are due to the ability to engage the host immune system in direct killing, induction of immunological memory, and modulation of the TME. These findings provide a deeper insight into the mechanism of BTE actions in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3d8175d96b7c6cd7d7b5ae734fb75666b210772" target='_blank'>
              Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
              </a>
            </td>
          <td>
            M. Zannikou, J. Duffy, Daniel Procissi, H. Najem, R. Levine, A. Thakur, D. Hambardzumyan, Catalina Lee-Chang, Lara Leoni, C. Horbinski, D. Simberg, Bin Zhang, A. Heimberger, J. Miska, Irina V. Balyasnikova
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="Immune checkpoint inhibitors have traditionally been understood to exert their effects primarily within the tumor microenvironment, particularly targeting CD8 + T cells. However, recent studies have highlighted a pivotal role of tumor-draining lymph nodes in mediating responses to immune checkpoint inhibitor therapy. This study aimed to elucidate the specific mechanisms by which tumor-draining lymph nodes respond to immune checkpoint inhibitor therapy and regulate the tumor microenvironment in human colorectal cancer. We performed single-cell RNA sequencing and T cell receptor sequencing on tumor-draining lymph nodes and tumor tissues from patients with colorectal cancer. Through in-depth analysis of the single-cell data, we established the connection between TDLNs and tumor, and explored the impact of immune checkpoint inhibitor therapy on the immune microenvironment of tumor-draining lymph nodes. In addition, we conducted animal experiments to validate these findings. Our findings revealed that immune checkpoint inhibitor treatment induced the expansion of tumor-specific CD8 + effector memory T cells within tumor-draining lymph nodes, which may serve as a source for the progenitor-exhausted CD8 + T cells in the tumor microenvironment. Moreover, conventional dendritic cells type 1 and macrophages within tumor-draining lymph nodes facilitated this process. We also observed that immune checkpoint inhibitor therapy promoted the expansion of tumor-specific CD4 + follicular helper T cells in tumor-draining lymph nodes, which may explain the increase of CD4 + follicular helper T cells in the tumor microenvironment after immune checkpoint inhibitor therapy. These hypotheses were corroborated through experiments in mice. Our findings delineate the critical regulatory function of tumor-draining lymph nodes in modulating the tumor microenvironment during Immune checkpoint inhibitor therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b9de1a203560b665a61560f8094ade12f18f1b7" target='_blank'>
              Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling
              </a>
            </td>
          <td>
            Jinzhu Zhang, Jian Ma, Yaru Niu, Jialiang Liu, Zhexue Wang, Jinyu Guo, Yongsheng Meng, Ruifang Sun, Zhen Zhang, Haiyi Liu, Juan Xu, L. Zan, Xu Guan, Xishan Wang
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related mortality worldwide, with its progression shaped not only by tumor-intrinsic factors but also by a complex and immunosuppressive tumor microenvironment (TME). Within this niche, diverse immune populations—including CD8+ cytotoxic T cells, CD4+ helper T cell subsets (Th1, Th17, Tregs), B cells, natural killer (NK) cells, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs)—collectively regulate immune surveillance and tumor escape. While effector lymphocytes mediate antitumor responses, their function is often attenuated by TAM- and MDSC-driven immunosuppression via cytokines (IL-10, TGF-β), metabolic disruption, and immune checkpoint expression. High densities of M2-polarized TAMs and MDSCs correlate with poor prognosis and resistance to therapy. Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have improved outcomes in lung cancer, yet therapeutic efficacy remains limited by the immunosuppressive TME. This review outlines the functional roles of key immune cell subsets in lung cancer and highlights emerging strategies to reprogram the TME and enhance immunotherapeutic responsiveness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec07b573d2c713f5c6d11528b863b0a4240be315" target='_blank'>
              Reprogramming the immune microenvironment in lung cancer
              </a>
            </td>
          <td>
            Kai Chen, Linqi Luo, Yong Li, Ge Yang
          </td>
          <td>2025-09-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="In people with HIV (PWH), T cell immune activation and endothelial inflammation are contributors of the increased cardiovascular risk, however the mechanisms remain poorly understood. PAR1 connects the coagulation cascade, endothelial cells and CD8 T cells at the site of endothelial inflammation and we hypothesized that HIV driven CD8 T cell immune activation alters endothelial repair mechanisms. Endothelial repair is partially mediated by angiogenic T (Tang) cells that facilitate proliferation of endothelial cells, and differentiation of endothelial progenitor cells at site of vascular injury. During LCMV infection, we identified a subset of CD31highCD8 T cells that exhibited a long-lived memory precursor phenotype (CD127+KLRG1-) and secreted the proangiogenic cytokine vascular endothelial growth factor (VEGF) after viral control. Furthermore, in PWH, the frequencies of CD8 Tang cells were reduced and showed an activated phenotype and expression of granzymes. GZMA+GZMB+CD8 Tang cells correlated with atherosclerotic cardiovascular disease (ASCVD) risk. In vitro, granzyme dependent PAR1 activation led to calcium mobilization and secretion of proinflammatory cytokines IL-6, IL-8 and angiopoietin-2 by primary human endothelial cells. Altogether, these findings suggest that CD8 T cells are involved in immunity against viruses and endothelial homeostasis and HIV driven immune activation alters these functions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/acdd1c0ab85da31af1de2dd25172bbc00e69e503" target='_blank'>
              Angiogenic CD8 T cells from PWH induce Granzymes-dependent PAR1 activation promoting endothelial inflammation
              </a>
            </td>
          <td>
            Tong Li, Chinmayee Mehta, Cooper James, Jinya Chen, Hui Chen, Gerard P Ahern, Ziang Zhu, Maitane Faus Cid, Maryam Abdussamad, Shiwen Yu, Jai Kumar, Princy Kumar, Colleen Hadigan, Kyle DiVito, Dorian B. McGavern, Leonid Pobezinsky, Marta Catalfamo
          </td>
          <td>2025-09-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2c146d74e58561771a7d91f4ca1977ff7215575" target='_blank'>
              Efineptakin alfa (NT-I7) improves overall survival and induces tertiary lymphoid structures in murine lung tumors
              </a>
            </td>
          <td>
            Trang Dinh, Judong Lee, Sidra Islam, Namita Nanda, Dijana Bjelivuk, Dathan Andrews, Jiasen Zhang, N. Mani, Jin Zhou, Alexandra A. Wolfarth, Donghoon Choi, Rafi Ahmed, Joseph J. Skitzki, Deyu Fang, Weihong Guo, Zhenghe Wang, Rebecca C. Obeng
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/688de0b03999304bfc55a9981de1437a71ee2384" target='_blank'>
              UBA1 Mutations Drive RIPK1-Mediated Cell Death and Monocyte Dysfunction in VEXAS Syndrome
              </a>
            </td>
          <td>
            P. Breillat, Samuel J. Magaziner, Stéphane Camus, L. Dionet, Benjamin de Valence, P. Sohier, Amine Majdi, Quentin Delcros, Federica Pallotti, N. Rivet, Kevin Chevalier, Margot Poux, P. Tharaux, Olivia Lenoir, Abdelrahim Zoued, Olivier Kosmider, David B Beck, Benjamin Terrier
          </td>
          <td>2025-10-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>53</td>
        </tr>

        <tr id="Abstract Background Numerous studies have demonstrated the promising efficacy of granulocyte colony‐stimulating factor (G‐CSF) in the treatment of couples with unexplained recurrent pregnancy loss (URPL) during early pregnancy. While neutrophils are recognised as the main effectors mediating immunoregulation, their G‐CSF‐mobilised phenotype and mechanisms regulating maternal–fetal immunity remain unclear. Methods Single‐cell RNA sequencing (scRNA‐seq) and single‐cell T‐cell receptor sequencing (scTCR‐seq) were conducted to uncover the immune reconstitution dynamics of peripheral blood under G‐CSF stimulation. Integrative analysis of transcriptomic‐proteomic profiles with functional validation revealed a unique immunomodulatory neutrophil population. Further, we used spatial transcriptomics, flow cytometry and immunohistochemistry to explore the spatial distribution characteristics of this population at the maternal–fetal interface, and validated its therapeutic efficacy in animal models. Results G‐CSF‐mobilised peripheral blood (G‐PB) displayed immune hyporesponsiveness. Unique neutrophils expressing high levels of CD177 and the S100A gene family expanded substantially in response to G‐CSF. These neutrophils exhibited a comparatively immature morphology and impaired T‐cell responses via contact‐dependent arginase 1 release, as well as upregulation of T‐cell immune checkpoints. A reduction of CD177+S100Ahi neutrophils was observed in both peripheral blood and decidua of URPL patients relative to healthy pregnant women. Functional validation in abortion‐prone murine models confirmed that exogenous supplementation of G‐CSF or adoptive transfer of CD177+S100Ahi neutrophils could successfully improve the pregnancy outcomes. Conclusion G‐CSF played a crucial regulatory role in improving pregnancy outcomes by selectively expanding CD177⁺S100Ahi neutrophils with polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs) properties, providing a solid theoretical foundation for the treatment of patients with URPL using G‐CSF. Key points G‐CSF induces peripheral blood immune hyporesponsiveness in patients with UPRL. First to characterize G‐CSF mobilised CD177+S100Ahi neutrophils displayed PMN‐MDSCs properties. Both CD177+S100Ahi‐LDNs and CD177+S100Ahi‐NDNs induce T cell hyporesponsiveness through coordinated activation of the ARG1/L‐Arg metabolic axis and synergistic upregulation of immune checkpoint molecules. CD177+S100Ahi neutrophils are diminished in the peripheral blood and decidua of patients with UPRL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6e8e769871352922cc92c745bad2ac8d159aa41" target='_blank'>
              Granulocyte colony‐stimulating factor induced T‐cell hyporesponsiveness via modulation of CD177+S100Ahi neutrophils in unexplained recurrent pregnancy loss
              </a>
            </td>
          <td>
            Ping-Fen Li, Xue Zhang, Peng-Sheng Zheng
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="The co-inhibitory receptor TIGIT suppresses excessive immune responses in autoimmune conditions while also restraining antitumor immunity. In viral infections, TIGIT alone does not affect viral control but has been shown to limit tissue pathology. However, the underlying mechanisms are incompletely understood. Here we found TIGIT+ T cells to express not only an immunoregulatory gene signature but also a tissue repair gene signature. Specifically, after viral infection, TIGIT directly drives expression of the tissue growth factor amphiregulin (Areg), which is strongly reduced in the absence of TIGIT. We identified regulatory T (Treg) cells, but not CD8+ T cells, as the critical T cell subset mediating these tissue-protective effects. In Treg cells, TIGIT engagement after T cell antigen receptor stimulation induces the transcription factor Blimp-1, which then promotes Areg production and tissue repair. Thus, we uncovered a nonclassical function of the co-inhibitory receptor TIGIT, wherein it not only limits immune pathology by suppressing the immune response but also actively fosters tissue regeneration by inducing the tissue growth factor Areg in T cells. Joller and colleagues show that the co-inhibitory receptor TIGIT induces the expression of the tissue growth factor amphiregulin (Areg) in regulatory T cells and contributes to tissue repair in response to viral infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0b61dd16412c6f14fc56828dfe7806631ed84034" target='_blank'>
              The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells
              </a>
            </td>
          <td>
            C. Panetti, Rahel Daetwyler, A. Moncsek, Nikolaos Patikas, A. Agrafiotis, Adelynn Tang, F. Andreata, Valeria Fumagalli, Jean de Lima, Lifen Wen, Carolyn G King, Ajithkumar Vasanthakumar, Matteo Iannacone, Axel Kallies, A. Yermanos, M. Hemberg, Nicole Joller
          </td>
          <td>2025-10-15</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>31</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/394995c0fcb10ae0448160919d2f62f9453d3170" target='_blank'>
              Comprehensive single-cell analysis reveals mast cells’ roles in cancer immunity
              </a>
            </td>
          <td>
            Hao Qian, Wenbo Wang, Jiaomeng Pan, Ming Zhao, Li Gao, Jia Zeng, Hang Gong, Guangyan Zhangyuan, Zi Li, Mao Zhang, Xia Shen, Yuanchi Weng, Xiaxing Deng, Yingying Huang
          </td>
          <td>2025-10-10</td>
          <td>Oncogene</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/276902406914fa26315122d32de7c8926d35072f" target='_blank'>
              Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing
              </a>
            </td>
          <td>
            Tanja Eisemann, M. Masihi, Theophilos Tzaridis, Veronika Pister, Isaac Youm, Kendall R. Chambers, Aditi Dutta, Alexander T Wenzel, Koei Chin, Scott L. Pomeroy, J. Mesirov, E. Fraenkel, Anindya Bagchi, Lukas Chavez, Robert J Wechsler-Reya
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6a9f3325348d0e9acac4d1170eb3ed6e4599ca92" target='_blank'>
              Co-Stimulatory Blockade Prevents Intragraft Accrual of Class-Switched, Activated B Cells Despite Failing to Prevent T-Cell Mediated Rejection
              </a>
            </td>
          <td>
            J. T. Caldwell, Tiffany Shi, Ashley R. Burg, Ashley Koby, Krishna M. Roskin, Anna L. Peters, E. DePasquale, E. Woodle, D. Hildeman
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="The elusive pathogenesis of sepsis-induced acute lung injury (ALI) combined with the absence of reliable diagnostic biomarkers, significantly hinders the development of targeted therapies and precision medicine approaches for affected patients. In this study, we employed scRNA-seq to profile the transcriptional landscape of the lungs in well-established murine models of sepsis-induced ALI. These findings were further validated experimentally leading to the identification of tri-lineage candidate biomarkers for sepsis-associated ALI: SCGB3A2 (in epithelial cells), AKAP12 (in endothelial cells), and CCL4 (in monocytes/macrophages, Mo/Mφ). In pulmonary immune microenvironment of sepsis-induced ALI, Mo/Mφ were identified as the dominant contributors to pulmonary immune heterogeneity during the acute inflammatory phase of sepsis-induced ALI. Among these, the Ccl4high Mo/Mφ subpopulation exhibited disease-specific lung infiltration and a distinct proinflammatory phenotype. Mechanistically, FPR1 was up-regulated in hyperinflammatory cluster of Ccl4high Mo/Mφ. Pharmacological inhibition of FPR1 in vivo selectively reduced pulmonary infiltration of Ccl4high Mo/Mφ and attenuated sepsis-induced ALI. Furthermore, we established a peripheral blood-based five-gene panel (CCL4, NFKBIA, IL1B, BATF, and XBP1) derived from signatures of Ccl4high Mo/Mφ, which robustly predicted sepsis-induced ALI in clinical cohorts. Collectively, our work delineates the transcriptional alterations of lungs in sepsis-induced ALI, identifies candidate biomarkers for sepsis-induced ALI, and establishes a clinically applicable diagnostic model for early detection. These findings enhance our understanding of the underlying mechanisms of sepsis-induced ALI and offer new targets for its precision diagnosis and therapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/10eb6c00cfbc9709c8027174f96c5e573b4815ab" target='_blank'>
              FPR1-dependent Pro-inflammatory Ccl4high monocytes/macrophages drive and predict sepsis-induced acute lung injury
              </a>
            </td>
          <td>
            Yuhang Li, Jia Shi, Tianyu Yu, Meiling Piao, Jin Tan, Yuyang Miao, Lirong Gong, Shuan Dong, Xiangyun Li, Huayang Liu, Jianbo Yu, Yuan Zhang, Qiang Zhang
          </td>
          <td>2025-11-05</td>
          <td>Respiratory Research</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Relapsed and refractory multiple myeloma (RRMM) remains a major clinical challenge, as most patients eventually relapse following standard treatments and are left with limited therapeutic options. Although b-cell maturation antigen (BCMA) CAR-T cell therapy has recently shown remarkable efficacy in select patients, broader implementation is hindered by its reliance on autologous cells, prolonged manufacturing timelines, high costs, and severe immune-related toxicities. These challenges have prompted an urgent demand for safer, more accessible, and rapidly applicable immunotherapeutic alternatives. CBMC (cord blood mononuclear cells) were cultured with irradiated BMMC (bone marrow mononuclear cells) from RRMM patients in the presence of defined cytokines, aiming to develop a new therapeutic immune cell product for RRMM. Their phenotypic and functional characteristics, including non-MHC-restricted and MHC-restricted cytotoxicity mechanisms, were analyzed using surface marker profiling, cytokine secretion assays, in vitro cytotoxicity assays, functional and blocking assays. Antitumor activity was evaluated in xenograft mouse models using MM.1 S and RPMI-8226 cells. We successfully generated CD8+ NKT-like cells through tumor priming, which exhibited potent cytotoxicity and elevated cytokine production against multiple myeloma cell lines and primary RRMM samples. Mechanistically, tumor-priming CD8+ NKT-like cells (TPNC) cytotoxicity was mediated by both non-MHC–restricted pathways involving LFA-1 and DNAM-1, and MHC-restricted, TCR-mediated recognition. TPNC efficiently formed immune synapses, rapidly polarized cytotoxic granules, and engaged in serial killing. In xenograft models, TPNC significantly suppressed tumor progression, prolonged survival, and persisted in circulation without observable toxicity. Based on these findings, we extended the tumor-priming strategy to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), successfully generating TPNC with robust cytotoxic activity. In ALL samples, TPNC exhibited cytotoxicity comparable to anti-CD19 CAR-NK cells. TPNC represents a novel cytotoxic lymphocyte product generated through tumor-driven priming. Their dual recognition capacity, functional versatility, and favorable safety profile highlight their potential as a scalable and personalized immunotherapy platform for hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93312d628496ab87e87c047dff1fc445e08f269c" target='_blank'>
              Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma
              </a>
            </td>
          <td>
            Juheon Lee, E. Choi, Bohwa Han, Jeongmin Kim, Dana Jung, Kyeong-Hee Kim, Sung Yong Oh, Sung-Hyun Kim, Kyungsoo Ha, Ji-Hoon Kim, Ji Hyun Lee, Duck Cho, Junsang Doh, Seok-Ho Kim
          </td>
          <td>2025-09-29</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background and objective Tumor antigen–escape variants undermine immunotherapy by subverting lymphocyte effector functions and reshaping tumor–immune dynamics. It is essential to delineate functional interplay within immune networks during tumor progression. We investigated whether homeostatic crosstalk between CD8+T cells and natural killer (NK) cells preempts tumor antigen–escape. Methods Adoptive CD8+T cell transfers were administered before (D–7, homeostatic pre-priming) or after (D+1) tumor establishment in Rag1−/− and Rag1−/−γc−/− mice. Antigen presentation, immune activation, proliferation, cytotoxicity, and memory were quantified by flow cytometry, live bioluminescence and confocal imaging. Monoculture, co-culture, and a 3D silica nanofiber carpet mimicking basement-membrane-like topography modeled intercellular interactions. Signaling arrays and motion metrics (Speed-Distance Index, deceleration) were conducted. Human ligand–receptor pairs engaged in CD8+T–NK crosstalk were probed in silico. Results and discussion Pre-tumor D–7 CD8+T cell transfer completely suppressed antigen–escape tumors with NK cells as major effectors showing elevated CD25, CD69, CD107a, and GzmB, marking activated and effector phenotype, and promoting central-memory CD62L⁺CD44⁺CD8⁺TCM precursors. By contrast, post-tumor D+1–transferred CD8+T cells allowed emergence of tumor variants resistant to antigen-specific cytolysis as assessed on day 25, despite those T cells retaining higher intrinsic cytotoxic capacity than the D–7 T cell cohort. Mechanistically, CD8+T and NK cells formed stable contacts through pseudopodial intercellular nanotubes enabling bidirectional membrane exchange and signaling via STAT, Akt, and mTOR pathways, augmenting NK effector function and promoting CD8+TCM differentiation. In silico analysis identified human ligand–receptor pairs engaged in CD8+T–NK adhesion, stimulatory and regulatory axes, including CD200–CD200R, PD-L1–PD-1, and CD18/CD11a–DNAM-1 (CD226). Together, data support a three-phase model of preemptive immunosurveillance initiated by early CD8⁺T–NK crosstalk. Conclusion Homeostatic conditioning and effector cooperativity between CD8+T and NK cells protect against tumor immune escape. The findings uncover a mechanistic axis of preemptive immunosurveillance that lays the foundation for next-generation preventive immunotherapies to control antigen–escape tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7da5a7fdb4ec2b2b9a760d690ae1d6009548f667" target='_blank'>
              CD8+ T–NK cell crosstalk establishes preemptive immunosurveillance to eliminate antigen–escape tumors
              </a>
            </td>
          <td>
            R. Uzhachenko, Salvador González Ochoa, T. Kanagasabai, H. Rajakaruna, Menaka C Thounaojam, M. T. D. de Aquino, Tanu Rana, L. Costa, A. Terekhov, William H. Hofmeister, Thomas J. Sayers, Claude Boyer, Alla Ivanova, J. S. Goodwin, A. Schmitt-Verhulst, A. Shanker
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/686609950c5f9a2748b6c9d3a59879f149b910cb" target='_blank'>
              Autoantibody origins in lupus and in relapse post CAR-T therapy
              </a>
            </td>
          <td>
            Amalie Grenov, Jongwon Yoon, Daniel M. Snell, Anna Mikolajczak, Hao Wang, Erdem Gürel, Ana Rodriguez Ronchel, G. Yegen, Lydia Lee, B. Esen, Anisur Rahman, P. Maciocia, Carola G. Vinuesa
          </td>
          <td>2025-10-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ee5dbb33a6a382fa70961ac781d31dc13ae0aa3f" target='_blank'>
              Tumor cell dissemination is facilitated through regulatory T cell-driven extracellular matrix remodeling
              </a>
            </td>
          <td>
            Ailen D. Garcia-Santillan, Jessanne Y. Lichtenberg, He Shen, Jasmine M. Rodriguez, Sandra Makar, Jonathan Barra, Nicholas M. Clark, Wei Du, Leandro M. Martinez, Ashley D. Hadjis, Taylor Calicchia, Mikhail G. Dozmorov, J. Bravo-Cordero, Amy L. Olex, Priscilla Y. Hwang, Paula D. Bos
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3a49d89fee1e264d07c077511659fd26ac325da0" target='_blank'>
              Lymph nodes fuel KLF2-dependent effector CD8+ T cell differentiation during chronic infection and checkpoint blockade
              </a>
            </td>
          <td>
            Carlson Tsui, Leonie Heyden, Lifen Wen, Catarina Gago da Graça, Nikita Potemkin, A. Frolov, Daniel Rawlinson, Lei Qin, Verena C. Wimmer, Marjan Hadian-Jazi, Darya Malko, Chun-Hsi Su, Sining Li, Kayla R. Wilson, Helena Horvatic, Sharanya K M Wijesinghe, Marcela L. Moreira, Lachlan Dryburgh, Dominik Schienstock, Lisa Rausch, Daniel T. Utzschneider, Cornelia Halin, Scott N. Mueller, M. Beyer, S. Bedoui, Zeinab Abdullah, Jan Schröder, Axel Kallies
          </td>
          <td>2025-09-15</td>
          <td>Nature Immunology</td>
          <td>2</td>
          <td>50</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/15ffe224afe018a4f7b0a537cc1b027c3c818db6" target='_blank'>
              An autologous human iPSC-derived 3D organoid infection model for preclinical testing of antiviral T cells
              </a>
            </td>
          <td>
            Ugarit Daher, V. Fernandez-Vallone, Morris Baumgardt, Benedikt Obermayer, Niklas Wiese, Achim Klaus Kirsch, Tanja Fisch, Anna Löwa, Michael Schmueck-Henneresse, A. Hocke, L. Amini, Harald Stachelscheid
          </td>
          <td>2025-09-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4abcaf5776ad97c1813abd2abb8852a605b524d" target='_blank'>
              Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies
              </a>
            </td>
          <td>
            A. Carturan, Mathew G. Angelos, P. Guruprasad, , R. Pajarillo, Andrew Lee, Yunlin Zhang, Yi-Hao Chiang, Wei Xie, Jesse L. Rodriguez, Jaryse Harris, Pooja Devi, Olabisi I. Afolayan-Oloye, Jason Xu, Jonathan Sussman, Omar Elghawy, Austin Yang, Adam Barsouk, J. Cho, Carolyn E. Shaw, Ekta Singh, O. Ugwuanyi, D. Espie, L. Paruzzo, Federico Stella, Shan Liu, Siena Nason, Antonio Imparato, Antonia Rotolo, Jean Lemoine, David M. Barrett, A. Posey, A. Rook, Vinodh Pillai, Adam Bagg, S. Pileri, Dongfang Liu, Kai Tan, S. Schuster, D. Teachey, P. Porazzi, M. Ruella
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>66</td>
        </tr>

        <tr id="Myeloid cells are a diverse group of immune cell types with systemic and organ-specific functions. Myeloid cells are frequently found in the tumor microenvironment and their infiltration correlates with survival and response to treatment. High myeloid infiltration is typically a poor prognostic factor, and the immune suppressive and prometastatic roles of myeloid cells are well established. However, there is an increasing appreciation of the antitumor functions performed by myeloid cells, which include direct tumor cell killing, phagocytosis, antigen presentation and T and natural killer cell recruitment. Moreover, advances in immune phenotyping have uncovered myeloid subsets with positive prognostic significance, including subsets correlating with higher response rates to immunotherapy. This review summarizes recent progress in mapping and dissecting the opposing effects of myeloid cells on cancer progression and immunotherapy response. The overall impact of myeloid cells is context-dependent, and combination therapies are needed to leverage the antitumor potential of these cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3823ee46218e3233f5b48e60b02f6fa9d09ba69f" target='_blank'>
              Positive and negative roles of myeloid cells in cancer immunotherapy
              </a>
            </td>
          <td>
            Jaroslav Zak, Judith A. Varner
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ed2e2b6e5867f00f570022e3faf5971a5955554" target='_blank'>
              Highly multiplexed imaging recovers immune and metabolic niches in multiple myeloma associated with disease progression and bone involvement
              </a>
            </td>
          <td>
            Ingrid Aass Roseth, Lukas Hatscher, Chiara Schiller, Håkon Skjalg Selland Johnstuen, T. Slørdahl, Håkon Hov, D. Schapiro, T. Standal
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18d334efdd4d167f301eb6b862ccafe18092402f" target='_blank'>
              Localized immunomodulation with cytokine-producing cells to mitigate host immune rejection responses in rodents and a non-human primate
              </a>
            </td>
          <td>
            Boram Kim, Dilrasbonu Vohidova, A. Nash, Yuen San Chan, Samantha Fleury, Shravani Deo, Danna Murungi, Peter D Rios, Ira Joshi, Hafsa Nasir, Daisy Lopez, Mor Sela Golan, Cassidy Hart, Jose Oberholzer, H. C. Hodges, O. Veiseh
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) exhibits profound immune dysregulation, driven in part by the opposing roles of regulatory T cells (Tregs) and T helper 17 (Th17) cells. Tregs facilitate tumor progression through immune suppression, angiogenesis, and checkpoint engagement, while Th17 cells display dual effects depending on the tumor microenvironment, either promoting anti-tumor responses or enhancing malignancy. Importantly, plasticity between these subsets, orchestrated by cytokines such as TGF-β, IL-6, and IL-1β, allows dynamic interconversion that shapes immune outcomes. This review comprehensively summarizes the differentiation, molecular mechanisms, and functions of Tregs and Th17 cells in NSCLC. We highlight recent advances in targeting the Th17/Treg axis via immune checkpoint inhibitors, Treg depletion, and metabolic reprogramming. Understanding this immunological balance offers promising avenues for restoring anti-tumor immunity and improving therapeutic efficacy in NSCLC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc2fe215418a201aa8b5de519c7cfb5b11dfb23a" target='_blank'>
              Rewiring immune suppression in NSCLC: Roles and plasticity of Tregs and Th17 cells
              </a>
            </td>
          <td>
            Shasha Zhu, Ning Zhou, Qingling Li, Xiaoxing Liu
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/842af96f572eb3d970548668b36cfda84da5efb2" target='_blank'>
              Glucocorticoid Receptor Signaling in Myeloid Cells Orchestrates Inflammation Resolution and Muscle Repair
              </a>
            </td>
          <td>
            Sirine Souali-Crespo, Joe G. Rizk, Emilia Calvano, Rajesh Sahu, Emina Colovic, Imane Chabba, Valentine Gilbart, Erwan Grandgirard, Bastien Morlet, Qingshuang Cai, Daniel Metzger, D. Duteil
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="T cell responses are generally curtailed by suppressive mechanisms within the tumor microenvironment (TME) that prevent T cell infiltration and function. Consequently, T cell-based therapies for solid tumors have yielded limited and often non-durable clinical responses. Tumors develop a hostile TME, where tumor-associated macrophages (TAMs) that initially support T cells are converted into immune suppressive TAMs that facilitate tumor evasion from T cell control. In fact, immune suppressive TAMs represent a dominant fraction of immune cells within the TME and their presence is associated with poor prognosis and resistance to immunotherapy. Often in close contact with effector T cells, TAMs directly suppress CD8+ T cells through mechanisms involving metabolic mediators, co-signaling receptors, their ligands and/or cytokines. Here, we revisit molecular interactions behind TAM-mediated suppression of T cell responses and address the potential targeting of such molecules and pathways to re-boost anti-tumor T cell immunity. This perspective, focusing on molecular interactions between TAM and T cells, may aid the improvement of T cell-based therapies for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c01dfbcf193a83248342e1e2c8db14cdc37f598" target='_blank'>
              Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy
              </a>
            </td>
          <td>
            R. M. Coelho, R. Debets, Dora Hammerl
          </td>
          <td>2025-10-16</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Myeloid cells play critical roles as Fc effector cells in antibody‐mediated immunity. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) is a pleiotropic cytokine that promotes the recruitment and activation of multiple myeloid populations and has been used in combination with vaccines/treatments against infectious diseases, inflammatory conditions and cancers. To evaluate GM‐CSF‐mediated kinetics of immune cell expansion and immune outcomes, we compared subcutaneous (subQ) and topical hypoosmolar (intravaginal/intrarectal) administration in vivo using rhesus macaques (RM), as they provide easy access to longitudinal mucosal tissue sampling and are a critical model species for vaccines/therapeutics development. While topical GM‐CSF did not result in a major change, neutrophils, eosinophils and monocytes were elevated within 1–3 days of subQ GM‐CSF administration, with peak eosinophil and neutrophil enrichment in blood at days 7 and 8, respectively. Corresponding elevations of neutrophils, eosinophils, total CD64+ and total CD32+ were observed at days 7 and 14 in rectal biopsies, indicating general Fc effector cell accumulation in these animals. Histological evaluations of vaginal biopsies showed myeloid cell infiltration at day 14 of subQ GM‐CSF treatment. Further, subQ GM‐CSF administration resulted in myeloid cell activation and trafficking, as evidenced by elevated levels of cytokines (CXCL13, MCP‐1, IL‐1RA). Importantly, neither subQ nor topical GM‐CSF administration induced overt systemic inflammation or adverse clinical impacts. Overall, our findings delineate the kinetics of systemic and mucosal myeloid cell expansion, activation and trafficking achieved by subQ GM‐CSF administration in RM. These findings will inform the use of GM‐CSF as an adjuvant in clinical applications where myeloid cell mobilization is advantageous.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/492d90767cafd39d09bc074bbefa23b57af9983b" target='_blank'>
              Myeloid cell recruitment and activation through systemic and mucosae‐directed cytokine therapy
              </a>
            </td>
          <td>
            C. Manickam, Rhianna Jones, Nihar R. Deb Adhikary, Kyle W. Kroll, Karen Terry, Hari Balachandran, Griffin Woolley, Georgia D Tomaras, François J. Villinger, R. K. Reeves
          </td>
          <td>2025-10-07</td>
          <td>Immunology and Cell Biology</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="The release of danger-associated molecular patterns (DAMPs) such as ATP from stressed or damaged cells is a key initiator of sterile inflammation. In autoimmune diseases, extracellular ATP acts as a potent pro-inflammatory signal by activating the purinergic receptor P2X7, which is expressed on both mononuclear phagocytes (MPs) and T cells—key drivers of pathological processes. While it is well established that P2X7 mediates ATP-dependent immune activation, its cell-specific contributions to innate versus adaptive immunity in autoimmune conditions remain unclear, especially in autoimmune uveitis. Here we used the experimental autoimmune uveoretinitis (EAU) mouse model to delineate the cellular mechanisms underlying P2X7’s role in autoimmune responses. Using a combination of multiple cell-specific conditional models and transcriptomic approaches, we showed a pivotal role forP2X7 expressed by MPs in orchestrating T-cell mediated autoimmune responses. P2X7 deficiency in MPs decreased disease severity. Additionally, cell-specific transcriptomic analyses, including single-cell analyses, revealed that P2X7 exerted distinct modulatory effects across monocyte-derived macrophages (MdM) versus microglia. In MdM, lack of P2X7 was associated with reduced expression of genes related to the inflammasome, phagocytosis pathways, and components of the complement system, leading to a marked decrease in pathogenic Th17 cell frequency in the retina. In microglia, P2X7 deficiency instead particularly impacted an IFN-responsive microglial subset that is normally characteristic of EAU. By specifically deleting P2X7 in microglia, we demonstrate its role in driving pathogenic processes in this cell population. These findings suggest that inhibition of P2X7 could be a promising therapeutic strategy in autoimmune neuroinflammatory disorders. P2X7 expressed on MPs, rather than on CD4+ T-cells, plays a primary role in the development of EAU. Lack of P2X7 expression by MPs not only down-regulated phagocytosis and inflammasome pathways but also complement components. P2X7 indirectly influences Th17 polarization through its expression in MPs. P2X7-deficiency in MPs reduced the frequency of the IFN-responsive microglial subset during EAU. P2X7 expression by microglia contributes to the development of EAU. P2X7 expressed on MPs, rather than on CD4+ T-cells, plays a primary role in the development of EAU. Lack of P2X7 expression by MPs not only down-regulated phagocytosis and inflammasome pathways but also complement components. P2X7 indirectly influences Th17 polarization through its expression in MPs. P2X7-deficiency in MPs reduced the frequency of the IFN-responsive microglial subset during EAU. P2X7 expression by microglia contributes to the development of EAU.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31d6dca4ac613c86885fb67afae84c460cb78a38" target='_blank'>
              Macrophage expression of P2X7 controls autoimmune uveitis
              </a>
            </td>
          <td>
            Paul-Alexandre Déchelle-Marquet, Yueshen Che, Camille Roux, Frédéric Blond, Kaitryn E. Ronning, S. Augustin, Pauline Lagouge-Roussey, C. Nous, Sara Touhami, Bahram Bodaghi, Jean Kanellopoulos, S. Adriouch, X. Guillonneau, Florian Sennlaub, Cécile Delarasse
          </td>
          <td>2025-09-25</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1dc5d3c63e2c8a598b2458f56705187d3452201c" target='_blank'>
              Neutrophils induce effective antibody responses to the pneumococcal conjugate vaccine by inhibiting regulatory T cells
              </a>
            </td>
          <td>
            Essi Y. I. Tchalla, Anagha Betadpur, Andrew Y. Khalil, Elena Lopez, Manmeet Bhalla, Musea Chang, Elizabeth A. Wohlfert, E. Ghanem
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Chronic inflammation can induce lymphocyte dysfunction, which is characterized by the expression of inhibitory immune checkpoints. For type 2 innate lymphoid cells (ILC2s), the acquisition of a state of hyporesponsiveness associated with PD-1 expression has been reported in severe allergic inflammation. However, the regulation of ILC2 reactivity in the context of cancer is less clear. The contribution of ILC2s to the antitumor immune response depends, indeed, on the type of tumor and the distinct cellular interplay within the microenvironment. Here, we show that ILC2s in malignant pleural effusions express the immune checkpoints PD-1 and CTLA-4. An in vitro model of the ILC2‒macrophage interaction demonstrated that this crosstalk is responsible for driving CTLA-4 expression and limiting ILC2 activation. Thus, by preventing ILC2 exhaustion, macrophages maintain ILC2 responsiveness to signals from the tissue. These results reveal that, unlike PD-1 expression, CTLA-4 expression on ILC2s is associated with the maintenance of a reactive state during chronic inflammation in the tumor microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d6d5467603d5e7f345ebab9e29b096e00e701725" target='_blank'>
              Macrophages regulate PD-1 and CTLA-4 expression on ILC2s and their responsiveness in the tumor microenvironment
              </a>
            </td>
          <td>
            Cecilia Ciancaglini, Silvia Santopolo, Stefania Martini, F. Scordamaglia, Giuseppe Pietropaolo, Mattia Laffranchi, G. Sciumè, Guido Ferlazzo, P. Vacca, Lorenzo Moretta, L. Quatrini
          </td>
          <td>2025-09-24</td>
          <td>Cellular and Molecular Immunology</td>
          <td>1</td>
          <td>45</td>
        </tr>

        <tr id="Cancer remains a leading cause of mortality worldwide, with rising incidence and death rates continuing to rise. While conventional treatments such as surgery, radiotherapy, and chemotherapy form the backbone of cancer care, they are often limited by adverse effects, recurrence risk, and incomplete tumor eradication. Tumor immunotherapy—particularly immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapy—has emerged as a transformative approach by activating and reprogramming anti-tumor immune responses. Despite these advances, significant challenges persist, including limited response rates to checkpoint inhibitors, the immunosuppressive nature of the tumor microenvironment (TME), and resistance mechanisms employed by tumor cells. Growing evidence suggests that immune cell senescence is a critical contributor to TME-driven immunosuppression. Senescent immune cells exhibit functional decline, elevated expression of inhibitory immune checkpoint molecules, and increased secretion of pro-inflammatory cytokines, collectively impairing anti-tumor immunity and reducing the efficacy of immunotherapy. This review highlights the role of immune cell senescence in shaping the immunosuppressive TME and driving resistance to immunotherapy. It further discusses emerging therapeutic strategies that combine immunotherapy with senescence-targeting interventions, aiming to provide novel insights into the development of more effective cancer treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56cdaa455cdfae646c5bce11b54ada6d03f2699c" target='_blank'>
              Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance
              </a>
            </td>
          <td>
            Duolun Gao, Peiyan Kan, Yanjie He, Siyu Sun, Lei Tang, Fan Yang
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/786ef752b978a035a89ee81980fbcbdfae5e26b6" target='_blank'>
              Platelet-Mediated Suppression of T Cell Function Drives Immune Evasion in Triple Negative Breast Cancer through the P-Selectin / P-Selectin glycoprotein ligand-1 Pathway
              </a>
            </td>
          <td>
            Margaret R. Smith-Oliver, Deepa Gautam, Emily M. Clarke, Grace Petrarca, Megan Sullivan, Giovanni Goggi, M. Spasic, Natalie Kane, Harvey G. Roweth, A. Garrido-Castro, Patricia E. Davenport, Joanna Baginska, Sandra S. McAllister, E. Battinelli
          </td>
          <td>2025-09-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Background/Objectives: Whilst adoptive cell therapy (ACT) using chimeric antigen receptor-engineered T (CAR-T) cells represents an efficient approach for the treatment of patients suffering from several hematological malignancies, solid tumors have been shown to be far more challenging to tackle, mainly due to the hostile tumor microenvironment that inhibits optimal T cell functionality. As proven by the broad clinical success of immune checkpoint inhibitors, blocking the interaction of programmed cell death ligand 1 (PD-L1) expressed on tumor cells and the checkpoint receptor programmed cell death 1 (PD-1) expressed on activated T cells allows an intrinsic T cell-mediated anti-tumor response to be unleashed. We developed a cellular product (MDG1015) consisting of New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/L antigen family member 1a (LAGE-1a)-specific CD8+ T cell receptor-transduced (TCR-)T cells co-expressing the costimulatory switch protein (CSP) PD1-41BB, which turns an inhibitory signal mediated by the PD-1:PD-L1 axis into positive T cell costimulation. Methods: In vitro co-cultures of MDG1015 and PD-L1-positive or -negative target cells were used to analyze TCR-T cell functionality, such as TCR-T (poly-)cytokine release, the killing of target cells, and TCR-T proliferation. The safety of MDG1015 was evaluated via different panels of antigen-negative cell lines or primary cells expressing or lacking PD-L1. Results: Preclinical analyses demonstrated TCR-gated activation of the CSP, leading to enhanced functionality of MDG1015 against antigen-expressing, PD-L1-positive tumor cells without any impact on antigen-negative target cells. Conclusions: The favorable, preclinical functionality and safety profile qualifies MDG1015 as a promising cellular therapy for explorative clinical testing in hard-to-treat solid tumor indications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0061d8fd9c6ec9b1979ffcc32d15a525ae895b20" target='_blank'>
              Preclinical Development of Costimulatory Switch Protein (CSP)-Armored NY-ESO-1/LAGE-1a-Specific TCR-T Cells for Therapy of Hard-to-Treat PD-L1-Positive Solid Tumors
              </a>
            </td>
          <td>
            M. Bürdek, Petra U. Prinz, Katrin Mutze, Miriam Bosch, S. Tippmer, A. Coluccio, C. Geiger, Snigdha Majumder, G. Longinotti, Dolores J. Schendel
          </td>
          <td>2025-09-26</td>
          <td>International Journal of Translational Medicine</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Background Combining chemotherapy with anti-programmed cell death protein-1 (PD-1) improves clinical outcomes in oesophageal squamous cell carcinoma (ESCC), yet the underlying synergistic mechanism remains obscured. Moreover, 30–50% of patients still derive no therapeutic benefit from the combination strategy, highlighting the need to decipher and overcome resistance. Objective We sought to investigate the mechanisms by which chemotherapy augments the responses to immune checkpoint blockade and elucidate the factors contributing to persistent resistance in non-responding patients. Design We designed a systematic investigation involving longitudinal sampling of ESCC tissues both from patients treated with chemotherapy plus anti-PD-1 and anti-PD-1 monotherapy. The tumour microenvironment (TME) was then comprehensively characterised using single-cell transcriptomics, T cell receptor repertoire analysis, multiplex immunohistochemistry and murine models. Results We demonstrated that combination therapy exerted superior antitumour efficacy by mitigating immune checkpoint engagements (TIGIT-NECTIN2 and NECTIN1-CD96) between epithelial-stress tumour cells and CD8+ T cells, thereby preventing T cells from exhaustion and boosting vitality. In non-responders, we identified a subset of tumour cells with high SLC1A3 expression, which localised at the tumour boundary and interacted with COL1A1+ myofibroblastic cancer-associated fibroblasts, inducing an extracellular matrix-enriched TME that hindered the infiltration of CD8+ T cells. Inhibiting SLC1A3 significantly enhanced the efficacy of chemotherapy plus anti-PD-1, underscoring its potential as a therapeutic target. Conclusion This study elucidates the synergistic mechanisms and identifies key resistance pathways underlying chemo-immunotherapy combinations in patients with ESCC, providing a scientific basis for refining future combination therapeutic regimens.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6499f1de5fd4e40b0e29e55c9717b0471e592e12" target='_blank'>
              Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma
              </a>
            </td>
          <td>
            Shu-Jing Xiang, Yanxing Chen, Chaoye Wang, Min Wang, Ye-Mei He, Zhichao Liu, Jin-Ling Zhang, Lu-Ping Yang, Yun-Fu Wei, Qi-Nian Wu, Zi-Xian Wang, Shao-Yan Xi, Zhigang Li, Qi Zhao, Rui-Hua Xu, Feng Wang
          </td>
          <td>2025-09-22</td>
          <td>Gut</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb0d181b971ab9d5141b1475ee18608b8080d802" target='_blank'>
              Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors
              </a>
            </td>
          <td>
            Md. Iftehimul, Robert H. Newman, Scott H Harrison, Roshonda B. Jones, P. Muganda, Bryan L. Holloman, M. T. Hossain, C. J. Rorie, Misty D. Thomas, Joseph L. Graves, H. Kaufman, Dipongkor Saha
          </td>
          <td>2025-10-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Background The tolerization of plasmacytoid dendritic cells (pDCs) within the tumor microenvironment facilitates immune evasion, thereby significantly limiting the efficacy of cancer immunotherapy. Metabolic regulators are crucial in determining immune cell fate. However, the specific metabolic modifications influencing tumor-associated pDCs (TA-pDCs) are largely uncharacterized. Methods We isolated TA-pDCs from patients with colon cancer and mouse models for RNA sequencing detection and immunofluorescence staining. Further, in vitro and in vivo models of colon cancer were used to explore the underlying mechanisms of the fatty acid oxidation (FAO) regulatory pathway of TA-pDCs and its immunosuppressive function. Results Peroxisome proliferator-activated receptor gamma pathway promotes FAO in TA-pDCs by upregulating the expression of carnitine palmitoyltransferase-1A (CPT1A). The inhibition of CPT1A significantly reduced the immunosuppressive checkpoint inducible co-stimulator ligand (ICOSL) and increased the levels of the immune-activating protein OX40L and pro-inflammatory cytokines interferon-α and tumor necrosis factor-α. These alterations enhanced CD8+ T-cell functionality and diminished the generation of regulatory T cells, thereby bolstering antitumor immunity. The efficacy of combined immunotherapy using anti-ICOSL and anti-programmed cell death 1-ligand 1 antibodies was markedly improved in murine models of colon cancer. Conclusions These findings elucidate the molecular mechanism of CPT1A-mediated FAO in TA-pDCs and its implications in immune evasion, suggesting a novel therapeutic strategy for colon cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6dd26361bcb4cdeceefec09bd4907a4fee0847a" target='_blank'>
              CPT1A inhibition alleviates plasmacytoid dendritic cell-mediated immune suppression in colon cancer through fatty acid oxidation modulation
              </a>
            </td>
          <td>
            Jing Wu, Shan Zhu, Guoxia Zang, Helei Wang, Ning Yang, Yuan Qiao, Qiuyu Wei, Liyan Wang, Ziyu Ren, Yong-Jun Liu, Jingtao Chen
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d873cf1a853679b8699fa77326e1c8cf526550ab" target='_blank'>
              Intestinal challenges shape the polarisation of protective dural memory CD4 T cells
              </a>
            </td>
          <td>
            Aaron Fleming, Rafael Di Marco-Barros, David A. Posner, C. Lee, Andrew P. Stewart, Z. Tuong, Karen Neish, Ana Ivis Peñalver, Mia Cabantous, N. Richoz, A. Portet, K. Harcourt, Eleanor Gillman, David Ruano-Gallego, Gad Frankel, David R. Withers, Simon Clare, M. Clatworthy
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Cold tumors, defined by insufficient immune cell infiltration and a highly immunosuppressive tumor microenvironment (TME), exhibit limited responsiveness to conventional immunotherapies. This review systematically summarizes the mechanisms of immune evasion and the therapeutic strategies for cold tumors as revealed by multi-omics technologies. By integrating genomic, transcriptomic, proteomic, metabolomic, and spatial multi-omics data, the review elucidates key immune evasion mechanisms, including activation of the WNT/β-catenin pathway, transforming growth factor-β (TGF-β)–mediated immunosuppression, metabolic reprogramming (e.g., lactate accumulation), and aberrant expression of immune checkpoint molecules. Furthermore, this review proposes multi-dimensional therapeutic strategies, such as targeting immunosuppressive pathways (e.g., programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors combined with TGF-β blockade), reshaping the TME through chemokine-based therapies, oncolytic viruses, and vascular normalization, and metabolic interventions (e.g., inhibition of lactate dehydrogenase A (LDHA) or glutaminase (GLS)). In addition, personalized neoantigen vaccines and engineered cell therapies (e.g., T cell receptor-engineered T (TCR-T) and natural killer (NK) cells) show promising potential. Emerging evidence also highlights the role of epigenetic regulation (e.g., histone deacetylase (HDAC) inhibitors) and N6-Methyladenosine (m6A) RNA modifications in reversing immune evasion. Despite the promising insights offered by multi-omics integration in guiding precision immunotherapy, challenges remain in clinical translation, including data heterogeneity, target-specific toxicity, and limitations in preclinical models. Future efforts should focus on coupling dynamic multi-omics technologies with intelligent therapeutic design to convert cold tumors into immunologically active (“hot”) microenvironments, ultimately facilitating breakthroughs in personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f521c611e55896b93cee504ac14c36afaf25953" target='_blank'>
              Igniting Cold Tumors: Multi-Omics-Driven Strategies to Overcome Immune Evasion and Restore Immune Surveillance
              </a>
            </td>
          <td>
            Xinyao Huang, Renjun Gu, Ziyu Li, Fangyu Wang
          </td>
          <td>2025-09-26</td>
          <td>Oncology Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Ankylosing spondylitis (AS) is a chronic immune‐mediated disease marked by sustained joint inflammation and aberrant bone remodelling. Although chronic antigen exposure usually enforces terminal exhaustion, emerging evidence indicates that a subset of CD8+ T cells in AS evades canonical exhaustion programmes while expressing programmed cell death protein 1 (PD‐1). These exhaustion‐resistant cells retain effector function and likely contribute to persistent tissue inflammation and structural damage. In this review, we dissect the cellular and molecular basis of exhaustion resistance in AS CD8+ T cells and focus on the convergence of intermittent T cell receptor (TCR) stimulation, metabolic adaptation that preserves mitochondrial fitness, and co‐stimulatory inputs from interleukin‐15 (IL‐15) and CD28. We propose an integrated three‐axis model governing CD8+ T cell fate and functional persistence in the AS context shaped by human leukocyte antigen‐B27 (HLA‐B27) and the gut–joint axis. Clarifying these mechanisms refines current views of T cell dysfunction in chronic inflammation and highlights therapeutic strategies aimed at reprogramming pathogenic immunity in AS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bcc208ede076a40cec13cb8b2e4d04e77729e53d" target='_blank'>
              Exhaustion‐Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three‐Axis Model
              </a>
            </td>
          <td>
            Xuhong Zhang, Lu Jia, Xueni Lin, Lamei Zhou
          </td>
          <td>2025-10-02</td>
          <td>Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Pathologic T cell-B cell interactions drive disease in systemic lupus erythematosus (SLE). The T cells that activate B cell responses include T peripheral helper (Tph) and T follicular helper (Tfh) cells, yet the developmental and clonal relationships between these B cell-helper T cell populations are unclear. Here we use T cell receptor (TCR) profiling to demonstrate substantial clonal overlap between Tph and Tfh cells in the circulation of patients with SLE. Expanded Tph and Tfh cell clones persist over the course of 1 year in patients with a new diagnosis of SLE, and clones are observed to shift both from Tfh to Tph cells and from Tph to Tfh cells over time. High resolution analysis of cells sorted as Tph cells (CXCR5− PD-1hi) from SLE patients revealed considerable heterogeneity among these cells and highlighted a subpopulation of cells with transcriptomic features of activated B cell-helper T cells. This cell population, marked by expression of TOX and CXCL13, was found in both sorted Tph and Tfh cells, and was clonally linked in these two populations. Analysis of B cell-helper T cells in murine pristane-induced lupus demonstrated similar populations of Tph and Tfh cells in both lung and spleen with strong clonal overlap. T cell-specific loss of Bcl6 prevented accumulation of Tfh cells and reduced accumulation of Tph cells in pristane-treated mice, indicating a role for Bcl6 in the survival and expansion of both populations. Together, these observations demonstrate a shared developmental path among pathologically expanded Tph and Tfh cells in SLE. The persistence of expanded Tph and Tfh cells clones over time may explain the lack of stable tolerance induction by immunosuppressive medications or by B cell depletion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6c7fe89148ab8005aeda1da56a66e78633625d4" target='_blank'>
              Clonal relationships between Tph and Tfh cells in patients with SLE and in murine lupus
              </a>
            </td>
          <td>
            Deepak A. Rao, Takanori Sasaki, John Sowerby, Yinan Xiao, Runci Wang, Snigdha Samarpita, Tatsuki Abe, K. Marks, Alice Horisberger, Yidan Gao, Pui Lee, Yujie Qu, Marc A. Sze, Stephen E. Alves, Marc C. Levesque, Keishi Fujio, Karen H Costenbader, Peter T. Sage
          </td>
          <td>2025-09-12</td>
          <td>Research Square</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="ABSTRACT Introduction Hepatocellular carcinoma (HCC) is a major cause of cancer-related death globally, characterized by an immunosuppressive tumor microenvironment (TME) that impairs immune surveillance. Immunotherapy has emerged as a transformative option; however, durable responses remain limited. The purpose of this review is to synthesize recent advances in HCC immunology, immunotherapy, and the TME. Areas Covered Literature was identified via PubMed and ClinicalTrials.gov (January 2001–May 2025), focusing on clinical and translational studies. We outline the immunological landscape of HCC, emphasizing the roles of T cells, natural killer cells, macrophages, dendritic cells, myeloid-derived suppressor cells, and regulatory T cells in shaping tumor immunity. TME components include cancer-associated fibroblasts, tumor-associated macrophages, suppressive cytokines, angiogenesis, hypoxia, metabolic reprogramming, and the gut-liver axis. Interactions with immunotherapy, mechanisms of resistance, and combination strategies were described. Emerging biomarkers – such as tertiary lymphoid structures, PD-L1, tumor mutational burden, gene signatures, and gut microbiota – are reviewed relative to patient stratification. Expert Opinion Immunotherapy has reshaped HCC management, but resistance, biomarker limitations, and heterogeneity remain major challenges. Advances will require TME reprogramming, multi-parametric biomarkers, and personalized strategies. Integration with targeted and locoregional approaches may achieve durable responses and move toward precision immuno-oncology, transforming HCC into a manageable or curable disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f81fb97115d4549912d0ac1a8a271a719cc8ad4" target='_blank'>
              Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: a comprehensive review
              </a>
            </td>
          <td>
            Miho Akabane, Yuki Imaoka, Ghee Rye Lee, T. Pawlik
          </td>
          <td>2025-09-29</td>
          <td>Expert Review of Clinical Immunology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Innate lymphoid cells (ILCs) are tissue-resident lymphocytes specialized in cytokine secretion that lack antigen-specific receptors. The contribution of ILCs to antiviral mucosal immunity in humans, particularly in the female genital tract (FGT), remains unexplored. Here we resolved human FGT ILC diversity by spectral flow cytometry and CITE-seq, spatial location within genital anatomical regions using ChipCytometry, and determined homeostatic function and antiviral responses. We uncovered spatial and functional specializations of genital ILC subsets under homeostasis, with compartmentalized age-related and pregnancy-related changes. CD161 expression differentially discriminated ILC subsets preloaded with cytokines at steady state. We identified a unique NKp44+CCR6+ ILC3 subset in the endometrium that actively degranulated at homeostasis and was located in lymphoid aggregates surrounded by B cells and T cells. By contrast, ILC1s were found scattered, enriched in the ectocervix and located close to the epithelium. Following in vitro HIV stimulation, genital ILCs displayed rapid subset-specific antiviral responses. These findings reveal distinct tissue and subset-specific features of FGT ILCs and their capacity to immediately respond to viral stimuli, providing a foundation for future studies to determine the potential role of ILCs in mucosal immune protection in the FGT. The authors spatially and functionally map innate lymphoid cells in the human female genital tract at homeostasis, uncovering tissue-specific and subset-specific distribution and functions, and rapid antiviral responses following HIV exposure.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d03715a8f07fa91481c2c31ff5ec2c676c366a9" target='_blank'>
              Spatial and functional diversity of innate lymphoid cells in the human female genital tract may contribute to antiviral responses to HIV
              </a>
            </td>
          <td>
            Alexandra E. Werner, Laura Moreno de Lara, Aleah Holmes, Siddharth Parthasarathy, Genna E. Moldovan, Anna Borchers, Francisco J Carrillo-Salinas, Jared M. Fortier, Vidya Iyer, Alison Vogell, Rebecca Jameson, Jacquelyn E. Stephens, Marta Rodriguez-Garcia
          </td>
          <td>2025-09-22</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="The lack of a favorable tumor immune microenvironment (TIME) results in limited response rates to immune checkpoint blockade (ICB) across human solid tumors, necessitating the development of novel combination strategies. In this study, we repurposed FK228, an US FDA-approved histone deacetylase inhibitor that is used clinically in non-solid tumor treatment, as a novel ICB sensitizer in solid tumors and revealed the diverse regulatory functions of FK228 in the TIME. FK228 serves as a novel necroptosis inducer in cancer cells by triggering endoplasmic reticulum stress. This in turn enhances the immunogenicity of cancer cells and increases the infiltration of tumor-killing immunocytes, including CD8+ T and natural killer cells, particularly activating tumor-infiltrated CD8+ T cells. Meanwhile, FK228 treatment shifts macrophages toward the pro-inflammatory phenotype. Moreover, the combined use of FK228 and a PD-L1 inhibitor significantly delay tumor growth and extend the survival of tumor bearing mice. Overall, our findings reveal new possibilities for the clinical application of FK228 in solid tumors and underscore the critical role of histone deacetylases in maintaining the immune-unfavorable TIME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85df6cdfef58879f77c94850344337149a493788" target='_blank'>
              FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy
              </a>
            </td>
          <td>
            Liang Gong, Lu Tian, He Li, Kexuan Zhou, Haocheng He, Shuai Xiao, Yizhun Zhu, Zhicheng Gong, Kaisa Cui, Youming Zhang
          </td>
          <td>2025-09-12</td>
          <td>Oncogene</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Abstract Background Mounting evidence shows that myeloid‐derived suppressor cells (MDSCs) reprogramming can significantly enhance the outcomes of immunotherapy. However, the therapeutic potential of targeting MDSCs alone is limited by persistent immunosuppressive cytokines and cellular crosstalk. In our previous study, we found that novel cryo‐thermal therapy (CTT) can drive MDSCs maturation and induce CD4+ T helper type (Th)1‐dominant differentiation, improving long‐term survival in spontaneous high metastatic mouse models. Considering the established roles of Interleukin (IL)‐6 and IL‐17A in non‐small cell lung cancer (NSCLC) progression and immune evasion, we developed a combination strategy integrating cytokine neutralization with CTT (combination therapy) in LLC1 tumor‐bearing mice. Although the combination therapy successfully promoted MDSCs maturation and Th1 differentiation, the underlying mechanistic basis remained unclear. Methods The combination therapy was implemented in LLC1 tumor‐bearing mice. We then observed its impacts on MDSCs maturation and Th1 differentiation and explored the related mechanisms by examining various aspects including the expression of CD40, the reactive oxygen species (ROS)‐nuclear factor‐kappa B (NF‐κB) pathway, and the induction of tumor necrosis factor‐α (TNF‐α). Results It was observed that the combination therapy increased the expression of CD40 on MDSCs through the ROS‐NF‐κB pathway‐dependent TNF‐α induction. This TNF‐α‐mediated CD40 upregulation facilitated Th1 polarization via CD40L engagement on CD4+ T cells. Our results provided the first mechanistic evidence that autocrine TNF‐α production by reprogrammed MDSCs governs CD40 expression following combination therapy. Conclusion Our research elucidated the methods and mechanisms of MDSCs reprogramming and offered a promising therapeutic strategy for patients with NSCLC and other types of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b5c584eeb86580107a4b77d49be11b90194d483" target='_blank'>
              Reprogrammed MDSCs promote Th1‐dominant antitumour response via CD40 induced by autocrine TNF‐α after combining cryo‐thermal therapy with IL6 and IL17A neutralization
              </a>
            </td>
          <td>
            Yuankai Hao, Shicheng Wang, Junjun Wang, Zelun Zhang, Yichen Yao, Ke-fu Wang, Ping Liu, Lisa X. Xu
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3651c50a8e2062accc65992142e066db9d98b287" target='_blank'>
              TET2 loss impairs MPLA-induced innate immune memory during infection and disrupts hematopoiesis via RIPK1 in mice
              </a>
            </td>
          <td>
            Alyssa N. L. Jarabek, Xenia D. Davis, Mary A. Oliver, Yongchao Wang, Heidi Chen, Julia K. Bohannon, Sandra S. Zinkel
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="ABSTRACT Background Multiple sclerosis (MS) is an autoimmune disorder driven by myelin autoantigen–specific autoreactive T cells, yet the most effective disease-modifying therapies (DMTs) target B cells. The mechanism underlying this paradox remains unclear. Here, we identify dual-expressor cells (DEs) -a novel lymphocyte population with hybrid T and B cell characteristics, including co-expression of the T cell receptors (TCRαβ) and surface B cell receptors (BCRs), primarily IgM—as potential contributors to MS pathogenesis and inadvertent targets of anti-CD20 DMTs. Methods DEs were examined in the peripheral blood and cerebrospinal fluid (CSF) of patients with relapsing-remitting MS (RRMS) compared to healthy controls. Their phenotype and functional properties were characterized, including responses to myelin autoantigens and susceptibility to depletion in a pilot cohort of seven RRMS patients treated with ocrelizumab. Results DEs were found at significantly higher frequencies in the peripheral blood of patients with RRMS compared to healthy controls and were further enriched in CSF, where up to 95% expressed CD20, versus ~60% in blood. Furthermore, most of DEs in CSF express CXCR3, indicating involvement of CXCR3-CCL-9, 10 and 11 in their recruiting and maintenance in the CSF of MS patients. Functionally, DEs exhibited robust responses to myelin autoantigens, supporting their relevance in disease. In a pilot cohort of seven RRMS patients, ocrelizumab significantly reduced circulating DE frequencies, confirming their susceptibility to CD20-mediated depletion. Conclusions These findings implicate DEs in MS and provide insight into the efficacy of anti-CD20 therapies in a traditionally T cell–driven disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b7959ad94aaedcb849cc967f8641003a8e42184d" target='_blank'>
              Myelin-Reactive TCR/IgM Dual-Expresser Lymphocytes in Multiple Sclerosis: Linking Pathogenesis to Anti-CD20 Therapy
              </a>
            </td>
          <td>
            Prajita Paul, Marjan Behzadirad, Rafid Al Hallaf, Susana C. Dominguez-Peñuela, Carlos A Pardo, Chunfa Jie, B. Nourbakhsh, A. R. A. Hamad
          </td>
          <td>2025-09-17</td>
          <td>Immunological Investigations</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f4351e4631d8211b190a8d6ec360061e187ffa46" target='_blank'>
              Convection-enhanced delivery of dexamethasone in glioma suppresses myeloid inflammation while avoiding systemic toxicities
              </a>
            </td>
          <td>
            Nathaniel W Rolfe, Nicholas B Dadario, Liang Lei, Damian E Teasley, Misha Amini, Peter J Chabot, Nkechime Ifediora, Nathan J Winans, N. Yoh, Anthony Tang, Nadine Khoury, J. Furnari, Corina P Kotidis, Clara H Stucke, Nivia M Urena, Yanping Sun, Pavan S. Upadhyayula, Michael G. Argenziano, Colin P. Sperring, Abby Brand, Ashwin Viswanathan, N. Humala, Peter A. Sims, B. Gill, Peter D Canoll, Jeffrey N. Bruce
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Ovarian cancer represents a typically immune “cold” tumor, where obvious immunosuppression, spatial T-cell exclusion, and cellular dysfunction collectively limit immunotherapy effectiveness. Especially in high-grade serous ovarian carcinoma (HGSOC), the immune low-response state is driven by complex interactions among tumor-associated macrophages (TAMs), suppressive stromal networks, and the T-cell compartment (regulatory T cells, Tregs, and exhausted effector T cells). Emerging multi-omics technologies—particularly single-cell RNA sequencing and spatial transcriptomics—have showed the heterogeneity and spatial immune organization underlying this suppressed state. Here, we integrate these datasets to describe TAM phenotypes and spatial niches, T-cell exhaustion, Tregs accumulation, NK-cell dysfunction, and stromal barriers that enforce exclusion. We then derive phenotype-guided combination strategies to remodel the tumor microenvironment and improve responsiveness to immune checkpoint blockade. This synthesis provides a concise, multi-dimensional framework for precision immunotherapy and for overcoming resistance in immune-low ovarian cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/880f6c405f773eb38fd078c68256074438417fa2" target='_blank'>
              Decoding immune low-response states in ovarian cancer: insights from single-cell and spatial transcriptomics for precision immunotherapy
              </a>
            </td>
          <td>
            Yalan Yan, Jiaan Lu, Huanyu Luo, Zizhang Wang, Ke Xu, Lexin Wang, Qin Wang
          </td>
          <td>2025-09-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Macrophages, the most abundant immune cells in many solid tumors, are no longer viewed solely as accomplices of cancer but as powerful therapeutic allies. This review charts the rapid rise of macrophage-based immunotherapies, from CD47/SIRPα checkpoint blockade and CAR-macrophages to macrophage-drug conjugates (MDCs). We emphasize emerging frontiers - RNA-based reprogramming, epigenetic modulation, small activating RNA and circRNA approaches, and macrophage-derived extracellular vesicles - that are redefining how tumor-associated macrophages can be targeted or harnessed. Distinct from earlier TAM reviews, we integrate outcomes from ongoing and completed clinical trials, highlight therapeutic platforms beyond classical depletion and polarization, and frame macrophages not only as targets but also as delivery vehicles. By spotlighting both innovative strategies and the challenges of moving them into the clinic, we aim to provide a forward-looking guide for researchers and clinicians shaping the next generation of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4428b6586c89846cb3b8b68bdea944ac3933e4e6" target='_blank'>
              Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances
              </a>
            </td>
          <td>
            Jan Brancewicz, P. Kucharzewska
          </td>
          <td>2025-10-02</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related death worldwide. Despite the success of immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1 pathways, a significant number of patients exhibit either primary resistance or acquire resistance over time. While genomic and epigenetic mechanisms contribute to this resistance, increasing evidence points to the pivotal role of immunometabolism—the interface of cellular metabolism and immune regulation. This review focuses on how altered metabolic states in both immune cells and cancer stem-like cells (CSCs) within the lung tumor microenvironment contribute to ICI resistance. We discuss key metabolic pathways involved in immune suppression, the metabolic plasticity of CSCs, and how these factors interact to shape a metabolically hostile tumor niche for immune effector cells. Finally, we explore emerging therapeutic strategies targeting immunometabolism to enhance immunotherapy efficacy in lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1ff0a30d0ef98d677493dbe8ab0f277a0639e63e" target='_blank'>
              Immunometabolic reprogramming in lung cancer: interplay between immune and stem-like cells in immune checkpoint inhibitor resistance
              </a>
            </td>
          <td>
            Ji-Yong Sung, Eui Tae Kim
          </td>
          <td>2025-10-29</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Background/Objectives: Colorectal cancer (CRC) remains a major global health challenge and current therapies are not always effective. In addition, certain immune cell populations, such as myeloid-derived suppressor cells (MDSCs), pose a significant barrier to immune-based treatments. Some phytochemicals, particularly compounds derived from Allium spp. like Propyl-Propane Thiosulfonate (PTSO), have shown strong immunomodulatory potential in digestive disorders. This study aims to investigate the capacity of PTSO to modulate immune responses and affect tumor progression in CRC models, in vitro and in vivo, with a focus on the immune cell populations that comprise the tumor microenvironment. Methods: Human peripheral blood mononuclear cells (hPBMCs) were incubated with PTSO (25 μM for 48 h) and characterized by flow cytometry. These cells (1 × 106) were then injected into NOD scid gamma (NSG) immunodeficient mice, which were simultaneously induced to develop a subcutaneous tumor by injection of HCT116 enriched cancer stem cells (CSCs) colonospheres (60,000 cells/mouse). Results: PTSO reduced MDSC populations, specifically, it significantly reduced monocytic (M-MDSCs, Control: 7.27 ± 0.53% vs. PTSO: 4.70 ± 2.39%; p = 0.0458) and polymorphonuclear (PMN-MDSCs, Control: 5.28 ± 0.99% vs. PTSO: 3.41 ± 1.58%; p = 0.0385) MDSCs. In parallel, PTSO increased T cell subpopulations, particularly interferon gamma (IFNG)-producing cytotoxic CD8+ T cells (Control: 9.52 ± 2.06% vs. PTSO: 15.04 ± 5.01%; p = 0.0685). In the humanized tumor xenograft mouse, the administration of PTSO-pretreated hPBMCs led to a significant reduction in tumor size (Control: 1.43 ± 0.82 cm3 vs. PTSO: 0.44 ± 0.35 cm3; p = 0.0068), accompanied by increased infiltration of CD4+ T lymphocytes and Natural Killer (NK) cells and downregulation of immunosuppressive genes. These effects resulted in a reduction in cancer cell proliferation and invasiveness. Conclusions: The dual effect of PTSO on immune cell populations, reducing immunosuppressive myeloid cells and enhancing effector T lymphocyte and NK cell responses, resulted in an anti-tumor effect, highlighting this bioactive compound as a promising adjuvant in CRC immunotherapy and opening avenues for future research combining immunotherapy with PTSO in alternative models to optimize dosing and enhance translational potential.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f1b9d6e925feb9fc117d019b92795dc3113b3db0" target='_blank'>
              Modulation of Human Immune Cells by Propyl-Propane Thiosulfonate (PTSO) Inhibits Colorectal Tumor Progression in a Humanized Mouse Model
              </a>
            </td>
          <td>
            María Jesús Rodríguez-Sojo, Luckman Gbati, José Alberto Molina-Tijeras, A. Ho‐Plagaro, T. Vezza, Laura López-Escánez, C. Griñán-Lisón, J. A. Marchal, A. Baños, María José Rodríguez-Sánchez, Jorge García-García, A. Ruiz-Malagón, Julio Gálvez, M. E. Rodríguez-Cabezas, A. Rodríguez‐Nogales
          </td>
          <td>2025-09-01</td>
          <td>Nutrients</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="Introduction Tumor-associated macrophages (TAMs) promote immunosuppression, hindering immune checkpoint blockade and immunotherapy efficacy. To overcome this, we developed a novel multifunctional nanovaccine based on hepatitis B core virus-like particles (HBc VLP) to synergistically remodel the immunosuppressive tumor microenvironment through integrated TAM reprogramming and B7-H3 checkpoint blockade. Methods The core VLP co-displayed tumor antigen peptide MAGE-A10 and TAM-targeting peptide M2pep via fusion expression. Immunostimulatory CpG oligodeoxynucleotide 1826 (CpG) was encapsulated within VLP. Anti-B7-H3 antibody (αB7-H3) and polyethylene glycol (PEG) were chemically conjugated to the surface for checkpoint blockade and prolonged circulation, forming CpG@VLP-αB7-H3-PEG. Results Structural characterization using transmission electron microscopy and dynamic light scattering confirmed the hollow spherical self-assembly of VLP. Nanovaccines efficiently targeted TAMs in vitro and in vivo. Following CpG encapsulation (5.60 µg/mg), the nanovaccine reprogrammed M2-like TAMs into an M1-like phenotype. This was achieved by elevating the M1/M2 ratios of CD86/CD206 and MHC II/CD206 to 15.50-fold and 3.11-fold, respectively, as determined by flow cytometry. Further conjugation of αB7-H3 (250 µg/mg) significantly enhanced T-cell activation in TAM-T cell co-culture assays. In B16-F10 melanoma-bearing mice, reprogrammed iNOS+ M1-like macrophages triggered robust antitumor immunity, achieving a tumor inhibition rate of 63.47%. These macrophages also function as antigen-presenting cells and increase the proportion of tumor-infiltrating Granzyme B+CD8+ T cells. αB7-H3 conjugation further boosted infiltrating immune cells, M1-like macrophages, activated CD69+CD4+/CD8+ T cells, and cytotoxic T lymphocytes. PEGylation amplified systemic tumor-specific immunity and increased tumor inhibition by 80.12%. Conclusion This HBc VLP-based nanovaccine constitutes a pioneering multifunctional platform designed to overcome TAM-mediated immunosuppression through synergistic integration of three modalities: antigen presentation, TAM phenotype reprogramming, and B7-H3 checkpoint blockade. To the best of our knowledge, this is the first nanovaccine architecture to enable coordinated immunomodulation. Its modular design supports the clinical translation of solid tumors and personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b26fad415e7667975cc7d27803dcdbb589e0756" target='_blank'>
              Multifunctional HBc Virus-Like Particles Reprogram Immunosuppressive Macrophages and Potentiate CD8+ T Cell Responses for Enhanced Cancer Immunotherapy
              </a>
            </td>
          <td>
            Shuntao Liang, Xiaoxuan Yin, Yongjie Chi, Keyue Wang, Li Ma, Zhuo Yang, X. Xue, Shoucheng Wang, K. Zhao, Lianyan Wang, Juan Ma
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="ABSTRACT Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Macrophages are highly plastic immune cells that adopt diverse functional states in response to the local microenvironment. The traditional M1/M2 polarization model that has long been used to describe macrophage activation is insufficient to capture the full spectrum of macrophage diversity observed in vivo. Advances in single-cell RNA sequencing (scRNA-seq) have revealed that macrophages exist in a continuum of transcriptional states formed by tissue-specific and disorder-specific cues. This insight has led to the recognition of disorder-specific macrophages, defined as macrophage subpopulations that emerge in response to pathological stimuli and play unique roles in disease progression. These macrophages exhibit distinct transcriptional signatures, epigenetic modifications, and functional properties shaped by their ontogeny and microenvironmental signals, arising from the reprogramming of resident macrophages or the differentiation of bone marrow–derived progenitors. Notable examples include macrophages in chronic infections (e.g., tuberculosis), immunosuppressive tumor-associated macrophages, lipid-associated macrophages in obesity, and disease-associated microglia in neurodegeneration. These subsets exhibit unique regulatory mechanisms, including enhancer remodeling driven by histone H3 lysine 27 acetylation in non-alcoholic steatohepatitis, CCAAT enhancer binding protein α-mediated differentiation in obesity, and Jmjd3-IRF4 axis control in allergic inflammation. Additionally, their function and fate are strongly influenced by their subtissular niche, as evidenced by crown-like structures in adipose tissue, tumor microenvironments, fibrotic lesions, and granulomas, where distinct microenvironmental cues shape macrophage behavior. Furthermore, interindividual heterogeneity in macrophage function, driven by genetic polymorphisms, is increasingly recognized, highlighting the role of host genetic background in disease susceptibility and macrophage-driven pathology. Here, we review the conceptual evolution of the disorder-specific macrophage, tracing its origins from the limited M1/M2 model to its refinement through scRNA-seq-based classification. We summarize the ontogeny, transcriptional regulation, and spatial heterogeneity of these macrophages across various disorders, emphasizing how the subtissular niche dictates functional specialization. Finally, we discuss potential therapeutic strategies targeting disorder-specific macrophage subsets, highlighting the need for integrative multi-omics approaches to refine their classification and functional characterization. Understanding the regulatory networks that govern disorder-specific macrophages will advance our knowledge of macrophage biology while facilitating the development of precision medicine for immune-related disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9feef19310b98a25e6e67c81bcaeb9daa262ec04" target='_blank'>
              Functional diversity of disorder-specific macrophages involved in various diseases
              </a>
            </td>
          <td>
            Yuichi Mitsui, Takashi Satoh
          </td>
          <td>2025-10-01</td>
          <td>Inflammation and Regeneration</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Immunotherapy is currently effective in less than half of patients with solid tumors, and most responders develop secondary progression. High infiltration of the tumor microenvironment (TME) with CD8+ cytotoxic T cells (CTLs) and low infiltration with regulatory T cells (Treg) predicts the patients’ responses to immunotherapy and long-term outcomes. To identify the mechanisms regulating long-term stability of CTL infiltration, we analyzed the impact of CTL-produced cytokines on the TME by co-culturing patient-isolated ascites cells with activated T cells. Unexpectedly, we observed that activated CTLs selectively induce cytotoxic T cell-attracting chemokines but not chemokines that attract T regulatory cells in ovarian cancer TME and tumor-associated myeloid cells, resulting in recruitment of additional CTLs without Tregs. This selectivity resulted from the unique dependence of CCL22 induction on both canonical and alternative NF-κB and the suppression of alternative NF-κB signaling by T cell-released IFNγ. Our data demonstrate that T cell-produced IFNγ suppresses alternative NF-κB signaling in TME-associated myeloid cells, allowing for the induction of CTL-attracting chemokines with the concomitant suppression of Treg-attracting CCL22. These novel functions of IFNγ and activated T cells in regulating the balance between canonical and alternative NF-κB signaling in myeloid cells provide new opportunities to enhance and stabilize the selective CTL influx in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5a5a14adab24415a821ab9194596f9d27a53e37" target='_blank'>
              IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells
              </a>
            </td>
          <td>
            Adam Brinkman, Ravikumar Muthuswamy, Bowen Dong, Robert P Edwards, Pawel Kalinski
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e655b3f34a47917eb0c1eab5cc8dbd65bd366140" target='_blank'>
              P2RY2 is a purinergic immune checkpoint linking extracellular ATP to immune evasion and adaptive resistance to immunotherapy
              </a>
            </td>
          <td>
            Zhaoqing Hu, Hitoshi Matsuo, Shangce Du, Cecilia Berzain Battioni, L. Jassowicz, Rafael Carretero, Melanie Sator-Schmitt, Xiyue Zhao, Beiping Miao, Cansu Eris, Helena Engel, Mohamed A.A. Mahmoud, Elke Laport, Yanling Xiao, Ilse Hofmann, Christel Herold-Mende, Chong Sun
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Adoptive T cell therapies (ACT) have revolutionized the management of hematologic malignancies; however, their efficacy in solid tumors remains limited. Accumulating evidence implicates the tumor microenvironment (TME) - a highly complex and immunosuppressive niche as a major barrier to their effectiveness. In this review, we propose that the next generation of ACT will require a fundamental shift from a reductionist focus on T cell engineering alone to an integrated approach that considers the interactions between immune cells and the TME. A comprehensive literature review identified several emerging strategies to enhance the efficacy of ACT, including reprogramming tumor vasculature, repolarizing immunosuppressive myeloid and stromal cells, leveraging oncolytic viruses to remodel antigen presentation, inducing acute sterile inflammation, and targeting the physical properties of the extracellular matrix. While many of these approaches remain in early-stage development, some have already progressed to clinical trials, indicating their potential for clinical translation. Additionally, we found that conventional therapies, such as surgery, chemotherapy, and radiotherapy, can be strategically integrated with ACT to improve therapeutic outcomes. These findings highlight a shift in the field toward more integrative approaches. Future advances will likely depend on reprogramming the TME to support T cell persistence and functions. Addressing these interconnected challenges will require closer collaboration between immunology, oncology, and bioengineering disciplines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5845940292899bbb8a96147c6b79326179c978e6" target='_blank'>
              Reprogramming the tumor microenvironment to boost adoptive T cell therapy
              </a>
            </td>
          <td>
            Maria Fernanda Meza Pacheco, Lee-Hwa Tai
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9df59581d16bbc7c53120355c1f9a6d0a14f9300" target='_blank'>
              The Role of Inflammation in CMML Pathobiology and Progression
              </a>
            </td>
          <td>
            Niraj Neupane, E. Padron
          </td>
          <td>2025-10-09</td>
          <td>Current Hematologic Malignancy Reports</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, frequently arising in the setting of chronic liver inflammation and cirrhosis. Immune checkpoint inhibitors have transformed the treatment landscape for HCC, although response rates remain variable with only a subset of patients deriving durable benefit. The present review provides a comprehensive overview of immune checkpoint biology in HCC, examining their mechanisms of action and their roles within the tumor microenvironment. The present review discusses not only well-established checkpoints (programmed cell death-1 and cytotoxic T-lymphocyte antigen-4) but also emerging inhibitory targets (lymphocyte-activation gene 3, T-cell immunoglobulin and mucin-domain 3, T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains, B and T lymphocyte attenuator, V-domain immunoglobulin suppressor of T-cell activation, B7 homolog 3, B7 homolog 4 and CD47) increasingly recognized in HCC immunology. The clinical implications of checkpoint expression patterns are explored, including their prognostic significance and potential as predictive biomarkers. Current therapeutic strategies are reviewed, from monotherapy approaches to combination regimens involving dual checkpoint blockade and anti-angiogenic agents. Despite recent advances, significant challenges persist, including primary and acquired resistance, the immunosuppressive liver microenvironment and safety concerns in patients with underlying liver dysfunction. Future directions focusing on novel checkpoint targets, innovative combination approaches, personalized cellular therapies and biomarker-driven treatment selection offer potential avenues to improve outcomes for patients with HCC in the future.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8b763ec8ba5df4dabd80400d1c9e55867e7483d0" target='_blank'>
              Immune checkpoint biology in hepatocellular carcinoma (Review)
              </a>
            </td>
          <td>
            Ching-Hua Hsieh, Pei-Chin Chuang
          </td>
          <td>2025-10-07</td>
          <td>Oncology Letters</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Objectives Preclinical models that accurately recapitulate the human immune response, particularly within the tumor microenvironment (TME), are needed for the translational and predictive testing of new therapies. Here, we examine whether the genO-BRGSF-HIS model—characterized by robust reconstitution of both human lymphoid and myeloid cells following engraftment with CD34+ cord blood cells—could be a translatable mouse model for human tumor biology and a relevant platform for evaluating novel immunotherapies. Methods genO-BRGSF mice were reconstituted with human CD34+ cord blood cells (genO-BRGSF-HIS) and treated with exogenous human Flt3 ligand (hFlt3L). Myeloid and dendritic cell functionality was analyzed following treatment with different compounds (TLR agonists, TREM1 agonist, STING agonist, or T-cell engagers) and following the implantation of different tumor cell lines (MDA-MB-231, A549, HPAF-II). Results We show that myeloid, dendritic and lymphoid cells (including NK and γδ T cells) are functional and recruited into the TME in genO-BRGSF-HIS mice implanted with different tumor cell lines, and that different immune cell populations are activated and get polarized within the TME. The composition of the TME is dependent on tumor type and tumor burden, demonstrating plasticity in the crosstalk between the human immune system and the tumor cells. Furthermore, we observed polarization of the cells recruited to the TME, as well as a wide diversity of recruited cell populations, suggesting that this model reproduces human physiopathology in the context of cancer. Based on the recruitment of the different cell populations according to tumor type, we also demonstrate that this model can be used for testing new therapies targeting lymphoid cells, such as T-cell engagers. Conclusions genO-BRGSF-HIS mice do not exhibit adverse effects associated with the development of human lymphoid and myeloid cells following CD34+ cord blood cell reconstitution, and their extended lifespan allows for longer experimental study windows. Overall, we show that this model develops functional myeloid and lymphoid cells which are recruited to the TME, making it a valuable tool for testing new immunotherapies that modulate the interaction between the tumor and the immune system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1662e798082e5fa1dd090b48ee63a699548c1383" target='_blank'>
              Tumor-dependent myeloid and lymphoid cell recruitment in genO-BRGSF-HIS mice: a novel tool for evaluating immunotherapies
              </a>
            </td>
          <td>
            Gaelle H. Martin, Siham Hedir, Florent Creusat, A. Gonon, Amélie Marguier, P. Martin-Jeantet, L. Nouveau, L. Cons, Florence Renart-depontieu, V. Moine, Marc Derive, Yacine Chérifi, Margarida T Grilo Ruivo, F. Sônego, Kader Thiam
          </td>
          <td>2025-09-17</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>19</td>
        </tr>

        <tr id="Autoimmune diseases are driven by a breach of self-tolerance, leading to chronic inflammation and organ damage. While the Th1 and Th17 paradigms have long dominated our understanding of T-cell-mediated pathology, a distinct subset of CD4+ T helper cells defined by the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) has emerged as a central and non-redundant pathogenic driver. These GM-CSF-producing Th cells orchestrate autoimmune pathology across a spectrum of diseases, including multiple sclerosis, rheumatoid arthritis, and type 1 diabetes, among others. Mechanistically, they act as critical amplifiers of inflammation by activating and recruiting myeloid cells, which in turn mediate tissue destruction. Furthermore, they establish vicious feedback loops, enhancing their own differentiation and promoting the function of other effector T cells. Despite their established importance, significant heterogeneity and plasticity exist in their phenotype and regulatory networks, with context-dependent variations across different diseases and species. This review synthesizes our current understanding of these pivotal cells, critically evaluating their classification, molecular identity, and the signaling pathways governing their differentiation. We further dissect their specific roles in major autoimmune diseases and provide a forward-looking perspective on their immense translational potential, from novel therapeutic strategies targeting the GM-CSF axis to their use as biomarkers for patient stratification and monitoring.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4e6daed52915c02f33af0850503172340f333d9" target='_blank'>
              GM-CSF+ Th: a central player in autoimmunity
              </a>
            </td>
          <td>
            Sha-Sha Fan, Xuan Xu, Yu-Bin Luo, Xiang-Yu Meng, Yi Liu
          </td>
          <td>2025-09-12</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="ABSTRACT Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Regulatory T cells (Treg cells or Tregs), a subset of CD4⁺ T cells with immunosuppressive properties, are essential for immune homeostasis and self-tolerance. Characterized by their immunosuppressive capabilities and reliance on the transcription factor Foxp3 (Forkhead box protein P3), Tregs employ multiple mechanisms, including cytokine secretion, metabolic control, and cell contact inhibition, to restrain excessive immune activation to prevent autoimmunity while maintaining tissue repair processes. However, dysregulation in their frequency or function—whether deficiency or hyperactivity—is implicated in diverse pathologies, spanning autoimmune disorders, cancer progression, transplant rejection, and emerging associations with neurological and cardiovascular diseases. Thus, Treg-targeted strategies represent a promising approach for restoring immune balance under various conditions. This review synthesizes current knowledge on Treg biology, from their discovery and definition of markers to their new regulatory mechanisms. We further explore the roles of Tregs across diseases, emphasizing their context-dependent therapeutic potential. Strategies to deplete or inhibit Tregs in cancer immunotherapy contrast with approaches to expand or stabilize their function in autoimmunity and transplantation. However, challenges persist, including achieving tissue-specific targeting, ensuring the functional stability of engineered Tregs, and minimizing off-target effects. By integrating mechanistic insights with translational innovations, this review provides a roadmap for advancing Treg-based therapies, ultimately aiming to restore immune equilibrium in a disease-specific manner.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4664303d5c8731e32a24c5f6aff938bbbbb96dc7" target='_blank'>
              Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
              </a>
            </td>
          <td>
            Lingling Wang, Ying Liang, Chunxia Zhao, Peijun Ma, Shulin Zeng, Dongen Ju, Minggao Zhao, Min Yu, Yun Shi
          </td>
          <td>2025-10-14</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>1</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/745f967a05c41eac9e9afeb28f2af2215f527b3c" target='_blank'>
              CD155 regulates tumor growth and immune evasion in diffuse midline glioma
              </a>
            </td>
          <td>
            Theophilos Tzaridis, Ester Calvo Fernandez, Tanja Eisemann, Augusto Faria Andrade, C. A. de Biagi-Junior, Jennifer L. Hope, O. Becher, Nada Jabado, Jon D. Larson, Suzanne J. Baker, Andrea Califano, Anindya Bagchi, M. Filbin, Linda M. Bradley, Peter D. Adams, Jovana Pavisic, Robert J Wechsler-Reya
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Chimeric antigen receptor T cell (CAR-T) is the main salvage therapy for relapsed or refractory large B-cell lymphoma (r/r LBCL). However, over 50% of patients relapse after CAR-T therapy. In this work, we transduced the CAR gene into hematopoietic stem cells (HSCs) using a lentiviral vector. Chimeric antigen receptor-modified HSC (CAR-HSCs) were transplanted into mice after lethal irradiation. CAR gene transduction did not compromise the ability of HSCs to expand, self-renew, or reconstitute. CAR was expressed on T cells, natural killer cells, B cells, monocytes, and neutrophils in the peripheral blood. CAR-HSCs transplantation significantly reduced CD19+ tumor burden and prolonged the survival of mice with preclinical tumor without severe toxicity. CAR-HSCs also differentiated into different CAR-expressing immune cells that reshaped the tumor microenvironment by increasing the proportion of antitumor cells (like CD8+ T cells) and the antitumor response, and by decreasing immunosuppressive cells, such as tumor-associated macrophage subtype 2. This study demonstrated a preclinical proof-of-principle for CAR-HSCs therapy in r/r LBCL, suggesting an opportunity for its clinical translation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/699a2afcf60d13e0d7c490646a6df52053b04045" target='_blank'>
              Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice
              </a>
            </td>
          <td>
            Tao Wang, Ping Liu, Dongliang Zhang, Zhiqiang Song, Mingyang Yu, D. Feng, Xuejun Yu, Na Liu, Gusheng Tang, Jianmin Yang
          </td>
          <td>2025-10-22</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In this study, we demonstrate through RNA sequencing and flow cytometry analyses of acute myeloid leukemia (AML) cell lines and primary patient samples that BCMA is also a relevant AML-associated antigen. Its robust surface expression on AML cells positions it as a promising candidate for targeted immunotherapy. Functionally, our findings indicate that BCMA in AML operates similarly to its role in MM – engaging the NF-kB pathway upon ligand binding, thereby activating gene expression programs that support leukemia cell survival and proliferation. We assessed several BCMA-targeted immunotherapeutic strategies, including bispecific T-cell engagers (TCE) and chimeric antigen receptor (CAR) transduced T-cells, NK-cells, and macrophages. We found that TCE treatment and BCMA CAR engineering markedly improved effector cell mediated cytotoxicity against AML cells, underscoring BCMA’s potential as a viable therapeutic target in AML. Furthermore, BCMA- directed TCE therapy significantly augmented the anti-leukemic activity of adoptively transferred CD8+ T-cells in a human AML xenograft model. Taken together, these findings support BCMA as a novel immunotherapeutic target in AML. Leveraging existing BCMA-directed treatments developed for MM could enable rapid clinical translation and broaden immunotherapy options for patients with AML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/436fa158d1ac2800e0090f3db5638326935534d4" target='_blank'>
              B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia
              </a>
            </td>
          <td>
            Ashley Varkey, Manpreet Bariana, Mark Batistick, John Church, Elena Cassella, Shaina A. Anuncio, Shabnam Samimi, Alexander J Vallone, Zephyr Hameem, Sarvarinder K. Gill, James McCloskey, Yiming Chen, Ming Tan, M. Albitar, Benjamin Tycko, Kar F Chow, Giuditta Mantile-Selvaggi, David S Siegel, Johannes L Zakrzewski
          </td>
          <td>2025-10-24</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies but faces significant challenges in solid tumor therapy. The tumor microenvironment (TME) of solid tumors, including the dense extracellular matrix (ECM) and immunosuppressive factors, creates physical and biochemical barriers that hinder CAR-T cell infiltration, function, and persistence. Despite advances in CAR-T cell engineering, overcoming these TME barriers remains a major obstacle. The ECM in solid tumors restricts CAR-T cell penetration and limits their antitumor efficacy. Recent studies have explored ECM modulation as a strategy to enhance CAR-T therapy. Nattokinase (NKase), a natural fibrinolytic enzyme, has shown potential in degrading ECM components, promoting TME remodeling, and improving therapeutic responses. In this study, we evaluate the therapeutic efficacy of NKase in combination with MSLN-targeted CAR-T cells for solid tumors. We hypothesize that NKase will reduce tumor fibrosis by degrading ECM components, facilitating CAR-T cell infiltration and enhancing their cytotoxic activity. In vitro and in vivo experiments will assess the effects of NKase on CAR-T cell infiltration, activation, memory phenotype maintenance, and antitumor activity. This study aims to optimize CAR-T therapy for solid tumors and supports the clinical potential of NKase as an adjunctive therapeutic agent.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ffa57177469f0ff558649a171c513941cf5b51e" target='_blank'>
              Nattokinase-driven remodeling of tumor microenvironment enhances the efficacy of MSLN-targeted CAR-T cell therapy in solid tumors
              </a>
            </td>
          <td>
            Lianfeng Zhao, Yan Zhang, Xinhao Yang, Tianyu Chen, Jiaqi Liu, Zhi-Cheng Guo
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Background By examining the B-cell receptor (BCR) repertoire of metastatic melanoma (MM) patients with favorable treatment outcomes, it is now possible to identify unique patterns of immune responses, with the potential of discovering novel antitumor antibodies. Methods Here, we isolated CD27-positive circulating memory B cells from non responders, partial responders, and complete responders MM patients to first-line therapy with anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab, to perform a BCR repertoire sequencing analysis. We looked for complementarity-determining region 3 (CDR3) sequences that were enriched (de novo formed) following ICI treatment. Fully-human immunoglobulins were then produced in Expi293F™ cells using CDR3-sequencing information and tested for specificity and sensitivity on different MM cell lines and patient-derived xenograft cells by flow cytometry and by immunohistochemistry on human tissue microarrays. Results As a result of immunotherapy stimulation in responder patients, we observed that some CDR3 clonotypes have emerged de novo. Among the nine candidate antibodies we assessed, two antibodies exhibited encouraging tumor-targeting properties, although they also showed a degree of cross-reactivity with normal skin and melanocytes. Conclusions Although our study is based on a limited number of individuals, our observations indicate that it may be possible to further investigate the human response to immunotherapy for the identification of rare mature B clonotypes targeting plasma membrane antigens on tumor cells. These preliminary findings could contribute to the future development of fully human-compatible immunotherapies, pending additional validation and in vivo studies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fb882d4a17f01ac5d97be071afdb716cc4bce647" target='_blank'>
              Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients
              </a>
            </td>
          <td>
            F. Nicolini, Anna Gaimari, Luciana Mazzotti, Anna De Lucia, Miriana Ghirelli, V. Ancarani, Patricia Borges de Souza, Matteo Zurlo, Luca Gazzola, Chiara Magnoni, Simona Capobianco, D. Angeli, S. Bravaccini, Claudio Cerchione, M. Guidoboni, Luisa Lanfrancone, F. Marocchi, R. Maltoni, M. Tumedei, Francesco Limarzi, Luigi Pasini, L. Ridolfi, Massimiliano Mazza
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e8782e43d5a359ec11f1397979fbb249cbe9fbe7" target='_blank'>
              Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
              </a>
            </td>
          <td>
            Alexandre Marraffa, C. Berrevoets, Margherita Mosiello, R. Wijers, Daphne Roelofs, Mandy van Brakel, Kim Kroese, Marlies J. W. Peeters, Wim Dik, A. Kunert, Rachel Judith Mary Abbott, Dora Hammerl, C. Schliehe, R. Debets
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="T cell-based therapies, involving ex vivo expansion of patients’ T lymphocytes, hold significant promise for chemotherapy resistant cases of breast cancer (BC), although their effectiveness remains challenging. Building on our previous findings that the expression of the antigen presenting molecule, HLA-DR, is crucial on tumor-infiltrating cytotoxic T lymphocytes (CTLs) for a favorable response to neoadjuvant chemotherapy, we further investigated the role of HLA-DR-expressing CTLs in anti-tumor responses and evaluated strategies to amplify these cells. Through in vitro and in vivo experiments, we demonstrated that HLA-DR expression on CTLs is important for effective tumor cell elimination. Notably, blocking HLA-DR or depleting CD4+ T cells impaired CTLs activation, suggesting a critical role for antigen presentation by CTLs to CD4+ T cells through HLA-DR in promoting robust anti-tumor responses. Based on these findings we optimized an ex vivo stimulation protocol that increases the proportion of HLA-DR+CTLs with improved cytotoxicity, prioritizing cell quality over yield. Moreover, we showed that adding anti-PD-1 to the stimulation, further upregulated HLA-DR expression, and intensified CTLs’ cytotoxic ability. This aligns with our in silico analysis suggesting a potential regulatory link between PD-1 and HLA-DR via non-coding RNAs. Overall, our findings open new avenues for advancing T cell-based therapies and improve the outcomes of chemotherapy-resistant-BC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8306ef56b938be304f4192ecb25cae36b9f4d781" target='_blank'>
              HLA-DR expression in cytotoxic T lymphocytes: a key to boost the therapeutic potential of T cell-based strategies for breast cancer
              </a>
            </td>
          <td>
            R. Salvador, B. F. Correia, D. Grosa, Telma Martins, Suelen Cristina, Soares Baal, D. P. Saraiva, So ﬁ a Cristo ´ vão-Ferreira, Isabel Lopes Pereira, Rebelo de Almeida, Rita Fior, A. Jacinto, C. Mathias, S. Braga, M. Cabral, Jacob T. Jackson, Wenda Zhong, Peiwen Ma, BF Correia, DP Saraiva, Cristo ´ vão-Ferreira, IL Pereira, M. Cabral
          </td>
          <td>2025-09-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of naturally developing neoplasms, as well as tumors responding to (immuno)therapy. In this setting, robust, acute but ultimately resolving type I IFN responses appear to support natural and therapy-driven cancer immunosurveillance by a number of mechanisms, including an accrued propensity of malignant cells to arrest their proliferation and undergo apoptotic cell death, as well as broad immunostimulatory effects on CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells (DCs) and tumor-associated macrophages (TAMs). Conversely, weak, indolent and ultimately non-resolving type I IFN responses de facto facilitate tumor progression, not only by promoting stemness in malignant cells (which is associated with increased metastatic dissemination and resistance to therapy), but also by favoring the establishment of a highly immunosuppressive lymphoid and myeloid tumor microenvironment. Here, we provide a critical discussion of the context-dependent impact of type I IFN signaling on cancer progression and response to treatment, focusing on the tumor-intrinsic and extrinsic factors that may account for such a heterogeneity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2e617f9f9711708567426eb2cf65f4ef606f0b6" target='_blank'>
              Context-dependent impact of type I interferon signaling in cancer
              </a>
            </td>
          <td>
            Ainhoa Ruiz-Iglesias, Emma Guilbaud, Lorenzo Galluzzi, Santos Mañes
          </td>
          <td>2025-10-30</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Exosomes, nanoscale extracellular vesicles secreted by various cell types, play pivotal roles in intercellular communication. In cancer, tumor-derived exosomes—referred to as cancer-derived exosomes (CDEs)—have emerged as critical regulators of immune evasion, tumor progression, and therapy resistance within the tumor microenvironment (TME). CDEs modulate immune cell function through the transfer of immunosuppressive proteins, cytokines, and non-coding RNAs, ultimately reprogramming immune surveillance mechanisms. This review provides an in-depth analysis of how CDEs influence major immune cell subsets—including T cells, B cells, NK cells, dendritic cells, macrophages, and myeloid-derived suppressor cells—thereby establishing an immunosuppressive TME. We also explore the potential of immune cell-derived exosomes (IDEs) as emerging immunotherapeutic tools capable of counteracting the suppressive effects of CDEs. Furthermore, we highlight exosome engineering strategies aimed at improving therapeutic cargo delivery, tumor targeting, and antitumor immune activation. Finally, we discuss how exosome profiling offers promise in liquid biopsy diagnostics and how integration with 3D tumor models and advanced bioengineering can accelerate the clinical translation of exosome-based cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eae1e39741f5db67d36338284089286232d39875" target='_blank'>
              Cancer-derived exosomes: mediators of immune crosstalk and emerging targets for immunotherapy
              </a>
            </td>
          <td>
            Ridwan Mahamed, Bernice Monchusi, Clement Penny, S. Mirza
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Recently, we have identified CD4+PD-1+CXCR5+ T-follicular helper (TFH) cells with a distinct cytotoxic phenotype and named them “killer TFH (TF K )” cells. In this study, we aim to elucidate their presence and functional relevance in two different lymphoma subtypes, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Flow cytometric analysis of tonsillar versus FL-cell suspensions revealed a heightened number of GZMK+NKG7/TIA-1+ TF K cells in the latter, accompanied by a significant increase in T-regulatory and T-follicular regulatory (TFR) cells. In contrast, DLBCL exhibited a decrease in TFH and TFR cell numbers, while concurrently demonstrating heightened frequencies of GZMK+TIA-1+ and especially GZMB+TIA-1+ TF K cells within the TFH population. Analysis of single-cell RNA sequencing data confirmed an origin-specific phenotype of TF K cells. Immunofluorescence staining of biopsy specimens detected CD4+BCL-6+TIA-1+ TF K cells within follicles and germinal centers (GC) in reactive lymph nodes and within their atypical counterparts in malignant lymph nodes. Their propensity to migrate into atypical GCs was more pronounced in higher grade FLs. Furthermore, the release of cytotoxic cargo by degranulation could be induced by stimulation of CD4+ cells in cultures of FL and DLBCL suspensions. In line, the direct cytotoxic capacity of TF K cells against lymphoma cells was demonstrated by killing assays with isolated cells, underscoring their potential as a prospective therapeutic target in lymphoma control.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f102197501ec1b3397057559e69720ba226376a3" target='_blank'>
              Cytotoxic CD4+ T-follicular cells may mediate killing against lymphoma cells
              </a>
            </td>
          <td>
            Yin Xiao, Sigrun S Haeusl, Gaurav Jethva, Johannes Weber, A. Rosenwald, F. Berberich-Siebelt
          </td>
          <td>2025-09-15</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="B7 homolog 3 (B7-H3, CD276) has emerged as a promising target for chimeric antigen receptor (CAR) T cell therapy, with limited expression in normal tissues and high level cell-surface expression across various tumor types. Clinical studies are ongoing, with a focus on pediatric cancers. As an immune checkpoint molecule of the B7-CD28 family, B7-H3 has a proposed immune-modulatory role, though the precise nature of B7-H3-mediated cell interactions and functional contributions to immune responses are contradictory and likely context-dependent. Within tumors, B7-H3 is expressed also on non-tumor cell types in the tumor microenvironment (TME), including myeloid immune cells, endothelial cells of abnormal vasculature and cancer-associated fibroblasts. Consequently, CAR T cells directed against B7-H3 will not only target tumor cells but also components of the TME, which will affect the nature and outcome of B7-H3-targeted therapeutic immune responses. Here we review the expression of B7-H3 protein in pediatric solid tumors and in various cell types known to infiltrate the TME of solid tumors. On this background, we discuss the potential of B7-H3-targeted CAR T cells to reshape the TME and the key challenges and future directions to improve B7-H3-targeted CAR T cell therapy for pediatric patients with solid cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/649b83099536525155f2e82b6d45425c1ee80892" target='_blank'>
              B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
              </a>
            </td>
          <td>
            Lena Jansen, J. Wienke, Ronja Molkenbur, Claudia Rossig, Ramona Meissner
          </td>
          <td>2025-10-11</td>
          <td>Cancer Metastasis Reviews</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8e4d37620ca392d7a89bb01813d9698710108a7a" target='_blank'>
              Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors
              </a>
            </td>
          <td>
            G. Carleton, Sébastien Levesque, Lauren G. Zacharias, João S. Patrício, Tracey Sutcliffe, Peter H Watson, Ralph J. DeBerardinis, Yannick Doyon, Julian J. Lum
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Circulating lymphocytes are essential for the immune response to helminth infections, as they secrete cytokines and thus coordinate subsequent immunological processes. In canine angiostrongylosis, a potentially fatal disease caused by the metastrongylid nematode Angiostrongylus vasorum, the underlying immune mechanisms driving disease progression remain poorly understood despite the severe clinical consequences. Canine peripheral blood mononuclear cells (PBMCs) were isolated from healthy dogs and stimulated with three different antigens of A vasorum, including adult excretory-secretory products (ESP), adult full-worm somatic antigen, and first-stage larval (L1) somatic antigen. Temporal dynamics and magnitude of relative cytokine expression (IFNγ, TNF, IL-4, IL-6, IL-10, IL-13) was evaluated after 4 h, 24 h, and 5 days of antigen exposure via quantitative reverse transcription PCR. To determine whether the cytokine expression changes translated into shifts in circulating mononuclear cell subsets or proliferative activity, phenotypic characterisation by flow cytometry was conducted after a 72 h stimulation with L1 antigen or ESP, and compared to unstimulated controls. Early responses varied across antigen types, with ESP promoting a regulatory cytokine profile with modest upregulation of IL-4, IL-6, and IL-10, and downregulation of IFNγ, TNF, and IL-13. Adult antigen induced increased expression of all examined cytokines, while L1 antigen triggered the strongest inflammatory response compared to the other antigens. At 24 h, all responses were amplified, particularly those to L1 and adult antigen, and showed a shift towards a Th2 cytokine profile with increased IL-4 and IL-13 expression. By five days, IL-4 and IL-13 remained predominant. No change in the relative abundance of major immune cell populations (CD4⁺ T cells, CD8⁺ T cells, B cells, neutrophils, monocytes, and CD14⁻ CD22⁻ antigen-presenting cells) was observed in flow cytometry following stimulation. However, a notable increase in Ki67 expression, a marker of cell proliferation, was detected in CD8⁺ T cells after L1 antigen stimulation. Distinct cytokine profiles elicited by different A. vasorum antigens suggest that the parasite’s modulation of host immunity and induction of stage-specific responses are key to persistence and clinical presentation of canine angiostrongylosis. Further investigation into the antigenic components and immune pathways may lead to tailored therapies, improved clinical management, and to a deeper understanding of stage-specific aspects of helminth infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/966d24f4232243990a6917d702fdc78980641c19" target='_blank'>
              In vitro cytokine response of circulating mononuclear cells from healthy dogs to stage-specific antigens of Angiostrongylus vasorum
              </a>
            </td>
          <td>
            Janine Hertaeg, U. Salazar, J. vom Berg, S. Leibundgut-Landmann, Andreas W. Oehm, Manuela Schnyder
          </td>
          <td>2025-10-02</td>
          <td>BMC Veterinary Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma characterized by a profoundly immunosuppressive tumor microenvironment. PD-L1 overexpression by tumor cells is a recognized immune escape mechanism and may underlie resistance to cellular therapies, including CAR T-cell therapy. We report a case of a 29-year-old woman with refractory stage IV-B THRLBCL treated with anti-CD19 CAR T-cell therapy (varnimcabtagene autoleucel), who achieved an initial response (day +28) but experienced disease progression by day +100 despite robust CAR T-cell expansion. Peripheral blood analysis revealed persistent absolute B-cell aplasia, while bone marrow biopsy confirmed CD19-positive disease. Comparative immunohistochemistry demonstrated markedly increased PD-L1 expression in post-CAR T-cell samples, suggesting adaptive immune resistance via PD-1/PD-L1-mediated CAR T-cell inhibition. Nivolumab was initiated at month +4 to overcome this checkpoint-mediated resistance. Notably, a complete metabolic response was documented on PET/CT after four doses of nivolumab (month +6). The patient remains in sustained remission, with persistent B-cell aplasia, four years post-intervention. This case provides clinical and pathological evidence supporting the use of immune checkpoint blockade to rescue CAR T-cell efficacy, highlighting the potential of this synergistic approach in THRLBCL and possibly other B-cell malignancies exhibiting similar immune evasion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/30bbc27d73802edea098491ebe987fd06d629f31" target='_blank'>
              Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report
              </a>
            </td>
          <td>
            Daniel Munárriz, O. López-Godino, N. Martínez-Cibrian, N. Albiol, H. Brillembourg, Sergio Navarro-Velázquez, M. Español-Rego, Sebastián Casanueva, Lucía García-Tomás, Guillermo Muñoz-Sánchez, L. Alserawan, D. Benitez-Ribas, L. Magnano, J. Correa, A. Rivero, P. Mozas, Eva Giné, L. Rodríguez-Lobato, A. Martínez-Roca, Mercedes Montoro-Lorite, P. Ayora, Jordi Esteve, Laura Frutos, Olga Balagué-Ponz, Á. Urbano-Ispizua, E. A. González-Navarro, Manel Juan, Julio Delgado, V. Ortiz-Maldonado
          </td>
          <td>2025-09-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that develop in non-lymphoid organs under pathological conditions of chronic inflammation, such as cancer, autoimmune diseases, chronic infections, organ transplantation, and age-related disorders. TLSs produce various cytokines and chemokines, and orchestrate local adaptive immune responses by serving as sites for antigen presentation. TLSs have attracted significant attention because of their multifaceted roles in various diseases. However, the diversity in cellular composition, development, and maturation of TLSs, depending on the disease context and organ, makes it challenging to fully understand their characteristics. Several basic and clinical studies have demonstrated the clinical and pathophysiological roles of TLSs, revealing both their protective and harmful effects. In cancer, TLSs generally activate anticancer immune responses, leading to the suppression of tumor growth. Additionally, they contribute to host defense against pathogens in infectious diseases. Conversely, they can provide a niche for autoantibody production, exacerbating autoimmune diseases and chronic rejection in transplanted organs. In age-related diseases, they may prolong tissue inflammation and hinder tissue repair. The pathophysiological significance of TLSs has prompted the development of therapeutic strategies that target their formation and maturation. However, their potential systemic immunological effects must be carefully considered. Recent advances in single-cell omics technologies have facilitated a deeper understanding of the diverse cellular components of TLSs and their cell–cell interactions, which may contribute to the development of TLS-specific therapies. The fact that TLSs can only be identified using invasive diagnostic methods remains a barrier to further research. Advances in artificial intelligence-driven pathology diagnostics and improvements in imaging technologies for noninvasive detection are expected to accelerate TLS research. Categorizing various conditions with TLSs as 'TLS-related diseases' could deepen our understanding of TLS pathophysiology and lead to the development of novel therapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d68ec50d653bb294f0085e58df7b58caa3d717c9" target='_blank'>
              The roles of tertiary lymphoid structures in orchestrating immune responses in peripheral organs
              </a>
            </td>
          <td>
            Keisuke Taniguchi, Takahisa Yoshikawa, M. Yanagita
          </td>
          <td>2025-09-30</td>
          <td>Inflammation and Regeneration</td>
          <td>0</td>
          <td>50</td>
        </tr>

        <tr id="Multiple sclerosis (MS) is a chronic, immune‐mediated autoimmune disease characterized by the infiltration of autoreactive T cells and other inflammatory immune cells from the periphery into the central nervous system. Currently, there is no cure for MS, and treatment consists of disease‐modifying therapies (DMTs), most of which modify or delete specific immune cell populations. These populations express crucial MS treatment‐associated receptors, which may be differentially expressed in each patient, and thus each drug may affect individuals differently. Here, we developed the first comprehensive 24‐parameter flow cytometry immunophenotyping panel to evaluate treatment‐associated receptor expression on the major MS‐associated immune cells in whole blood. Analyzing whole blood samples from treatment‐naïve individuals with MS using this panel, we demonstrated that expression levels of these receptors vary between individuals. Response to the chosen DMT treatment also differed across participants. When monitoring the receptor expression during the course of treatment, we detected an increased response to treatment when receptor expression was elevated at the start of treatment. This panel reliably detects these receptors in MS treatment‐naïve participants and enables monitoring of their expression throughout treatment. This tool will enable deep interrogation of the immune receptors targeted by MS therapies and highlights that treatment‐associated receptor expression levels might be used to predict or correlate with treatment response.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/019f2dcb4e902228e625f81330b78afadd2958ea" target='_blank'>
              Monitoring Treatment‐Associated Receptor Expression in Multiple Sclerosis Using a Newly Developed Panel for Spectral Flow Cytometry
              </a>
            </td>
          <td>
            Katharina Robichon, Jennifer Taylor, Imogen Milner, Kathryn E Hally, A. L. La Flamme
          </td>
          <td>2025-09-23</td>
          <td>Cytometry Part A</td>
          <td>1</td>
          <td>27</td>
        </tr>

        <tr id="Distinct from conventional Foxp3+ regulatory T cells (Tregs), T-bet+ Tregs represent a stable subset of immunosuppressive T cells characterized by co-expression of the transcription factors (TFs) Foxp3 and T-bet. Given that Tregs were also reported to co-express Foxp3 together with effector T cell TFs such as GATA3, or RORγt, we propose the term hybrid Tregs (hTregs) to distinguish between these Tregs that co-express Foxp3 together with effector T cell TFs from conventional Foxp3+ Tregs. Therefore, this review will focus on hTreg cells, a specific subset of CD4+ T cells, and discuss the different types of hTregs with particular emphasis on T-bet+ hTregs. T-bet+ hTregs exhibit unique features including IFN-γ production, high expression of immune checkpoints (PD-1, CTLA-4, GITR, OX40, TIGIT), and chemokine receptors (CXCR3, CCR5). Through secretion of IL-10, TGF-β and IFN-γ, T-bet+ hTregs modulate both innate and adaptive immune responses within the tumor microenvironment (TME). Their high expression of CD73 contributes to adenosine-mediated immunosuppression, while CXCR3 and CCR5 facilitate their recruitment to inflammatory sites. T-bet+ hTregs were reported to accumulate in multiple human cancers, including lung, ovarian, and colorectal carcinomas. Despite these advancements, the function of hTregs in diseases such as cancer remains poorly understood, and requires further investigations. For instance, some studies suggest T-bet+ hTregs to be anti-inflammatory due to their production of IL-10, TGF-β, and superior suppressive capacity compared to conventional Tregs. Yet, other studies have reported that T-bet+ hTregs exhibit enhanced proinflammatory functions in colitis and other pathologies. We will then highlight current known mechanisms that promote the differentiation and functions of T-bet+ hTregs in cancer. Lastly, we will discuss the advancements and opportunities for therapeutic targeting of T-bet+ hTregs in cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b1b199c5c7e77a91a50e430bccd367ec9c53c27c" target='_blank'>
              Hybrid regulatory T cells: camouflaged architects of tumor immunity
              </a>
            </td>
          <td>
            Parviz Azimnasab-sorkhabi, Maryam Soltani-asl, José Roberto Kfoury Júnior, Ephraim A. Ansa-Addo
          </td>
          <td>2025-09-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Tumor immune evasion and incomplete responses to immunotherapy are some of the most significant obstacles in current cancer treatment. Since tumor-draining LNs (tdLNs) are cradles for anti-tumor immunity, and tumor-specific memory cells in tdLNs are the bona fide responders to immune-checkpoint blockade, tdLNs are increasingly valued in oncoimmunology research and cancer treatments. Recent progress has revealed that lymph nodes (LNs) are innervated and regulated by sensory and sympathetic nerve fibers. Because tumor cells, nerves, and immune cells coexist inside tdLNs—sites where anti-tumor immunity is initiated and compromised—it is critical to investigate whether tumor-neuro-immune crosstalk also occurs in these nodes. Although direct evidence in tdLNs is lacking, we synthesize emerging evidence supporting this possibility. We argue that validating this hypothesis will be essential for elucidating immune evasion mechanisms and advancing surgical and immunological strategies against tumors. In this review, we first introduce LN anatomy, highlighting its innervation by sensory and sympathetic fibers. We then examine the neural regulation of immune activities, especially those within LNs and those associated with a tumor context. We further discuss the multifaceted roles of tdLNs in tumor immunology, including orchestration of anti-tumor immunity and local immunosuppression, pre-metastatic LN remodeling, and induction of systemic tumor-specific immune tolerance. Furthermore, we look into tumor-neural interactions from two angles: tumor-induced nerve growth and activation, and neural regulation of tumor progression. Finally, we propose potential tumor-neuro-immune interactions in tdLNs, discuss current perspectives on LN handling in cancer therapy, and discuss clinical implications of the progress summarized in this review.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aab5fd4af47b27933d6fc3e53d0b08f085e3a967" target='_blank'>
              Nerves, nodes, and neoplasia
              </a>
            </td>
          <td>
            Minjun Wang, Censhan Ran, Quan Liu
          </td>
          <td>2025-09-15</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/32e4ebc6d8827d761aced444544586c3de7b9082" target='_blank'>
              High-throughput heterospheroid-based screening identifies drugs that reprogram tumor-associated macrophages
              </a>
            </td>
          <td>
            Hiroyuki Tsuchiya, T. Hanaki, Mayu Obora, Jun Yoshida, Mikiya Kishino, Y. Fujiwara, Daisuke Nanba
          </td>
          <td>2025-11-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="CD8+ T lymphocytes are central effectors of anticancer immunity. Their abundance and spatial distribution within solid tumors are strongly correlated with patient prognosis and response to immune-checkpoint inhibitors (ICIs). Tumors have been categorized into “hot,” “excluded,” and “cold” types based on the infiltration patterns of CD8+ T cells, which reflect the underlying immune contexture and therapeutic potential. However, many tumors remain resistant to T-cell infiltration, posing a significant barrier to immunotherapy. This review systematically outlines the seven critical steps of the Cancer-Immunity Cycle that govern CD8+ T-cell infiltration: antigen release, antigen processing and presentation, T-cell priming, trafficking through the vasculature, tumor infiltration, target recognition, and cytolytic activity. At each step, tumor-intrinsic and microenvironmental barriers—including low tumor mutational burden, defective antigen-presenting machinery, immunosuppressive cytokines (e.g., TGF-β, IL-10), abnormal vasculature, fibroblast-derived extracellular matrix, and inhibitory cell populations (e.g., Tregs, MDSCs, TAMs)—can stall the immune response. We further discuss the roles of immune-checkpoint signaling, metabolic competition, and suppressive cell networks in shaping T-cell exhaustion and exclusion. Cutting-edge technologies—such as single-cell RNA-sequencing, spatial transcriptomics, imaging mass cytometry, and TCR repertoire profiling—have revealed spatial and functional heterogeneity within intratumoral CD8+ T cells and informed the design of rational combination therapies. Understanding and targeting these barriers is critical for converting immune-cold tumors into immune-infiltrated, therapy-responsive states. We conclude with a perspective on the future of immunoengineering and immune-atlas integration to optimize CD8+ T-cell–based interventions in solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efa77bd4c813b73b425c3c8514e6eec6c6ede00f" target='_blank'>
              Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment
              </a>
            </td>
          <td>
            Ouyang Peng, Jianhong Zhang, Xiao He, Congcong Yang, Dingcheng Zeng, Daofeng Xu
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="The gut microbiome and its metabolites are critical regulators of intestinal homeostasis, with emerging evidence highlighting their influence on humoral immune responses and vaccine efficacy. The development of effective humoral immunity depends on the magnitude and quality of germinal centers (GCs), which are driven by follicular T helper (Tfh) cells. Here, we investigate the role of short‐chain fatty acids (SCFAs) in shaping humoral immunity, with a particular focus on Tfh cells. In ex vivo assays, we found that sodium butyrate, not sodium acetate or sodium propionate, directly suppresses Tfh cells differentiation and helper functions. Using antigen‐specific and influenza virus infection models, we further demonstrate that sodium butyrate impairs Tfh cell differentiation, leading to diminished GC B cell responses and compromised humoral immunity during systemic infection. Notably, mice treated with sodium butyrate succumbed to virus infection, underscoring its effect on impairing protective immunity. Mechanistically, our findings reveal that sodium butyrate mediates these suppressive effects on Tfh cells via histone deacetylase (HDAC) inhibition. Together, our findings establish sodium butyrate as a negative regulator of humoral immunity by directly suppressing the Tfh‐cell differentiation and Tfh‐derived GC responses. These insights provide a mechanistic link between gut microbiome‐derived metabolites and humoral immunity, with potential implications for vaccine efficacy and therapeutic interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad0621066f9656ea06370b6413e5bbc50ed7d207" target='_blank'>
              Short‐Chain Fatty Acid Sodium Butyrate Suppresses Protective Humoral Immunity by Inhibiting Follicular T Helper Cell Differentiation
              </a>
            </td>
          <td>
            Bhushan Nikam, Someshwar Nath Jha, Yatish Thakare, P. Coshic, Nimesh Gupta
          </td>
          <td>2025-10-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with chronic liver inflammation being a major risk factor. Tertiary lymphoid structures (TLS) have been associated with improved survival and better response to immune checkpoint inhibitors in several cancers. However, their role in HCC remains unclear, and findings are often contradictory. Methods: The study investigated the presence and composition of TLSs across multiple liver disease models, including livers containing HCC. TLSs were characterized to identify the essential cellular components for functional lymphoid activity. The functional role of age-associated B cells (ABCs) was further explored by blocking T-bet expression in B cells, thereby preventing their differentiation into ABCs. Results: TLS frequency was increased in livers containing HCC. Characterization confirmed the presence of key immune cell subsets supporting lymphoid function. Blocking T-bet in B cells led to a reduction in ABCs, which resulted in smaller TLS, a specific decrease in hepatic B cells, and reduced tumor lesion size in HCC-bearing mice. Conclusions: These findings demonstrate that ABCs promote TLS formation and growth, facilitating B-cell recruitment to the liver and supporting HCC progression. Targeting T-bet–dependent ABC differentiation may represent a novel strategy to limit TLS formation and slow HCC progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e21fbe2d38cd74b5f2d808bff239d29949051ea0" target='_blank'>
              Age-associated B cells enhance tertiary lymphoid structures in the liver and promote HCC formation
              </a>
            </td>
          <td>
            Anne E Morsing, Kenneth Green, Signe Clausen, Camilla R Benjaminsen, Mathilde S. Blaavand, Julia K Demtröder, Johannes Skraep, Lisbeth Jensen, Peter Breining, Mads Kjølby, Mikkel Vendelbo, S. Degn, Martin K Thomsen
          </td>
          <td>2025-09-22</td>
          <td>Hepatology Communications</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Activated PI3K delta syndrome 1 (APDS1) is caused by a heterozygous germline gain‐of‐function (GOF) variant in PIK3CD, which encodes the p110δ catalytic subunit of phosphoinositide 3‐kinase (PI3K). APDS1 patients display a broad range of clinical manifestations and perturbations in cellular phenotype. One of the most striking features is the dysregulation of the T‐cell compartment, characterized by an increase in memory T cells, including Tfh cells, and a concomitant decrease in naïve T cells. We have previously shown that many of these changes in T‐cell populations were T‐cell extrinsic and were also induced in WT T cells that developed in the presence of PI3K GOF cells. Here we dissected the drivers of dysregulated T‐cell activation using a mouse model of APDS1. This revealed that PI3K GOF macrophages and DCs made little contribution to the aberrant T‐cell activation. Instead, PI3K GOF T cells were able to drive the loss of WT naïve CD4+ T cells, while dysregulated PI3K GOF B cells mediated an increase in Tfh cells. Surprisingly, despite previous reports of increased PI3K signalling driving dysregulated inflammatory Tregs, we saw no evidence for Pik3cd GOF Tregs acquiring an inflammatory phenotype and driving T‐cell activation. These studies provide new insights into the role of PI3K in immune cells and how increased PI3K can drive T‐ and B‐cell dysregulation and contribute to the phenotype of APDS1 patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b02f686f7f272f7136a7b1186843ff70bd4a00c9" target='_blank'>
              PI3K GOF leads to dysregulation of T and B cells that both contribute to extrinsically driving activation and differentiation of other CD4 + T cells
              </a>
            </td>
          <td>
            Julia Bier, A. Lau, Katherine Jl Jackson, Stephanie Ruiz-Diaz, Timothy J. Peters, Robert Brink, S. Tangye, E. Deenick
          </td>
          <td>2025-09-14</td>
          <td>Immunology and Cell Biology</td>
          <td>0</td>
          <td>103</td>
        </tr>

        <tr id="Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and few studies have comprehensively investigated the immune microenvironment and rare lymphocyte-predominant (LP) cells. Here we develop a NLPHL specific lymphocyte-predominant ecotype (LPE) model to identify 34 distinct cell states across 14 cell types that co-occur within 3 LPEs for 171 cases. LPE1 and LPE2 were characterized by immunosuppressive microenvironments with high expression of B2M on LP cells, CD8 T-cell exhaustion, immune checkpoint genes expressed by follicular T-cells, and an improved freedom from progression compared to LPE3 in training (n = 109, with 65% LPE1/2) and validation cohorts (n = 62, with 61% LPE1/2). We validate the co-occurrence and co-localization of cell states using spatial transcriptomics. Protein expression of HLA-I and HLA-II on LP cells and SSTR2 on dendritic cells was predictive of LPE1 (C-statistic=0.69), LPE2 (C-statistic=0.79), and LPE3 (C-statistic=0.60). This study establishes a clinically relevant biologic categorization for NLPHL. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer. Here, the authors develop a NLPHL specific model to identify 34 distinct cell states across 14 cell types that co-occur within 3 lymphocyte predominant ecotypes (LPEs) for 171 cases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/687e04fd2e7cfd53da0cba5d8ceaacb2510f65e8" target='_blank'>
              Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma
              </a>
            </td>
          <td>
            Ajay Subramanian, Shengqin Su, J. Flerlage, S. Alig, S. Younes, L. Marks, Chelsea C. Pinnix, F. Vega, Raphael Steiner, Priyadarshini Kumar, Heidi Mocikova, A. Sýkorová, V. Procházka, Cristiane Milito, Pamela Allen, D. Paulino, Alan Ramsay, T. Flerlage, Monica Palese, Robert West, ChunFang Zhu, Troy Noordenbos, J. Schroers-Martin, Shuchun Zhao, N. J. Park, A. Kalbasi, E. J. Moding, Aaron M. Newman, R.H. Advani, Richard T Hoppe, Maximilian Diehn, Y. Natkunam, A. Alizadeh, M. Binkley
          </td>
          <td>2025-09-26</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="Pathogen-associated cancers account roughly 15–20% of all malignancies worldwide and arise from chronic infections by oncogenic viruses, bacteria and parasites. Pathogens can alter the tumor microenvironment (TME) into an immune-suppressive niche using multiple mechanisms, including immune checkpoint manipulation, chronic inflammation, metabolic reprogramming, and direct epigenetic modifications. Immune dysfunctions related to infections linked to cancers can include M2-polarized macrophages, expansion of MDSCs, exhausted T/NK cells, and tolerogenic dendritic cells, all progressing immune evasion and resistance to cancer therapy. Advances in therapeutics exist in prophylactic vaccines, immune checkpoint inhibitors, and next-generation methods such as the engineered Salmonella to deliver to hypoxic tumors and the targeting the microbiome. The advancement of pathogen-, cancer-, and patient-specific therapeutics is not without its challenges, including heterogeneity of the pathogens, absence of clinically useful biomarkers, concerns about the safety of the restoring anti-pathogen immunity and challenges of scale for manifold interventions. This review will provide a synthesis of the mechanistic aspects of pathogen-mediated TME remodeling, contemporary clinical therapeutics, and ongoing investigations into using pathogen/host dynamics to enhance measurable precision immunotherapy strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5c3df00e71b61c4351ef47d4ffaceec6dacd20b" target='_blank'>
              The immune microenvironment of pathogen-associated cancers and current clinical therapeutics
              </a>
            </td>
          <td>
            Xiao-Yu Wei, Hui-Jing Feng, Ying-Yin Zhu, Shi-Jing Guo, Hong Wang, Ming Li, Qi Mei
          </td>
          <td>2025-10-02</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Significance Mice are essential for studying immune responses, but functional differences between human and murine systems limit their utility, particularly for neutrophils. Humanized mice with a human immune system have advanced understanding of human immunity, yet suboptimal myelopoiesis and lack of functional neutrophils remain challenges. We developed MaGIC mice, a model expressing human CD47, M-CSF, GM-CSF, IL-6, and thrombopoietin while reducing murine CD47 on the C57Bl/6 N background. MaGIC mice support robust human hematopoiesis, including functional neutrophils, monocytes, and tissue macrophages. These neutrophils, phenotypically and developmentally comparable to human neutrophils, exhibit chemotaxis, phagocytosis, reactive oxygen species production, and neutrophil extracellular trap formation in response to inflammatory stimuli, providing an innovative platform to study human neutrophils in infectious, autoimmune, and inflammatory diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/126240af442ecbc18a530ec09fcfd6b09d5cb9e6" target='_blank'>
              Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrow
              </a>
            </td>
          <td>
            Esen Sefik, William Philbrick, Fengrui Zhang, Kriti Agrawal, Brian Van Lee, Johannes Sam, Kutay Karatepe, Yunjiang Zheng, Kaixin Liang, Sophia Peng, Haris Mirza, Athreya Rangavajhula, Perrine Simon, N. Arun, Priyanka Babu, E. Eynon, Michael Chiorazzi, L. Shan, Stephanie Halene, Hongbo R. Luo, A. Rongvaux, Y. Kluger, Richard A. Flavell
          </td>
          <td>2025-09-16</td>
          <td>Proceedings of the National Academy of Sciences of the United States of America</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/845631fe3ce87dcd33184e4a8746401a67c1d8b2" target='_blank'>
              PU.1 Shapes Host Epigenetic Responses to Mycobacterium tuberculosis and Represents a Target for Host Directed Therapy
              </a>
            </td>
          <td>
            Jérémie Poschmann, Liu Jie, Caio Bomfim, Alice Molle, Wenjie Sun, Taylor W. Foreman, Colette Cruesy, Gosset Pierre, Deepak Kaushal, Gennaro de Libero, C. Cougoule, Shyam Prabhakar, Amit Singhal
          </td>
          <td>2025-09-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/36d5b919ff4c0f1e65c48676350abe4ef162d1ad" target='_blank'>
              Pan-cancer single-cell and spatial transcriptomics implicate cancer-associated fibroblasts in neutrophil immunosuppressive phenotypic transitions and immunotherapy resistance
              </a>
            </td>
          <td>
            Zhiyu Guo, Xujia Li, Lingli Huang, Yue Yan, Mengge Gao, Jinsheng Huang
          </td>
          <td>2025-10-10</td>
          <td>Functional & Integrative Genomics</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Emerging evidence reveals that exercise modulates immune signaling to enhance the efficacy of immunotherapy in diseases like allergic rhinitis (AR) and nasopharyngeal carcinoma (NPC). By influencing immune cell trafficking, reprogramming inflammatory pathways within the tumor microenvironment (TME), and altering drug pharmacokinetics, exercise improves immune responses and therapeutic outcomes. Exercise enhances immune cell activation and infiltration into tumors, modulates checkpoint and cytokine signaling cascades, and mitigates treatment-related side effects, thereby improving patient compliance. Recent advancements in single-cell technologies, such as single-cell RNA sequencing and spatial omics, provide unprecedented insights into immune cell heterogeneity and signal transduction dynamics in the TME, uncovering new targets for exercise-modulated therapies. This review explores the synergistic effects of combining exercise with immune-based therapies, particularly in cancer treatment, highlighting the role of exercise in reshaping TME inflammation, overcoming immune evasion, and enhancing immune-mediated drug bioavailability. Personalized exercise regimens, tailored to individual patient profiles, are critical for optimizing therapeutic responses. Integrating exercise with immunotherapy, guided by single-cell and systems-level analyses, may provide a transformative approach for improving the clinical outcomes of AR and NPC patients, paving the way for more effective, individualized cancer treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/383016a745417bbcac5cfaacd289ccec795aa759" target='_blank'>
              Exercise induced immune regulation and drug efficacy in rhinitis nasopharyngeal carcinoma implications for tumor microenvironment single cell immune signal transduction
              </a>
            </td>
          <td>
            Guanwen He, Weijing Bao, Jiansheng Yang, Xiuqin Guo, Wenxian Lu, Xiuhui Ji, Shang Gao, Rifu Wei, Yisheng Chen
          </td>
          <td>2025-10-13</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d337f9005b90e93fdf29316d67b193863ed97ca" target='_blank'>
              CAR T-cells dysfunction in the central nervous system is mediated by BBB-induced activation-induced cell death
              </a>
            </td>
          <td>
            Yarden Aharony-Tevet, O. Ravid, A. Yanir, Amilia Meir, Hadar Levi, Daniel Burstein, Aviya Amram, Tamar Feuerstein, S. Izraeli, Itzik Cooper, E. Jacoby
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b55c35cb06dbcb951b8f88a8b1249e1f91df0097" target='_blank'>
              Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance
              </a>
            </td>
          <td>
            A. Alsugair, Abhishek Mangaonkar
          </td>
          <td>2025-09-26</td>
          <td>Current Hematologic Malignancy Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Cancer continues to be a significant global health issue, influenced by genetic mutations and external factors like carcinogenic exposure, lifestyle choices, and chronic inflammation. The myelocytomatosis (MYC) oncogene family, including c-MYC, MYCN, and MYCL, is essential in the development, progression, and metastasis of various cancers such as breast, colorectal, osteosarcoma, and neuroblastoma. Beyond its well-known roles in cell growth and metabolism, MYC significantly shapes the tumor immune microenvironment (TIME) by altering immune cell dynamics, antigen presentation, and checkpoint expression. It contributes to immune evasion by upregulating checkpoints such as programmed death-ligand 1 (PD-L1) and cluster of differentiation (CD)47, suppressing antigen-presenting major histocompatibility complex (MHC) molecules, and promoting the recruitment of suppressive immune cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). While direct targeting of MYC has proven challenging, recent advances in therapeutic strategies, including MYC-MYC-associated factor X (MAX) dimerization inhibitors, bromodomain and extra terminal domain (BET) and cyclin dependent kinase (CDK) inhibitors, synthetic lethality approaches, and epigenetic modulators, have shown promising results in preclinical and early clinical settings. This review discusses MYC's comprehensive impact on TIME and examines the promising therapeutic strategies of MYC inhibition in enhancing the effectiveness of immunotherapies, supported by recent preclinical and clinical findings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec1348f06f8cc8d1b1f7ddaa9bea0e5801ca6bda" target='_blank'>
              The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions.
              </a>
            </td>
          <td>
            B. Nirala, Jason Yustein
          </td>
          <td>2025-09-23</td>
          <td>Frontiers in bioscience</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90b18a409c0370d1134904ae4308fd7620389d03" target='_blank'>
              GDF15 regulates necroptotic cell death through direct interaction with RIPK3
              </a>
            </td>
          <td>
            Anastasia Piskopou, Isabella Vinson, Kong Sit, Els Sweep, M. Altelaar, Kelly E. Stecker
          </td>
          <td>2025-10-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Melanoma, the deadliest form of skin cancer, poses a significant challenge due to its genetic heterogeneity and high metastatic potential. While cytotoxic T cell (CTL)‐based immunotherapies have made remarkable progress in recent years, the therapeutic potential of natural killer‐(NK) cells is increasingly recognized. However, resistance mechanisms to both CTL‐ and NK‐cell‐mediated immunotherapies hinder effective treatment. To evaluate the exclusive role of NK‐cells in anti‐melanoma immunity, we performed 2D and 3D co‐culture‐based cytotoxicity assays under varying conditions. Our findings revealed a protective phenotype in melanoma cells following prolonged exposure to primary NK‐cells. By combining experimental data with bioinformatic analyses, we identified key genes and pathways involved in melanoma cell adaptation to NK‐cell‐mediated killing (NKmK). We found that cytokines such as IFNγ play a major role in suppressing NKmK with MHC II surface expression being a critical factor. Targeting the master regulator CIITA, which governs MHC II expression and is affected by IFNγ, significantly reduced melanoma cell resistance to NKmK. This study provides potential strategies to overcome resistance to NK‐cell‐based immunotherapies and offers novel insights into melanoma immune escape mechanisms.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5764eda312a5162e966ee86f3fed7809fb2be1df" target='_blank'>
              The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity
              </a>
            </td>
          <td>
            Lena C M Krause, Rixa-Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski
          </td>
          <td>2025-10-13</td>
          <td>Molecular Oncology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/122eb17de2469e40c3c0527892590ac5486b1c27" target='_blank'>
              Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition
              </a>
            </td>
          <td>
            Stacey N. Lee, Riley J Arseneau, Thomas Arnason, Jeanette E. Boudreau
          </td>
          <td>2025-09-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Diffuse large B-cell lymphoma and follicular lymphoma exhibit complex metabolic and immune microenvironments that influence disease progression and treatment response. Metabolic reprogramming, including glycolysis, amino acid, and lipid metabolism, supports tumor growth while suppressing anti-tumor immunity. Immune components such as tumor-infiltrating lymphocytes and checkpoint molecules (PD-L1, LAG-3, TIM-3) further modulate prognosis. Elevated tumor metabolic volume and glycolytic activity correlate with aggressive disease and poor outcomes. Conversely, high TIL density often predicts better responses. Integrating metabolic and immune biomarkers enhances risk stratification and therapeutic strategies, highlighting the potential for combined metabolic inhibitors and immunotherapies to improve precision medicine in lymphoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35d2711154e88d30ee1749837827464d818a40eb" target='_blank'>
              Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL
              </a>
            </td>
          <td>
            Chengqian Chen, Wei Guo, Haotian Wang, Luming Cao, Out Bai
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Glioblastoma, the most common and lethal primary brain tumor, creates profound immunosuppression that has resisted clinical interventions. The mechanisms behind immunotherapy failures in glioblastoma remain unclear. We conducted a systematic comparison of different immunotherapeutic approaches in mouse models to better understand treatment responses.



 Using multiomic single-cell analysis and spatial profiling, we evaluated GL261 glioma-bearing mice treated with anti-PD-L1 antibodies, NKG2D-CAR-expressing T cells, natural killer (NK) cells, or macrophages.



 All treatment models induced immune cell migration through chemotaxis. Additionally, PD-L1 and CAR T cell treatments led to an exhaustion-associated T cell signature alongside increased cytotoxic T cell presence. Further, we observed higher numbers of immunomodulatory lymphocytes and macrophages associated with these two immunotherapies. CAR macrophages and CAR NK cells exhibited enhanced cytotoxic gene signatures without increasing T cell numbers. Also, the immunomodulatory macrophage response appeared attenuated in CAR NK cells and macrophages. Notably, CAR NK cells demonstrated an enhanced antiviral response with interferon-beta expression that was not observed in other models.



 While PD-L1 and CAR cell treatments successfully polarized the lymphoid compartment toward cytotoxic phenotypes, these approaches alone appear insufficient as they were accompanied by pronounced immunomodulatory cell responses. CAR NK cells and macrophages were characterized by attenuated immunomodulatory responses. Our findings suggest that cytotoxic lymphocytes alone fail to override tumor-associated immune suppression. This is in line with recent evidence on T helper cell roles in CAR therapy. Future immunotherapy approaches should balance cytotoxic and helper lymphocyte populations while enhancing inflammatory macrophages to overcome the immunosuppressive environment of glioblastoma
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde65cb7289ab4952a15cc4d954df652b303b749" target='_blank'>
              P08.22.B SYSTEMATIC COMPARISON OF IMMUNOTHERAPIES IN GLIOBLASTOMA REVEALS DISTINCT IMMUNE RESPONSE PATTERNS
              </a>
            </td>
          <td>
            Y. Liu, T. Look, J. Fang, A. Dalmau Gasull, M. Prinz, T. Weiss, R. Sankowski
          </td>
          <td>2025-10-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fdbae78251ccd4fa8f2487fe48e2a546a3022eef" target='_blank'>
              Antiviral and Anti-inflammatory Effects of Cannabidiol in HIV/SIV Infection
              </a>
            </td>
          <td>
            AL Ellison, J. Rosado-Franco, L. Mamun, S. Knerler, M. Daniali, K. Mehta, S. Williams-McLeod, J. Alvarez, SS Joyner, R. Vandrey, Elise M. Weerts, Peter J. Gaskill, MJ Corley, LC Ndhlovu, DW Williams
          </td>
          <td>2025-09-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, thus, there is an urgent need to develop more effective therapeutic options for this dismal condition. Tumor-infiltrating lymphocytes (TILs) are associated with improved response to immune checkpoint blockade in HCC, but their low abundance in most cases limits their therapeutic efficacy. Here, we demonstrate, in mice, that low-dose intratumoral immunovirotherapy with the trivalent measles, mumps, and rubella vaccine (MMR) induces superior tumor-growth delay and extended host survival compared to individually administered vaccines for measles, mumps, or rubella viruses. Further, our results show that MMR therapy synergizes with PD-1 and CTLA-4 blockade to reprogram the tumor microenvironment, resulting in increased CD8+ TIL infiltration and reduced PD-1 expression on TILs, among other effects. These changes in the immunological landscape translated into greater survival and more durable tumor-specific and memory immune responses for hosts. Comprehensive toxicology analysis revealed no evidence of MMR-induced liver or kidney toxicity after intrahepatic administration. This work reinforces an unrecognized role of MMR plus ICB in reprogramming the immune landscape in HCC through multimodal immune activation, providing a strong rationale for further development of MMR-based therapies for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0ee9f74230079389edd57b51b6b1e849660e18a" target='_blank'>
              Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
              </a>
            </td>
          <td>
            M. Tesfay, Aleksandra Cios, K. U. Ferdous, Randal S. Shelton, Bahaa Mustafa, Camila C Simoes, Murat Gokden, I. Miousse, Kimberly J. Krager, Marjan Boerma, Alicja Urbaniak, Anuradha Kunthur, S. Obulareddy, Joshua M. Eichhorn, Steven R Post, J. C. Chamcheu, Omeed Moaven, C. Chabu, D. Duda, Matteo Conti, Bruno Nardo, Rang Govindarajan, M. Fernandez-Zapico, Lewis R. Roberts, M. Borad, Martin J Cannon, Alexei G. Basnakian, B. Nagalo
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Introduction Kidney transplant rejections are classified as active antibody mediated rejection (AMR) and cell mediated rejection (TCMR), with AMR primarily driven by antibodies produced by B cells, whereas TCMR is mediated by T lymphocytes that orchestrate cellular immune responses against the graft. Emerging evidence highlights the essential roles of innate immune cells in rejections, especially monocytes/macrophages and natural killer (NK) cells. However, the roles of specific innate immune cell subpopulations in kidney allograft rejection remain incompletely understood. Methods We performed the spatial transcriptomics using the formalin-fixed paraffin-embedded (FFPE) core needle biopsies from human kidney allografts. Results We demonstrated that non-rejection, AMR, acute TCMR and chronic active AMR have distinct transcriptomic features. Subclusters of monocytes/macrophages with high Fc gamma receptor IIIA (FCGR3A) expression were identified in C4d-positive active AMR and acute TCMR, and the spatial distribution of these cells corresponded to the characteristic histopathological features. Key markers related to monocyte/macrophage activation and innate alloantigen recognition were upregulated, along with metabolic pathways associated with trained immunity in AMR and TCMR. Discussion Taking together, these findings revealed that intragraft monocytes/macrophages with high FCGR3A expression play a critical role in kidney transplant rejections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1fe937879ab369d45f22b51042e1b560cb3fdbb3" target='_blank'>
              Spatial transcriptomics reveals distinct role of monocytes/macrophages with high FCGR3A expression in kidney transplant rejections
              </a>
            </td>
          <td>
            Yan Chen Wongworawat, Chirag Nepal, Mark Duhon, Wanqiu Chen, Minh-Tri Nguyen, Adam Godzik, Xinru Qiu, Wei Vivian Li, Gary Yu, R. Villicana, Craig Zuppan, Michael De Vera, Michael T. Eadon, Mark Haas, Charles Wang
          </td>
          <td>2025-09-15</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, presents major therapeutic challenges due to molecular heterogeneity and high relapse rates. While autologous hematopoietic stem cell transplantation (ASCT) has been a cornerstone for relapsed/refractory (R/R) B-cell lymphoma, its efficacy is often compromised by minimal residual disease (MRD) persistence and an immunosuppressive tumor microenvironment. Chimeric antigen receptor (CAR)-T cell therapy has transformed treatment paradigms but faces limited long-term durability due to antigen escape and T-cell exhaustion. The integration of ASCT with CAR-T therapy may offer a complementary approach to address these limitations, leveraging ASCT-induced immune reconstitution to enhance CAR-T-cell persistence and reprogram the tumor milieu. Emerging clinical evidence supports this approach, indicating improved disease control and progression-free survival. Although preliminary clinical outcomes are encouraging, unresolved challenges persist, particularly in terms of cumulative toxicity, optimal therapeutic sequencing, CAR-T-cell longevity, and financial feasibility associated with these advanced therapies. This review provides a comprehensive overview of mechanistic synergies between ASCT and CAR-T therapy, critically evaluates emerging clinical evidence on treatment sequencing, and explores innovative strategies to increase safety, efficacy, and accessibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8dabb02a640eb6c1d29c8aa3a2cf213056349991" target='_blank'>
              Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma
              </a>
            </td>
          <td>
            Xumeng Zhao, Jiaying Wu, Xiaojian Zhu, Yi Xiao
          </td>
          <td>2025-10-01</td>
          <td>Cell Transplantation</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Introduction Chronic lymphocytic leukemia (CLL) has proven difficult to treat with chimeric antigen receptor (CAR) T cell therapy. CLL cells can negatively alter T cell fitness and induce a pseudohypoxic state. We hypothesized that production of CAR T cells under restricted oxygen conditions resembling physiological oxygen levels that can be encountered in tissues (i.e. 2% O2) could promote outgrowth of hypoxia-tolerant CAR T cells. Methods We performed in vitro phenotypic and functional assessments of CD19-directed CAR T cells produced in either 21% (NorCAR) or 2% (HypCAR) O2 derived from healthy donors (HDs) or patients with CLL. Results Production of HD-derived CAR T cells in 2% O2 promoted the enrichment of a naïve-like subset. HypCAR and NorCAR cells were functionally distinct; CD4+ HypCAR cells produced more IL-2 and tumor necrosis factor than CD4+ NorCAR cells. Production in 2% O2 was not detrimental to viability or proliferation upon cognate antigen-stimulation and led to increased activation. After chronic stimulation in hypoxia, HypCAR-product remained enriched in naïve-like cells, and demonstrated cytotoxic and cytokine production capacity. In CAR T cells derived from patients with CLL, NorCAR and HypCAR subsets were functionally and phenotypically comparable, but displayed different mitochondrial metabolism. Discussion We demonstrated that production in 2% O2 is not detrimental, confers subtle but lasting functional and phenotypic changes in CAR T cells warranting further research on the impact of hypoxic production on CAR T cell functionality in hypoxic tumor microenvironments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f224ca2fb20ea305b58dbbe807b058fa17875b2" target='_blank'>
              Production of functional CD19 CAR T cells under hypoxic manufacturing conditions
              </a>
            </td>
          <td>
            Isabella Micallef Nilsson, Thomas Poiret, Jinhye Ryu, Mohammadali Mohammadpour, Johan Henriksson, Anders Österborg, Jonas Mattsson, Anna Schurich, Isabelle Magalhaes
          </td>
          <td>2025-10-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33f595a851feb78b9e34d0fe80e0a4c2dc6649c2" target='_blank'>
              FPR3 sustains the immunosuppression of tumor-associated macrophages and accelerates the progression of gastric adenocarcinoma
              </a>
            </td>
          <td>
            Minqiong Sun, Zhenya Tan, Keqiong Lin, Zhiling Chang, Zhi Yang, Xue Yang, Gu Tang, Yakun Liu, Chun Li, Jicheng Zhu, Chen Kan, Chunwei Peng, Hong Zheng
          </td>
          <td>2025-09-23</td>
          <td>Oncogene</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) remains the most prevalent and lethal form of lung cancer worldwide. Among the diverse components of the tumor microenvironment, tumor-associated macrophages (TAMs) are increasingly recognized as key regulators of NSCLC progression, metastasis, and treatment resistance. TAMs, particularly those polarized toward the M2-like phenotype, facilitate tumor growth through immunosuppression, angiogenesis, epithelial–mesenchymal transition, and extracellular matrix remodeling. They promote immune evasion via PD-L1, IL-10, and TGF-β signaling, and confer chemoresistance through activation of the IL-6/STAT3 and P2X7/STAT6 pathways. Moreover, high infiltration of M2-TAMs and their expression of immune checkpoint ligands have been associated with poor prognosis and, paradoxically, with improved response to PD-1/PD-L1 blockade in certain patients. Emerging therapeutic strategies aim to reprogram TAM phenotypes, inhibit their recruitment, or selectively suppress their immunosuppressive functions. However, challenges such as macrophage plasticity, lack of specific biomarkers, and potential systemic toxicity remain significant barriers. This review provides a comprehensive overview of the biological functions, mechanistic roles, and clinical implications of TAMs in NSCLC, highlighting both their value as prognostic indicators and their potential as therapeutic targets in the era of precision oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4441ad90191ecc9c56fe31f7ae42ae5d7cc0668" target='_blank'>
              Targeting tumor-associated macrophages in non-small cell lung cancer: mechanisms, prognosis, and therapeutic opportunities
              </a>
            </td>
          <td>
            Dameng Hao, Shengjie Chen
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="ABSTRACT Cancer‐associated fibroblasts (CAFs) are pivotal stromal components that shape the tumor microenvironment through their remarkable heterogeneity and dynamic functions. This review comprehensively examines the biology of CAFs, starting with their diverse cellular origins and induction mechanisms via key signaling pathways. We highlight the spatial‐temporal heterogeneity of CAF subsets and propose an updated classification system that encompasses eight functionally distinct subtypes based on recent single‐cell transcriptomic studies. The tumor‐promoting roles of CAFs are explored in depth, including their contributions to tumor behavior through novel mechanisms such as neutrophil extracellular traps formation, and multidrug resistance via metabolic reprogramming. A major focus is placed on CAF‐mediated immunotherapy resistance through immune checkpoint regulation, recruitment of immunosuppressive cells, and metabolite secretion. This review also highlights key technologies that are advancing CAF research, including patient‐derived 3D models, artificial intelligence‐enhanced spatial multiomics, clustered regularly interspaced short palindromic repeats (CRISPR)‐engineered mouse systems, and machine learning approaches for analyzing CAF heterogeneity and function. Finally, we evaluate therapeutic strategies targeting CAF activation, secreted factors, and immune crosstalk, while critically analyzing ongoing clinical trials. Overall, this review not only clarifies the biology of CAFs but also provides a translational framework for developing next‐generation stromal‐targeted therapies to overcome treatment resistance in cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e1dae86be5576422570b1acdcb11b97738bdec4b" target='_blank'>
              Cancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy
              </a>
            </td>
          <td>
            Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding
          </td>
          <td>2025-10-28</td>
          <td>MedComm</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Innate immune cells and pathways are central to shaping the tumor microenvironment (TME), where they influence tumor growth, metastasis, and responsiveness to immunotherapy. Although research on innate immunity in cancer has expanded considerably, the mechanisms driving immune dysfunction remain incompletely understood. This review summarizes current knowledge on the functional states of innate immune cells within the TME and highlights how metabolic reprogramming contributes to immune suppression and tumor progression. We further discuss recent advances in therapeutic strategies targeting innate immune pathways, emphasizing their translational potential. Importantly, we also examine unresolved controversies and knowledge gaps across innate immune cells, metabolic networks, and innate immune factors such as complement and cytokines, outlining key challenges for clinical translation. By linking mechanistic insights with emerging interventions and identifying future directions, this review provides a framework for integrating innate immunity into next-generation cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c04681fced7ce655cf3c2cb9b142258798132d57" target='_blank'>
              Innate immunity in tumors: roles and therapeutic targets
              </a>
            </td>
          <td>
            Songze Leng, Yuyue Ren, Yao Tian, Weiwei Zhao, Yue Mou, Xingyu Chen, Hong Zhou, Wei Wang
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Introduction Crohn’s disease (CD) is a relapsing inflammatory disease that is currently not curable. Despite the availability of anti-inflammatory treatments, 30–60% of patients develop resistance, necessitating the need for novel therapeutic approaches. Data from colitis models in mice indicate that granulocytemacrophage colony-stimulating factor (GM-CSF)-activated monocytes (GMaMs) may serve as a promising cellular therapy. However, it remains unclear whether inflammatory mediators, medication, or intrinsic defects impair the functionality of monocytes in active CD (aCD), potentially affecting their therapeutic efficacy. Methods Monocytes from 8 aCD patients and healthy donors (HDs) were activated in vitro with GM-CSF, and their migratory capacity, adherence, metabolic activity, surface marker expression, and cytokine release were assessed. Cells were stimulated with lipopolysaccharides (LPS) to evaluate their inflammatory response. Results The GMaM phenotype was characterized by increased metabolic activity, enhanced production of inflammatory cytokines, stronger adhesion, and remodeling of surface receptors involved in T-cell activation, compared to naïve monocytes. These features were largely comparable between aCD patients and HDs. LPS stimulation of GMaMs from both groups resulted in a significant production of pro-inflammatory and chemotactic cytokines, particularly interleukin (IL)-8 and monocyte chemotactic protein 1. Both are crucial recruiters of neutrophils and monocytes. Notably, monocytes from aCD patients showed an increased IL-10 response to GM-CSF, while the LPS-induced tumor necrosis factor-alpha and interferon-gamma release were reduced compared to HDs. Discussion Peripheral monocytes from aCD patients retain functional responsiveness to GM-CSF activation, displaying preserved migratory, adhesive, metabolic, and cytokine responses. Differences in cytokine production by aCD monocytes may reflect disease-specific regulation, but do not appear to limit their suitability as cellular therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a144942872b55d9aca9ca371e925b5fb9f47b96d" target='_blank'>
              Peripheral monocytes from Crohn’s disease patients retain functional responsiveness to GM-CSF during active disease
              </a>
            </td>
          <td>
            Paul P Winkel, Wendy Bergmann-Ewert, Johannes Reiner, A. Huth, Dana Kleimeier, Rosaely Casalegno Garduño, I. M. Wrobel, G. Domanska, Jan Däbritz, E. Wirthgen
          </td>
          <td>2025-09-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="The Epidermal Growth Factor Receptor (EGFR) and its ligand, amphiregulin (AREG) are critical for epithelial cell proliferation but their important role in inflammation and infection is increasingly described. We recently discovered that the EGFR ligand, amphiregulin, could identify a cohort of infants with sepsis, even when CRP was low, identifying it as a potentially adjunctive biomarker for early infection. Its role in adult sepsis however, has yet to be delineated. We conducted a prospective observational study of 42 critically ill septic adult patients on the Intensive Care Unit, comparing serum amphiregulin levels and the frequencies of EGFR-expressing myeloid and lymphoid cells (using spectral flow cytometry) in sepsis survivors and non-survivors, and 20 healthy volunteers. We demonstrate, for the first time, the strong association between serum amphiregulin and in-hospital mortality (AUROC = 0.87). Moreover, we demonstrate that a higher frequency of circulating CD4+ and CD8+ lymphocytes express either the ligand (AREG) or receptor (EGFR) ex vivo, in sepsis, and expression of CD4+ lymphocyte EGFR was associated with several features of immunosuppression. Together, our data suggest that EGFR-signaling represents a novel candidate of T cell dysregulation in sepsis and warrants further investigation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b5b7254851e5526055f4ea34291b33e1a26d9daf" target='_blank'>
              The amphiregulin- epidermal growth factor receptor axis as a therapeutic target in sepsis
              </a>
            </td>
          <td>
            Rebecca Walsh, Timothy Arthur Chandos Snow, Alexandra Z. Martinez, D. Brealey, M. Singer, Abhishek Das, N. Arulkumaran
          </td>
          <td>2025-09-23</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>31</td>
        </tr>

        <tr id="Simple Summary Donor-derived Vγ9Vδ2 T cells demonstrate potent anti-leukemic activity both in vitro and in vivo, offering a promising immunotherapeutic approach for acute myeloid leukemia (AML). These γδ T cells efficiently induce apoptosis in AML cells in vitro, highlighting their direct cytotoxic potential. In an aggressive AML xenograft mouse model, treatment with donor-derived Vγ9Vδ2 T cells significantly prolonged survival, indicating their therapeutic relevance in a clinically challenging setting. Importantly, these cells remain effective against venetoclax-resistant AML; in vivo studies further show that Vγ9Vδ2 T cells extend survival in mouse survival with or without venetoclax. These findings suggest the therapeutic potential of harnessing donor-derived Vγ9Vδ2 T cells as a novel strategy to overcome drug resistance and improve outcomes in AML, including in patients with limited responses to existing therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6e72a592035e114a06e58e1013ea6e52ae060ba" target='_blank'>
              Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach
              </a>
            </td>
          <td>
            Amanda Eckstrom, Anudishi Tyagi, Maryam Siddiqui, Jenny Borgman, Jieming Zeng, Adishwar Rao, A. Maiti, V. Battula
          </td>
          <td>2025-09-29</td>
          <td>Cancers</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease originating from hematopoietic stem cells. While treatment with tyrosine kinase inhibitors (TKIs) effectively eliminates the majority of leukemia cells in patients, residual leukemia cells can still be detected in those achieving deep molecular remission, ultimately leading to drug resistance or relapse. But the exact mechanism is unclear. In recent years, the immune microenvironment has been a hot research topic in hematologic malignancies. CML patients exhibit abnormalities in antitumor immunity. Myeloid-derived suppressor cells (MDSCs), which possess immune-suppressing functions, inhibit the proliferation and activation of CD4+/CD8+ T cells, Tregs, B cells, and NK cells, and play a central role in the antitumor immune response in a wide range of cancers. Abnormalities in numbers and functions of MDSCs are exhibited in CML patients, which affect the immune status of CML patients through multiple mechanisms. This review summarizes the biological properties of MDSCs, their alterations in CML patients, their roles and specific mechanisms in the development of CML, and how these mechanisms can be leveraged to develop new therapeutic strategies, aiming to provide novel insights and approaches for the treatment of CML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bc96fb2e2a382163dd0d6a3fe8a72e0940472ac8" target='_blank'>
              Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia
              </a>
            </td>
          <td>
            Xing Meng, Yue Zhang, Hong Xu, Yanyan Zhang, Hao He, Jianmin Ma, Xiaoyan Zhang
          </td>
          <td>2025-09-19</td>
          <td>Journal of Cancer Research and Clinical Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Multiple sclerosis (MS) is an autoimmune and neuroinflammation disease characterized by axonal damage, inflammatory demyelination, and neurodegeneration. However, the precise mechanisms underlying MS pathogenesis remain largely unclear. Here, we identify ZNRF1, an E3 ubiquitin ligase, as a critical regulator of experimental autoimmune encephalomyelitis (EAE), a murine model that recapitulates the autoimmune demyelination features of MS. Mice lacking ZNRF1 exhibit increased susceptibility to EAE progression. Notably, ZNRF1 depletion in peripheral myeloid cells, but not in microglia, leads to enhanced immune cell infiltration into the central nervous system, resulting in demyelination and exacerbated disease severity. The heightened EAE severity in Znrf1-deficient mice is associated with increased polarization of Th1 and Th17 cells, elevated antigen-specific T helper cell proliferation, and amplified immune responses. Furthermore, following EAE induction, macrophages from Znrf1-deficient mice display elevated surface expression of MHC class II (MHC-II) molecules. Collectively, our findings suggest that ZNRF1 in peripheral myeloid cells plays a suppressive role in neuroinflammation by regulating MHC-II surface expression, thereby controlling antigen-specific T-cell proliferation and activation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f962a55325851d781ba99d1de0343d57aac16244" target='_blank'>
              Myeloid ZNRF1 suppresses autoimmune demyelination and neuroinflammation by regulating MHC-II-mediated T cell activation
              </a>
            </td>
          <td>
            Yung-Chi Chang, Ching-Chih Wu, Fu-Ting Hsiao, You-Sheng Lin, Ting-Yu Lai, Kang-Hsuan Huang, Shiue-Cheng Tang, Chih-Yuan Lee, Shen-Ju Chou, Li-Chung Hsu
          </td>
          <td>2025-10-22</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Despite the clinical success of immune checkpoint inhibitors (ICIs), therapeutic resistance and the unpredictable development of immune-related adverse events (irAEs) remain major challenges. While the use of ICIs in combination can improve treatment efficacy, this also leads to an increase in the frequency and severity of irAEs. This has created an urgent need to enhance anti-tumor immunity without triggering immunotoxicity. However, current preclinical models are limited in their ability to model both ICI efficacy and irAE development. This is due to mouse strains commonly used for studying anti-tumor immunity, such as C57BL/6 and BALB/c mice, being resistant to ICI-induced irAEs and failing to recapitulate the full spectrum of clinical responses seen in patients with cancer. To overcome these limitations, we generated transplantable, syngeneic tumor models with variable ICI responses using the autoimmune-prone non-obese diabetic (NOD) mouse. The NOD model, which spontaneously develops multiple autoimmune diseases, exhibits a broad range of irAEs following ICI treatment with a shared etiology to clinical conditions. This approach offers insight into how genetic predisposition to autoimmunity influences both ICI response and irAE susceptibility, enabling us to explore how autoimmune-associated host-intrinsic factors uniquely alter the tumor microenvironment and contribute to ICI resistance. In ICI-resistant NOD tumors, CD8+ T cells exhibited a naïve-like phenotype, marked by elevated TCF-1 and reduced PD-1 and CTLA-4 expression, compared to ICI-sensitive tumors. Despite comparable CD8+ T cell frequency and number, these phenotypic differences led us to investigate other immune cell populations that regulate ICI response and CD8+ T cell activation. Single-cell RNA sequencing and spectral flow cytometry revealed enrichment of immunosuppressive γδ T cells in ICI-resistant tumors. These γδ T cells highly expressed the transcription factors RORγt+ and TCF1+ and lacked expression of T-bet and the mouse Vγ1 TCR chain, suggesting that distinct γδ T cell subsets may play different roles in tumor control. Functionally, antibody-mediated blockade of the γδ T cell receptor (γδTCR) significantly improved tumor control in ICI-resistant, but not ICI-sensitive, models, implicating γδ T cells in promoting tumor growth. Tumors enriched with immunosuppressive RORγt+ and TCF1+ γδ T cells also exhibited increased B cell infiltration. In B cell-deficient NOD mice, γδ T cells skewed toward T-bet and Vγ1 expression, which correlated with enhanced CD8+ T cell activation. These findings reveal a coordinated immunosuppressive network between γδ T cells and B cells that limits anti-tumor immunity. Given their roles in promoting autoimmunity, these cell types may represent therapeutic targets to boost anti-tumor immunity and overcome ICI resistance without exacerbating irAEs.



 Camille Hansen, Arabella Young. Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B006.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20c2f1122af538bc8b86e2d6ae32fff845b95bc3" target='_blank'>
              Abstract B006: Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="The immunosuppressive microenvironment and limited immune cell infiltration into the tumor bed contribute to the proliferation, metastasis, and invasion of breast cancer (BC) cells. Reprogramming the tumor immune microenvironment has emerged as a promising therapeutic target for BC, but remains challenging in clinical practice. Artemisia annua, a medicinal plant, has shown immune-enhancing and anti-tumor activities, although its potential therapeutic applications in BC remain underexplored. Extracellular vesicles (EVs) were isolated from fresh Artemisia annua using gradient centrifugation and characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), Zetasizer Nano ZS90, ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS/MS), and high-performance liquid chromatography (HPLC). Single-cell RNA sequencing (scRNA-seq) analysis was performed to investigate the mechanism of AEVs on tumor growth in vivo and mRNA sequencing (mRNA-seq) was employed to further explore the mechanism of AEVs-induced polarization shift from M2-like to M1-like macrophages. In vitro and in vivo assays were conducted to assess the polarization of macrophages and recruitment of T lymphocytes into the tumor bed. AEVs were successfully isolated and characterized. In vivo, AEVs inhibited tumor growth by shifting macrophage polarization from the M2-like to the M1-like phenotype, and synergistically enhancing the recruitment of CD8+ and CD4+ T cells into the tumor microenvironment. AEVs activated the NF-κB signaling pathway while inhibiting the PPARγ pathway, thereby promoting the M1-like polarization of macrophages. Polarized M1-like macrophages secreted chemokines (CCL5 and CCL3), which facilitated T lymphocyte infiltration into the tumor bed. Notably, AEVs reshaped the BC immune microenvironment without inducing systemic toxicity. AEVs from Artemisia annua efficiently reprogrammed the immune microenvironment of breast cancer by inducing macrophage polarization and enhancing T lymphocyte infiltration. This study lays the foundation for using AEVs as a potential immunotherapy for BC and highlights the medicinal value of Artemisia annua in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ae2b76c7e2982ae527e2b31089269c261024d90" target='_blank'>
              Artemisia annua-derived extracellular vesicles reprogram breast tumor immune microenvironment via altering macrophage polarization and synergizing recruitment of T lymphocytes
              </a>
            </td>
          <td>
            Yun Wang, Lin Meng, Sicheng Su, Yu Zhao, Xiaoxian Hu, Xiaoqing Xu, Chao Han, Jianguang Luo, Zhong-Rui Li
          </td>
          <td>2025-10-01</td>
          <td>Chinese Medicine</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="


 CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that they must infiltrate tissues to execute their primary function of cell killing. It is well established that naive T cell responses do not originate in these tissues. Rather, prior to antigen-driven activation, naïve T cells are restricted to lymph nodes, spleen, and blood. T cell activation by cognate antigen drives expression of multiple immune checkpoint inhibitors, including programmed cell death protein-1 (PD-1) and/or cytotoxic T lymphocyte associated protein-4 (CTLA-4), as well as migration to nonlymphoid tissues. Work over the last two decades has harnessed T cell effector activities by blocking PD-1 and/or CTLA-4, which has revolutionized cancer care and demonstrated remarkable efficacy in diverse cancer types. However, many patients do not respond to checkpoint blockade therapy, and worse, other patients develop autoimmune-like immune-related adverse events (irAEs), limiting the utility of this approach. To maximize the therapeutic benefit of checkpoint blockade without accelerated irAE development, targeted approaches are needed to increase recruitment of protective CD8 T cells to tumors while preventing pathogenic T cell entry into sensitive tissues. However, an inability to granularly measure recruitment into non-lymphoid tissues has created a significant gap in knowledge in: 1) how checkpoint inhibitors impact T cell entry rates into tissues, 2) whether these entry rates are different for tumors and lesional irAE tissues, 3) where recruited cells localize, and 4) the precise functional contributions of recruited versus resident T cells in driving tumor regression or autoimmunity. To fill this gap in knowledge, we are utilizing an intravenous antibody labeling approach to mark CD8 T cells in the blood prior to entry into tissues, an approach which enables a 72-hour window to track tissue entry. Using this approach in the preclinical setting, we are interrogating how PD-1 inhibitors impact CD8 T cell recruitment to tumors as well as the pancreas in the context of Type 1 Diabetes. In our tumor studies, we have found that PD-1 inhibitors induce an increase in the number of recently recruited CD8 T cells, and that these recruited T cells have a less exhausted phenotype than the T cells that have been in the tumor for longer. In our diabetes studies, we have found that PD-1 inhibitors impact CD8 T cells both in the periphery and the pancreas, and in some mice cause an increase in migration to the pancreas. These studies support a model where peripheral CD8 T cell recruitment can positively contribute to productive anti-tumor immunity but can also exacerbate autoimmunity. Thus, our studies emphasize the doubled-edged nature of T cell recruitment, and our future studies will examine ways to both improve recruitment to tumors and mitigate recruitment to lesional irAE tissues.



 Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick K. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken. Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B001.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7cd824c6703eab6c26623afbbb67ccbb6990fccd" target='_blank'>
              Abstract B001: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade
              </a>
            </td>
          <td>
            O. Adewunmi, Arielle G. Dessens, A. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Immune cell migration plays a pivotal role in coordinating inflammatory responses and maintaining immune surveillance. Here, we provide a comprehensive overview of the migratory behaviors of key immune cell subsets, including Th1, Th2, regulatory T cells, macrophages, dendritic cells, and neutrophils and the molecular mechanisms that guide their trafficking from lymphoid organs to inflamed tissues. We highlight the stepwise migration cascade: priming in secondary lymphoid organs, trafficking through blood vessels, adhesion to endothelium, and extravasation into tissues. Each step is critically regulated by chemokines, selectins, integrins, and proteases. We also examine current pharmacological strategies that target immune cell migration in inflammatory diseases, such as integrin blockers and chemokine receptor antagonists, emphasizing both therapeutic potential and clinical limitations. In addition, we discuss emerging technologies including intravital imaging, CRISPR-based screening, and computational modeling that provide novel insights into immune cell dynamics and may guide the development of next generation migration-targeted therapies. Overall, this review integrates fundamental immunological principles with translational medicine by identifying key challenges, unresolved controversies, and future directions in the therapeutic modulation of immune cell migration.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b35de878e1a4e6dc7dfbb8b9e6a7a5a5cdb3f5d" target='_blank'>
              Targeting immune cell migration as therapy for inflammatory disease: a review
              </a>
            </td>
          <td>
            Bingfeng Song, Wenbo Guo, Ying He, Xingli Yao, Jintang Sun, Shijun Wang
          </td>
          <td>2025-09-25</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that they must infiltrate tissues to execute their primary function of cell killing. It is well established that naive T cell responses do not originate in these tissues. Rather, prior to antigen-driven activation, naïve T cells are restricted to lymph nodes, spleen, and blood. T cell activation by cognate antigen drives expression of multiple immune checkpoint inhibitors, including programmed cell death protein-1 (PD-1) and/or cytotoxic T lymphocyte associated protein-4 (CTLA-4), as well as migration to nonlymphoid tissues. Work over the last two decades has harnessed T cell effector activities by blocking PD-1 and/or CTLA-4, which has revolutionized cancer care and demonstrated remarkable efficacy in diverse cancer types. However, many patients do not respond to checkpoint blockade therapy, and worse, other patients develop autoimmune-like immune-related adverse events (irAEs), limiting the utility of this approach. To maximize the therapeutic benefit of checkpoint blockade without accelerated irAE development, targeted approaches are needed to increase recruitment of protective CD8 T cells to tumors while preventing pathogenic T cell entry into sensitive tissues. However, an inability to granularly measure recruitment into non-lymphoid tissues has created a significant gap in knowledge in: 1) how checkpoint inhibitors impact T cell entry rates into tissues, 2) whether these entry rates are different for tumors and lesional irAE tissues, 3) where recruited cells localize, and 4) the precise functional contributions of recruited versus resident T cells in driving tumor regression or autoimmunity. To fill this gap in knowledge, we are utilizing an intravenous antibody labeling approach to mark CD8 T cells in the blood prior to entry into tissues, an approach which enables a 72-hour window to track tissue entry. Using this approach in the preclinical setting, we are interrogating how PD-1 inhibitors impact CD8 T cell recruitment to tumors as well as the pancreas in the context of Type 1 Diabetes. In our tumor studies, we have found that PD-1 inhibitors induce an increase in the number of recently recruited CD8 T cells, and that these recruited T cells have a less exhausted phenotype than the T cells that have been in the tumor for longer. In our diabetes studies, we have found that PD-1 inhibitors impact CD8 T cells both in the periphery and the pancreas, and in some mice cause an increase in migration to the pancreas. These studies support a model where peripheral CD8 T cell recruitment can positively contribute to productive anti-tumor immunity but can also exacerbate autoimmunity. Thus, our studies emphasize the doubled-edged nature of T cell recruitment, and our future studies will examine ways to both improve recruitment to tumors and mitigate recruitment to lesional irAE tissues.



 Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick K. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken. Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-10.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bd96650135ea1d6c5e4e2bfdec0bd0131105df25" target='_blank'>
              Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade
              </a>
            </td>
          <td>
            O. Adewunmi, Arielle G. Dessens, A. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Type I interferonopathy encompasses disorders marked by systemic inflammation and neurological involvement, arising from genetic mutations that result in the upregulation of type I IFN signaling through various mechanisms. Currently, therapeutic options are limited, and no standard therapy exists. This study aims to develop a strategy for identifying new therapeutic targets for type I interferonopathy using induced pluripotent stem cells (iPSCs). The IFIH1 R779H variant was introduced into iPSCs through genome editing. RNA sequencing of iPSC-derived dendritic cells (DCs) was performed, and differentially expressed genes (DEGs) were identified. IFN-α secretion, reactive oxygen species (ROS), and mitochondrial oxygen consumption rate (OCR) were analyzed in iPSC-derived DCs. An in silico prediction of compounds binding to the OAS-like domain was conducted. Candidate compounds were evaluated for their ability to inhibit IFN secretion from IFIH1 R779H-mutated iPSC-derived DCs. Transcriptome analysis indicated upregulation of the IFN-related and metabolic pathways. IFIH1 R779H-mutated iPSC-derived DCs exhibited increased OCR and ROS generation, and blocking mitochondrial metabolism significantly reduced excessive IFN-α secretion. Among the DEGs, PML was upregulated, and targeting this gene with arsenic trioxide (ATO), a PML antagonist, suppressed IFN-α secretion from IFIH1 R779H-mutated iPSC-derived DCs. Additionally, bisantrene, phthalylsulfathiazole and ganaplacide were predicted to bind to the RNA binding groove of OAS-like domain of human OASL in silico, effectively inhibiting IFN-α secretion from IFIH1 R779H-mutated DCs. Our iPSC-based disease modeling and drug investigation approach provides a robust platform for validating the efficacy and toxicity of candidate therapeutic agents for rare and intractable human diseases such as type I interferonopathy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/edecf89b22f86463f35039c7248cef00e476ffcf" target='_blank'>
              Identification of Potential Therapeutic Agents for Type I Interferonopathy Using iPSC-Based Disease Modeling
              </a>
            </td>
          <td>
            B. Natsumoto, H. Shoda, M. Tsuji, M. Otsu, Hideki Taniguchi, Kazuhiko Yamamoto, K. Fujio
          </td>
          <td>2025-09-30</td>
          <td>Journal of Clinical Immunology</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="As a key lymphocyte population in shaping and controlling adaptive immune response, T cells play an important immunomodulatory role in the early stages of autoimmune diseases. Although CD3+CD4−CD8− T (DNT) cells constitute only a small proportion of peripheral T lymphocytes, they may be closely linked to the occurrence and development of autoimmune diseases. However, the role of DNT cells in autoimmune disease pathogenesis still needs to be elucidated. In this review, we first present the origin, functions, and heterogeneity of DNT cells. We then summarize the role of DNT cells in the pathogenesis of various autoimmune diseases. Subsequently, we clarify the recent advances in the applications of DNT cell-based therapy for autoimmune diseases and outline potential drugs (including active ingredients extracted from Chinese medicinal treatments) and approaches that can target the proliferation and expansion of DNT cells. Lastly, the limitations and challenges of applying DNT-cell-based therapy are analyzed. In conclusion, we present an overview to further the understanding of the role of DNT cells in autoimmune disease pathogenesis and of DNT cells as a potential therapeutic tool for immune disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130f579f8c6e0a3374a93d0e8f2050f3b8d8e91f" target='_blank'>
              CD3+CD4−CD8− T cells: a new potential therapeutic target in treating autoimmune diseases
              </a>
            </td>
          <td>
            Xin Li, Di Guo, Isabelle Xinyue Zou, Lingyan Zhao, Na Yang, Yang Liu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Despite promising safety profiles, B7-H3 CAR T cell therapies have yet to demonstrate meaningful clinical efficacy in diffuse intrinsic pontine glioma (DIPG), a devastating pediatric brain cancer characterized by a profoundly immunosuppressive tumor microenvironment (TME). This TME is dominated by tumor-associated macrophages (TAMs) and suppressive resident microglia that restrict CAR T-cell activation and persistence. Importantly, broad myeloid targeting risks eliminating macrophages essential for supporting T cell activation and anti-tumor immunity. We identified CD123 as a selective marker of suppressive TAMs in DIPG and hypothesized that dual targeting of CD123+ TAMs alongside B7-H3+ tumor cells would effectively remodel the TME, restore T cell function, and enhance therapeutic efficacy.



 Using immunocompetent DIPG models, we evaluated a sequential combination of CD123 and B7-H3 CAR T cells to remodel the TME and improve tumor control. In vitro assays included cytotoxicity, repeated antigen stimulation, and co-cultures with M1- or M2-polarized macrophages. Endpoints included TAM depletion, TME remodeling, tumor burden, and survival.



 In vitro, M2 macrophages suppressed B7-H3 CAR T cell proliferation, persistence, and cytokine secretion; these effects were reversed by co-treatment with CD123 CAR T cells. CD123 CAR T cells selectively depleted M2-like TAMs and microglia without cytotoxicity against B7-H3+ DIPG tumor cells. In vivo, CD123 CAR T cell treatment reduced immunosuppressive TAMs and shifted the tumor microenvironment toward a pro-inflammatory phenotype, as demonstrated by intracellular cytokine staining and comprehensive flow cytometry analyses. Notably, administration of CD123 CAR T cells after B7-H3 CAR T cell infusion failed to rescue antitumor activity. However, administering CD123 CAR T cells within a four-day window prior to B7-H3 CAR T cell infusion significantly enhanced tumor control. Dual CAR therapy substantially decreased tumor burden, limited suppressive myeloid and microglial infiltration, and improved T cell activation and persistence, resulting in extended survival compared to monotherapies, with some mice achieving durable tumor remission. Ongoing transcriptomic studies are underway to elucidate the mechanisms driving this robust, lasting antitumor immunity.



 Priming the TME with CD123 CAR T cells significantly improves B7-H3 CAR T cell efficacy in aggressive DIPG models. Dual targeting of CD123+ TAMs and B7-H3+ tumor cells reprograms the DIPG TME and enhances CAR T-cell function by overcoming immunosuppressive barriers while preserving supportive immune populations. This strategy offers a promising mechanistic approach to improving CAR T therapy in DIPG.



 Khatereh Khorsandi, Kaleem Coleman, Jaquelyn T. Zoine, M.Paulina Velasquez, Dalia Haydar. Reprogramming the Myeloid Tumor Microenvironment with CD123 CAR T Cells Enhances B7-H3 CAR T Cell Therapy in DIPG [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2):Abstract nr A039-PR007.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9467562ec35cf64972931c9ccd0b2e56a2414e52" target='_blank'>
              Abstract A039-PR007: Reprogramming the Myeloid Tumor Microenvironment with CD123 CAR T Cells Enhances B7-H3 CAR T Cell Therapy in DIPG
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem L Coleman, Jaquelyn T. Zoine, M. Velasquez, Dalia Haydar
          </td>
          <td>2025-09-25</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Fractionated focal radiation therapy (RT) induces immunogenic cell death and activates the type I interferon pathway via the cGAS/STING pathway, promoting tumor antigen cross-presentation by conventional dendritic cells (cDCs) and driving tumor-specific T-cell activation. However, the impact of RT on tumor regression is often limited by its complex effects on the tumor immune microenvironment (TiME). Several studies have shown that RT increases both the frequency and functional activity of regulatory T cells (Tregs), due in part to their intrinsic radioresistance and to RT-induced modulation of recruitment signals such as TGFβ, CCL17, and CCL221-2. In a recent study, we showed that RT combined with immunotherapy can remodel the TiME3, et persistent infiltration of activated Tregs can dampen the full immunostimulatory effects of RT-driven viral mimicry responses4. Here, we evaluated whether combining RT with blockade of the myeloid checkpoint SIRPα could modulate Treg infiltration and activity. Using mouse models of luminal (TSA) and triple-negative (AT3) breast cancer, we tested RT in combination with a blocking anti-SIRPα antibody (MY1; SIRPα-b). While MY1 monotherapy showed minimal activity, its combination with RT led to enhanced regression of irradiated tumors and inhibition of non-irradiated (abscopal) tumor growth in both tumor models. This effect was lost upon conditional cDC depletion using Zbtb46-DTR mice, highlighting the importance of cDCs in mediating the therapeutic synergy. To dissect the immune mechanisms underlying this synergy, we performed single-cell RNA-sequencing and CITE-seq on CD45+ tumor-infiltrating cells from TSA tumors treated with RT ± SIRPα-b. We observed a significant reduction in Treg infiltration in SIRPα-b–treated tumors, with or without RT. Furthermore, expression of Treg activation markers OX40, CTLA-4, and GITR was reduced, particularly in the RT + SIRPα-b group. Among infiltrating CD45+ cells, expression of Treg recruiting Ccl22 and Ccl17 chemokines was observed only in a highly activated cluster of CCR7high cDCs expressing SIRPα, CXCL16, PD-L1, and IL-15Rα. Notably, expression of both chemokines was strongly decreased following SIRPα-b treatment, suggesting that SIRPα signaling supports Treg recruitment via this cDC population.Studies to understand the mechanisms of Treg recruitment to the tumor via chemokine secretion by CCR7high cDCs and their role in tumor regression after RT + SIRPα-b are underway. Intra-tumoral CCR7high cDCs are known to support the activation and cytotoxic function of CD8+ T cells and NK cells in the tumor through transpresentation of Il-155. Our results suggest that this population also plays a key immunoregulatory role in shaping the TiME. Targeting the CD47/SIRPα axis may thus improve RT efficacy by modulating the dual functions of CCR7high cDCs in both effector stimulation and Treg recruitment.
 1- PMID: 28970196 2- PMID: 30042205 3- PMID: 37620372 4- doi: 10.1038/s41392-023-01462-z 5- PMID: 34343496



 Maud Charpentier, Claire Lhuillier, Alicia Alonso, Doron Betel, Paul Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria. Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr A023.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/acbd70f4779618ff4cf0238d208283c1e692a84a" target='_blank'>
              Abstract A023: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression
              </a>
            </td>
          <td>
            M. Charpentier, Claire Lhuillier, Alicia Alonso, D. Betel, P. Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Abstract Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb). Despite significant advancements in anti-tuberculosis treatment strategies in recent years, TB remains a major infectious disease threat worldwide. Chronic Mtb infection drives T cell exhaustion—characterized by upregulated co-inhibitory receptors—which correlates with TB chronicity, treatment failure, and relapse. Immune checkpoint inhibitors (ICIs) targeting co-inhibitory receptors have achieved groundbreaking progress in the treatment of various malignancies. However, their application in the field of tuberculosis remains controversial. This study provides a comprehensive analysis of TB disease assessment and treatment from the perspective of T cell exhaustion. We investigate the correlation between co-inhibitory receptor expression levels and both disease activity and progression. Furthermore, we analyze the dual impact of targeting these receptors on anti-TB immunity: While blockade of co-inhibitory receptors in T cell exhaustion states restores anti-tuberculosis immunity, excessive inhibition—particularly in hyperimmune conditions—induces detrimental hyperinflammation, exacerbating tissue damage and disrupting immune homeostasis, ultimately worsening clinical outcomes. To address this duality, we emphasize the necessity of personalized immunotherapy strategies based on individual immune profiling, alongside developing novel co-inhibitory receptor blockers and immune modulatory vaccines. This review presents a novel perspective on the application of targeting co-inhibitory receptors in tuberculosis treatment, which will advance the development and application of immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c0f1ff6028430a892143fee8eb49b3d748087cae" target='_blank'>
              Regulatory Mechanisms of Co-Inhibitory Receptors in Tuberculosis Immunity: Implications for Therapeutic Targets
              </a>
            </td>
          <td>
            Huicong Liu, Haoran Li, Shanshan Li, Y. Shang, Shenjie Tang, Y. Pang
          </td>
          <td>2025-10-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) play critical roles in tumor immune evasion. These heterogeneous cells are broadly classified into granulocytic (G-MDSC), monocytic (M-MDSC), and their immature precursors, early-stage MDSCs (e-MDSCs). Elucidating their differentiation and expansion mechanisms is crucial for advancing cancer immunotherapy. This review examines the key signaling pathways (e.g., JAK/STAT, NF-κB, Notch), regulatory cytokines, metabolic factors, and epigenetic modifications central to MDSC biology. A comprehensive understanding of these intricate networks provides valuable insights into tumor immune evasion and facilitates the identification of novel therapeutic targets designed to overcome MDSC-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4682b63ca9757bb9c1ba2dada7a0f722d5dd5cac" target='_blank'>
              Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            Ke Wang, Xiao Wang, Nan Sun
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Type 2 innate lymphoid cells (ILC2s) are critical mediators of type 2 immunity that play non-redundant context-dependent modulatory functions. Primarily associated with responses against helminths and allergens via the activation of a potent epithelial-ILC2 axis, a growing body of evidence also suggests that a crosstalk between ILC2 and T cells is equally important in maintaining tissue homeostasis. In barrier tissues and secondary lymphoid organs, ILC2s co-localize with T cells, forming hubs where bi-directional signals are exchanged. Here, we describe the diversity of functional interactions between ILC2s and T cells, detailing known contact-dependent and -independent mechanisms, including a relatively new and still poorly defined antigen-presenting function during inflammation. Understanding these complex interactions is necessary to fully elucidate how this specific crosstalk helps maintain tissue homeostasis and regulate inflammatory responses. Identifying the spatial and temporal specificities of these interactions will certainly open new avenues for future targeting of this axis to improve immune-mediated host protection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9091d8a7d8543597d9b4583a6f2834ed1e2f0b" target='_blank'>
              Unspoken words: decoding the dialog between type 2 innate lymphoid cells and T cells
              </a>
            </td>
          <td>
            Zahra Jamila Ikra, Qiutong Huang, Huiyang Yu, Gabrielle T. Belz, Craig N. Jenne, Nicolas Jacquelot
          </td>
          <td>2025-10-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="


 Adoptive cell transfer-based immunotherapies have shown limited efficacy against most solid tumors. A key barrier to success is the immunosuppressive tumor microenvironment (TME). Beyond local effects, tumors induce systemic immune disturbances that further hinder anti-tumor immunity and promote disease progression. In this study, we investigate how tumor-driven systemic immunosuppression compromises the function of both endogenous and adoptively transferred natural killer (NK) cells, identifying potential strategies to enhance immunotherapeutic outcomes.



 We utilized syngeneic murine cancer models to systematically characterize alterations in immune cell populations within the circulation and spleen. Comprehensive and in-depth assessment of immune cell function, transcriptional activity, and metabolic state was performed using flow cytometry, Seahorse metabolic analysis, RNA sequencing, metabolic tracing, and ex vivo co-culture systems.



 In our PDAC mouse models, tumor burden elicited a robust systemic inflammatory response marked by expansion of myeloid lineage cells, particularly MDSCs, within the TME, peripheral blood, and spleen. Tumor growth led to reduced frequencies and functional deficits in both endogenous and adoptively transferred NK cells in circulation and spleen. Depletion of Gr-1+ MDSCs effectively restored NK cell effector functions. Mechanistic analyses demonstrated that MDSCs in tumor-bearing mice promote NK cell dysfunction through induction of lipid peroxidation. Notably, we observed pronounced upregulation of apolipoprotein E (ApoE)—a central lipid metabolism regulator—in MDSCs, which drove increased lipid oxidation and reactive oxygen species (ROS) production. Disruption of the ApoE-LDL receptor (LDLR) axis in MDSCs, achieved via genetic ablation, reprogrammed their metabolic activities and significantly reduced their immunosuppressive capacity toward both endogenous and transferred NK cells. Furthermore, pharmacological inhibition of lipid utilization rescued NK cell function and, when combined with NK cell adoptive transfer, produced synergistic anti-tumor effects in PDAC models.



 Our results emphasize the pivotal role of MDSC expansion in mediating systemic immunosuppression in tumor-bearing hosts. We identify the ApoE/LDLR axis as a promising therapeutic target to disrupt MDSC-driven immunosuppression, thereby enhancing the efficacy of NK cell–based immunotherapies. These findings underscore the importance of resolving systemic immune dysregulation in cancer patients to maximize the benefits of immunotherapy.



 Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He. Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B026.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7a0540abd909233af3d6405eb6004cd58b6e6586" target='_blank'>
              Abstract B026: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy
              </a>
            </td>
          <td>
            Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The complicated interplay between the central nervous system (CNS) and immune system is critical for both neuroprotection and neurodegeneration. T lymphocytes are key players in CNS immunity, with distinct subgroups that work in a highly dynamic and, sometimes, antagonistic manner depending on the disorder. This review covers T-cell subgroups with a focus on pathogenic Th1 and Th17 cells and their role in mediating neuronal death and demyelination in multiple sclerosis (MS) and stroke, as well as the neurotoxic nature of CD8+ cytotoxic T lymphocytes and the neuroprotective and immunosuppressive roles of regulatory T cells (Tregs) that promote CNS homeostasis. In answer to the overwhelming need for effective pharmacotherapy, we overview of available pharmacotherapies that have the potential to target the aforementioned T-cell subsets. Treatments ultimately include broad-spectrum immunosuppressants, highly specific monoclonal antibodies, and new small-molecule inhibitors. Clinical data are added whenever possible to assess how these therapies interact with T-cell activity to restore immune balance in the CNS. This review highlights the evolution of treatment progress and the growing paradigm shift towards precision medicine through the targeting of T-cell subsets in neuroinflammatory diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f1bfc0154223e061070a8b7a519f3cb3fb6bc934" target='_blank'>
              Beyond the blood–brain barrier: unraveling T cell subsets in CNS immunity and disease
              </a>
            </td>
          <td>
            Mustafa M. Shokr
          </td>
          <td>2025-09-24</td>
          <td>Inflammopharmacology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors show minimal activity in patients (pts) with epithelial ovarian cancer (EOC), in part due to an immunosuppressive tumor microenvironment (TME). We are currently investigating the safety and preliminary efficacy of an autologous intraperitoneal cytokine-induced memory-like NK cell therapy in pts with recurrent EOC (NCT06321484). We aimed to define NK cell dysregulation in EOC ascites to inform potential mechanisms of resistance to NK cell therapies in the TME.



 Ascites and matched peripheral blood (PB) were collected from 4 pts with advanced EOC. O-link target 48 was performed on paired ascites and serum from 3 pts; Luminex was performed on ascites from 4 additional EOC pts. 10x Single cell RNA sequencing (scRNAseq) was performed on cells isolated from paired ascites and PB from 3 pts; downstream analyses were conducted using Seurat, ggplot2 and EnrichR using Wilcoxon rank sum test for significance.



 Consistent with prior studies, ascites-derived NK (A-NK) cells exhibited reduced cytotoxic capacity compared with matched PB- derived NK (PB-NK) cells. PB-NK cells showed activation (IFN-g release) and degranulation (CD107a+) in response to cytokine stimulation and target cell exposure, respectively; however matched A-NK cells did not respond to target stimulation. Multiplex immunoassays performed to identify ascites factors contributing to NK cell dysfunction showed enrichment of multiple immunomodulatory secreted factors including CXCL10, IL-6, TGF-b, VEGF-A, CXCL9, CCL2, and CCL8. In line with the functional data, scRNAseq analysis revealed lower expression of cytotoxicity-related genes (PRF1, GZMB, GZMA, GNLY, NKG7) in A-NK compared to PB-NK cells (p<0.0001, n=3 paired samples). Additionally, A-NK showed significant enrichment in type I interferon (IFN) signaling (p≤0.0001), suggesting chronic overstimulation. Flow cytometry revealed elevated CD69 (p<0.05) and NKG2A on A-NK, hallmarks of chronic overstimulation. In a module score analysis using genes for glycolysis and oxidative phosphorylation (e.g. CAPN5, STC2, VEGFA, HK2, CTH, GNE, GLRX, VLDR and CYC1, GRPEL1, TIMM17A), A-NK showed significantly lower expression than PB-NK (p<0.0001). To address this immune dysfunction, we engineered an IL-12-secreting CAR-NK cells targeting mesothelin that maintain high cytotoxic activity in the presence of EOC ascites. Notably, IL-12 CAR NK cells highly express the genes within our metabolic modular score, suggesting increased metabolic fitness.



 Ascites-derived NK cells demonstrate marked immune and metabolic dysfunction, and we hypothesize that IL12-engineering may overcome ascites-induced dysfunction via metabolic reprogramming. Ongoing efforts are focused on RNA and ATAC sequencing analyses of ascites-exposed IL-12-secreting CAR NK to elucidate epigenetic changes that mediate their resistance to the TME.



 Grace C. Birch, Mubin Tarannum, Maily Nguyen, Khanlinh Dinh, Mila Stanojevic, Ursula A. Matulonis, Rizwan Romee, Rebecca L. Porter. Ascites-derived natural killer (NK) cells exhibit chronic overstimulation and metabolic dysfunction in patients with advanced epithelial ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr B062.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb6b7187b3a8993d43f3efb3c4cfbff661cd8daf" target='_blank'>
              Abstract B062: Ascites-derived natural killer (NK) cells exhibit chronic overstimulation and metabolic dysfunction in patients with advanced epithelial ovarian cancer
              </a>
            </td>
          <td>
            G. Birch, Mubin Tarannum, Maily Nguyen, K. Dinh, Mila Stanojevic, U. Matulonis, R. Romee, Rebecca L Porter
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Adoptive cell transfer-based immunotherapies have shown limited efficacy against most solid tumors. A key barrier to success is the immunosuppressive tumor microenvironment (TME). Beyond local effects, tumors induce systemic immune disturbances that further hinder anti-tumor immunity and promote disease progression. In this study, we investigate how tumor-driven systemic immunosuppression compromises the function of both endogenous and adoptively transferred natural killer (NK) cells, identifying potential strategies to enhance immunotherapeutic outcomes.



 We utilized syngeneic murine cancer models to systematically characterize alterations in immune cell populations within the circulation and spleen. Comprehensive and in-depth assessment of immune cell function, transcriptional activity, and metabolic state was performed using flow cytometry, Seahorse metabolic analysis, RNA sequencing, metabolic tracing, and ex vivo co-culture systems.



 In our PDAC mouse models, tumor burden elicited a robust systemic inflammatory response marked by expansion of myeloid lineage cells, particularly MDSCs, within the TME, peripheral blood, and spleen. Tumor growth led to reduced frequencies and functional deficits in both endogenous and adoptively transferred NK cells in circulation and spleen. Depletion of Gr-1+ MDSCs effectively restored NK cell effector functions. Mechanistic analyses demonstrated that MDSCs in tumor-bearing mice promote NK cell dysfunction through induction of lipid peroxidation. Notably, we observed pronounced upregulation of apolipoprotein E (ApoE)—a central lipid metabolism regulator—in MDSCs, which drove increased lipid oxidation and reactive oxygen species (ROS) production. Disruption of the ApoE-LDL receptor (LDLR) axis in MDSCs, achieved via genetic ablation, reprogrammed their metabolic activities and significantly reduced their immunosuppressive capacity toward both endogenous and transferred NK cells. Furthermore, pharmacological inhibition of lipid utilization rescued NK cell function and, when combined with NK cell adoptive transfer, produced synergistic anti-tumor effects in PDAC models.



 Our results emphasize the pivotal role of MDSC expansion in mediating systemic immunosuppression in tumor-bearing hosts. We identify the ApoE/LDLR axis as a promising therapeutic target to disrupt MDSC-driven immunosuppression, thereby enhancing the efficacy of NK cell–based immunotherapies. These findings underscore the importance of resolving systemic immune dysregulation in cancer patients to maximize the benefits of immunotherapy.



 Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He. Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-01.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45b7331df483f27859df652eb5ed860e47a52d18" target='_blank'>
              Abstract PR-01: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy
              </a>
            </td>
          <td>
            Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/38b3a5cd9720e830d3635ba4d8aafd19d2266c87" target='_blank'>
              SPP1+ Neutrophils Mediate Resistance to lmmune Checkpoint Blockade in BAP1-Inactivated Tumors.
              </a>
            </td>
          <td>
            Jiahao Shi, Shiyun Huang, Yixiong Zhou, Guopei Zheng, Zhe Zhang, Xianqun Fan, Jianfeng Shen
          </td>
          <td>2025-09-12</td>
          <td>Cancer research</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Chronic neuroinflammation and neurodegeneration are critical but unresolved drivers of disability accumulation in progressive multiple sclerosis (MS). Chronic active white matter lesions, identifiable radiologically as paramagnetic rim lesions (PRL), indicate progression-relevant chronic neuroinflammation. Using single-cell transcriptomics (scRNAseq) and T-cell receptor sequencing (scTCR-seq), we profiled cerebrospinal fluid (CSF) and blood immune cells of 34 radiologically characterized adults with MS (17 untreated, 6 treated with B-cell-depletion) and 5 healthy controls. Coupled with proteomics, we found PRL-associated enrichment of interferon (IFN) signaling and upregulation of TCR signaling in CSF and blood. This was accompanied by clonal expansion of CD8+ T effector memory (TEM) cells, with the highly expanded clonal cells exhibiting T helper type 1 (TH1)-like and cytotoxic profiles. Validating the cytotoxic immune profile in blood using flow cytometry, we identified a cellular correlate of PRL exhibiting features of CD8+ TEMRA cells. Despite chronic B-cell depletion, PRL-associated neuroinflammation, driven by myeloid activation and CD8+ T-cell cytotoxicity, persisted. Serum and CSF proteomic networks showed PRL-pertinent signatures, including networks unaffected by B-cell depletion. CSF:serum protein ratios revealed compartmentalized myeloid activation in cases with PRL. Using in silico perturbation, we nominated therapeutic targets, including MYD88, TNF, MYC, TYK2, JAK2, and BTK, for alleviating chronic neuroinflammation in MS. Our findings highlight mechanisms of chronic neuroinflammation in MS and point to potential biomarkers for monitoring disease progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1fa3caa3cc29a10980dc0ec5a031cd39c41d34cf" target='_blank'>
              Maintenance of chronic neuroinflammation in multiple sclerosis via interferon signaling and CD8 T-cell-mediated cytotoxicity
              </a>
            </td>
          <td>
            D. Reich, S. Raza, Yoshimi Enose-Akahata, Anna S Blazier, Lauren M. Guerra, E. Beck, M. Gaitán, Nyater Ngouth, Jefte M. Drijvers, E. Dammer, Devan Moodley, Kory Johnson, Martina Absinta, V. Ramaglia, J. Gommerman, Timothy J. Turner, Richard M. Ransohoff, Steven Jacobson, D. Ofengeim, Ellen Cahir-McFarland
          </td>
          <td>2025-09-25</td>
          <td>Research Square</td>
          <td>0</td>
          <td>50</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a9e7ede42ec807daf3ed73c2764d1a68e5042cc8" target='_blank'>
              Sialoglycans on human T cells attenuate death programs executed through the Fas pathway
              </a>
            </td>
          <td>
            Vanessa Affe, Qianmeng Lei, Tim S. Veth, Emmajay Sutherland, Hani Choksi, Fauzia N. Izzati, Qingyu Shi, Haissi Cui, N. Riley, Landon J. Edgar
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="Among white blood cells (WBCs), neutrophils are the most abundant and multifunctional immune cells in the blood, which are also involved in diverse physiological and pathological processes, particularly affecting the deterioration of the tumor. Neutrophil extracellular traps (NETs), composed of chromatin DNA studded with granule proteins, play a crucial role in reactive sterile inflammation. Recently, neutrophils have garnered focus in cancer research due to their participation in cancer initiation, proliferation and metastasis. As important players in the tumor microenvironment (TME), tumor-associated neutrophils (TANs) are viewed as “a double-edged sword” in cancer pathophysiology.In this review, we introduce the NETs formation and associated signaling pathways. Meanwhile, recent studies on the mechanisms through by which neutrophils could promote tumors development will be described. Additionally, we outline the complex complicated molecular mechanisms underlying cancer therapy resistances and associated preface tumor treatment. Finally, we highlight latest advances in NETs-targeting treatment strategies designed to improve the efficacy of cancer therapies. The oncogenic effect of neutrophils is included. The formation of NETs promotes tumor initiation, metastasis and the therapy resistance of cancer conventional drugs. Almost all signaling pathways associated with NETs have been summarized in tumor progression and metastasis. We comprehensively discussed the important role of neutrophils in the development of cancer and proposed the strategy of reducing NETs formation in the future treatment of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efe8918cec0a80e34562dafad728e61b8804c7f1" target='_blank'>
              Neutrophils and neutrophil extracellular traps: double-edged swords in cancer pathophysiology and therapy resistance
              </a>
            </td>
          <td>
            Yao Shen, Huijie Fang, Huiqi Xie, Siqi Zhu, Xiaoqi Wang, Shuang Liu, Jiayu Sui, Yage Xu, Yunfei Bo, Junjie Zhao, Jiaqi Jin, Jingwen Du, Peng Huang
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/670883db43566497565d37fb3fd302bbe45873a6" target='_blank'>
              αGalCer/CD1d treatment induces pro-inflammatory iNKT1-associated immune responses without aggravating doxorubicin-induced cardiotoxicity
              </a>
            </td>
          <td>
            Sarojini Singh, R. H. Nanjundappa, H. Kolla, Deepak S. Chauhan, Aahana Palyada, Prasanna Krishnamurthy, C. S. Umeshappa
          </td>
          <td>2025-09-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="


 Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are major negative regulators of anti-tumor immunity. Identifying tumor secreting factors and signaling pathways that enhance their pro-tumorigenic activity could lead to new strategies to enhance immunotherapy efficacy. We have identified tumor-secreted epidermal growth factor-like 6 (EGFL6) as a new mediator of tumor immune suppression. In-vitro and ex-vivo analyses indicated that EGFL6 binds beta integrins to activate spleen tyrosine kinase (SYK) signaling, functioning as (i) a chemotactic factor for myeloid cell migration and (ii) a driver of their differentiation into immunosuppressive phenotypes. In syngeneic mouse models of ovarian cancer, EGFL6 expression promoted intra-tumoral accumulation of MDSCs and TAMs with high SYK, CXCL2, and IL-10 expression. In an immune ‘hot’ tumor model, EGFL6 completely abrogated the response to anti-PD-L1 therapy, whereas Egfl6 neutralization decreased the accumulation of tumor-infiltrating CD206+ TAMs and MDSCs and thereby restored the efficacy of a-PD-L1 therapy. Spatial transcriptomic datasets of human ovarian cancer tissues revealed strong correlation between tumor EGFL6 and myeloid cell SYK expression. Dual immunohistochemistry confirmed increased SYK+ macrophages in ovarian cancer compared to normal ovary. We therefore tested whether SYK inhibition could hinder EGFL6-induced signaling in myeloid cells and reprogram them from an immunosuppressive to an immunostimulatory phenotype. Treatment with the SYK inhibitor fostamatinib (R788) prolonged survival in Egfl6+/- ID8p53-/- tumor-bearing mice, reduced the number of intra-tumoral granulocytic MDSCs, and decreased VEGF, M-CSF, and CXCL5 levels in ascites. scRNA-seq revealed that SYK inhibition depleted specific CCL8+ TAM and CXCL2+ MDSC subsets, induced immunostimulatory myeloid cell populations, and reduced exhausted of TIGIT+CTL4+ CD8 T cells. These findings demonstrate that targeting the EGFL6-SYK axis, via EGFL6 blockade or SYK inhibition, can reprogram the ovarian tumor microenvironment to enhance anti-tumor immunity and restore responsiveness of “cold” tumors to immunotherapy.



 Sandra Cascio. Reprogramming tumor-associated myeloid cells to improve ovarian cancer therapies [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr IA014.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/435cc8383bb8db54f60eb41477b03e6ce3d7d946" target='_blank'>
              Abstract IA014: Reprogramming tumor-associated myeloid cells to improve ovarian cancer therapies
              </a>
            </td>
          <td>
            S. Cascio
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Introduction Airway epithelial cells function as the first physical barrier against pathogens and are key regulators of immune responses by producing a wide array of cytokines involved in both innate and adaptive immunity. Methods This review summarizes recent advances in our understanding of epithelial-derived cytokines in severe asthma (SA) pathogenesis and highlights promising therapeutic strategies. Results Epithelial-derived cytokines can be functionally classified into the following four main groups: alarmins [interleukin [IL]-25, IL-33, thymic stromal lymphopoietin [TSLP]], proinflammatory cytokines (IL-1, IL-6, tumor necrosis factor-α), chemokines (CCL2, CCL5), and antiviral cytokines [interferon (IFN)-α, IFN-β, IFN-λ]. Alarmins are rapidly released in response to epithelial injury and play a pivotal role in initiating immune responses by activating dendritic cells, type 2 innate lymphoid cells, and eosinophils. Proinflammatory cytokines intensify inflammation by promoting immune cell activation and cytokine cascades, while chemokines guide immune cells to sites of injury. Antiviral cytokines enhance epithelial defenses by inducing the expression of antiviral genes. In SA, epithelial-derived cytokines play a central role in initiating and sustaining type 2 (T2) inflammation by activating the IL-4, IL-5, and IL-13 axis, leading to increased eosinophils, elevated serum IgE, and heightened airway hyperresponsiveness. These cytokines are also implicated in non-T2 inflammation, particularly in refractory asthma phenotypes. Discussion Growing insights into epithelial cytokines and their complex signaling networks with the airway microenvironment have opened new avenues for developing targeted and personalized treatment in SA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8eb55c8560e23bf8affb96884a6f7229a13afcc2" target='_blank'>
              Epithelial-derived cytokines in the pathogenesis of severe asthma
              </a>
            </td>
          <td>
            D. Pham, Tae-Bum Kim
          </td>
          <td>2025-10-15</td>
          <td>Frontiers in Allergy</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Simple Summary Acute myeloid leukemia remains difficult to treat due to its high relapse rates after standard therapies. T-cell engagers are a promising new approach that redirects the body’s own T cells to attack leukemia cells by binding both T cells and specific markers to AML cells. Targets such as CD33, CD123, and others have been studied. Several TCE formats—including BiTEs and DARTs—are being developed to improve effectiveness and reduce side effects. However, no TCEs in AML have moved beyond early-stage (Phase I/II) clinical trials, mainly due to the lack of an optimal target in AML and safety concerns with immune-related side effects like cytokine release syndrome. This review explores the current progress, key targets, and challenges in developing TCEs for AML treatment. Abstract The treatment of acute myeloid leukemia (AML) remains challenging, largely due to high relapse rates following standard therapies. T-cell engagers (TCEs) offer a promising immunotherapeutic approach by redirecting T cells to recognize and kill AML cells. These therapeutic proteins bind CD3 to T cells and a tumor-associated antigen to AML cells, facilitating targeted immune activation. While CD33 and CD123 are the most commonly targeted AML antigens, others such as CD135, CD38, and CLEC12A/CLL-1 are being evaluated in preclinical and clinical studies. In parallel, various TCE formats—including BiTEs, DuoBodies, DARTs, and DARPin-based constructs—have been developed to optimize pharmacokinetics, stability, and immune engagement. Despite the growing number of TCEs entering clinical evaluation, none have advanced beyond early Phase (I/II) trials, primarily due to the lack of optimal target antigens and challenges in balancing antileukemic activity with the risks of immune-related toxicities such as cytokine release syndrome (CRS). This review aims to summarize the current landscape of TCE development in AML, highlighting key targets, formats, and challenges.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bac31cf0d00849ef822f10610d70f5922a428ae0" target='_blank'>
              T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges
              </a>
            </td>
          <td>
            Hunter Daws, Kate Gallinero, Amanda Singh, Sanela Bilic
          </td>
          <td>2025-10-01</td>
          <td>Cancers</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Objectives Dendritic cells (DCs) are pivotal antigen-presenting cells capable of bridging innate and adaptive immunity, making them promising candidates for cancer immunotherapy. While canine mature DCs (cmDCs) have been successfully generated from circulating mononuclear cells (CMCs) in healthy dogs, their derivation and immunomodulatory capacity in tumor-bearing dogs (TbDs) remain poorly characterized. Methods In this study, we evaluated the efficiency of cmDC generation from peripheral blood of both healthy donors (HDs) and TbDs and investigated their functional responses to Toll-like receptor (TLR) agonists and mRNA-based genetic modification. Results CD14+ monocytes were successfully isolated from peripheral blood using immunomagnetic sorting and differentiated into cmDCs using recombinant canine GM-CSF and IL-4. The differentiation efficiency was comparable between the two groups. In both cohorts, cmDCs upregulated key maturation markers (CD1a, CD80, CD83) and restored DLA class II expression in TbDs. Stimulation with LPS and R848 significantly increased CD80 and CD83 expression and triggered IL-12/p70 and IL-8 production, confirming the acquisition of a functional immunostimulatory phenotype. To assess their amenability to genetic engineering, cmDCs were transfected using DE-DOPE/mRNA lipoplexes. These lipoplexes exhibited favorable physicochemical properties and achieved robust mRNA delivery, resulting in 100% GFP-positive cells and >60% viability, outperforming electroporation in terms of cytocompatibility. Conclusions Our findings demonstrate that cmDCs derived from both HDs and TbDs are phenotypically and functionally competent and can be efficiently transfected using a non-viral mRNA delivery system. This strategy offers a viable platform for the development of personalized, DC-based cancer vaccines in canine patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/214b1855d713559c7344f3f9c1196e520714ee7a" target='_blank'>
              Toll-like receptor activation and gene delivery efficiency in canine dendritic cells: a model for comparative oncology
              </a>
            </td>
          <td>
            S. Capellero, R. De Maria, Lisa Adele Piras, L. Marconato, Lorenza Parisi, Eugenio Mazzone, C. Marchiò, E. Berrino, S. Bellomo, A. Sapino, G. P. Stola, Valeria Chiono, L. Nicoletti, Luca Aresu
          </td>
          <td>2025-10-03</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are a dominant immune component within the glioma microenvironment and are increasingly recognized as key contributors to therapeutic resistance, the major challenge in glioma management. Understanding their role is critical for developing novel therapies. This review synthesizes current knowledge on TAM-mediated chemoresistance in glioma. TAMs originate from bone marrow-derived monocytes and resident microglia, exhibiting significant heterogeneity and plasticity, particularly between pro-inflammatory (M1) and pro-tumorigenic (M2) phenotypes. M2-like TAMs drive resistance through multiple mechanisms: (1) Modulating drug metabolism/clearance (e.g., via CYP450 enzymes and P-glycoprotein); (2) Secreting protumor factors (TNF-α, ILs like IL-4/IL-6/IL-10, chemokines like CCL5/CCL22, growth factors like VEGF/EGF) that activate survival pathways, induce immunosuppression, promote angiogenesis, and enhance epithelial-mesenchymal transition (EMT); (3) Interacting with glioma stem cells (GSCs) to maintain stemness; (4) Facilitating microenvironmental adaptation (e.g., hypoxia/HIF-1α response); (5) Remodeling the extracellular matrix (ECM) via MMPs, increasing stiffness and impairing drug penetration. Targeting TAMs offers promising approaches to overcome resistance. Strategies include: (1) Reprogramming M2 to M1 phenotypes using agonists (TLR, STING, CD40) or inhibitors (STAT3/STAT6); (2) Metabolic modulation (targeting glycolysis, fatty acid oxidation, glutaminolysis); (3) Blocking recruitment axes (CCL2/CCR2, CSF-1/CSF-1R, CXCL12/CXCR4); (4) Depleting M2-TAMs (e.g., trabectedin, CAR-T cells, M2pep-drugs); (5) Enhancing phagocytosis (anti-SIRPα/CD47, anti-SIGLEC). TAMs are pivotal mediators of chemoresistance in glioma through diverse molecular and cellular mechanisms. Targeting TAM recruitment, polarization, function, or metabolism represents a promising therapeutic avenue. However, the complexity of the glioma microenvironment and blood-brain barrier necessitate combination strategies for clinical translation. Further research is needed to optimize specificity and overcome challenges like compensatory pathways and drug delivery.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af7b44f62f9ab81285800350b0fbea1b42e0f4e9" target='_blank'>
              Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma
              </a>
            </td>
          <td>
            Xuebo Liu, Qi Yu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, represent a pivotal approach in the treatment of multiple myeloma (MM). However, the complex immunosuppressive tumor microenvironment (TME) poses significant challenges to their efficacy. Among the immunosuppressive cells in the MM TME, granulocytic myeloid-derived suppressor cells (G-MDSCs) are predominant; however, their functions remain incompletely understood. In this study, a comprehensive analysis of G-MDSCs was conducted using single-cell transcriptomic data from 7 MM patients before and post CAR-T therapy. Given the limited sample size and inter-patient heterogeneity, the findings should be regarded as exploratory and hypothesis-generating. The pathological activation and immunosuppressive roles of G-MDSCs were suggested to be potentially linked to patient prognosis. Functional enrichment analysis revealed that G-MDSCs are key modulators of immune responses within the TME. GSEA analysis suggested that G-MDSCs may regulate immune responses via the IFN-α/γ signaling pathway. Furthermore, G-MDSCs may facilitate immune evasion of MM cells by promoting cell proliferation through the IGF1-IGF1R axis and inhibiting T cells and other immune cells via the SIRPA-CD47 pathway. A risk prediction model based on G-MDSC gene signatures was constructed using RNA-seq and survival data from 713 MM patients, demonstrating high prognostic accuracy (AUC = 0.94) and validated by Kaplan-Meier analysis. Additionally, PTGS1 was identified as a key marker associated with high-risk groups, suggesting its potential as a therapeutic adjunct target to improve CAR-T treatment outcomes. Further in vitro experiments demonstrated that G-MDSCs may exert immunosuppressive functions through PTGS1 expression. Taken together, this study provides preliminary insights into the role of G-MDSCs in the MM TME and highlights potential therapeutic strategies to enhance CAR-T therapy efficacy, while acknowledging that larger and more diverse cohorts are required to substantiate these observations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e8ff33894cad405d661ae879b8aae448cec342e" target='_blank'>
              Functional Role of Granulocytic Myeloid-Derived Suppressor Cells in CAR-T Therapy: Insights from Single-Cell RNA Sequencing in Multiple Myeloma.
              </a>
            </td>
          <td>
            Chao Zhang, Fang An
          </td>
          <td>2025-11-06</td>
          <td>Immunopharmacology and immunotoxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Simple Summary Chimeric Antigen Receptor (CAR)-T cell therapy has shown significant success in treating hematological cancers, but commercialized autologous CAR-T therapies face challenges such as high costs, manufacturing delays, complex standardization and the risk of tumor relapses due to single-antigen targeting. To address these issues, a novel allogeneic CAR-T therapy with broader target specificity was developed, optimizing its manufacturing process. Using CRISPR/Cas9, TCR and HLA class I complex expression were eliminated from donor T cells to reduce the risk of immune rejection and graft-versus-host disease. Additionally, NKG2D CAR, targeting eight ligands upregulated in both solid and hematological tumors, was lentivirally transduced. This study optimized CAR-T cell manufacture by testing various interleukin supplements (IL-2, IL-7/IL-15, IL-7/IL-15/IL-21). Results showed that IL-7/IL-15/IL-21 supplementation produced CAR-T cells with the most suitable characteristics in terms of genetic modification efficiency, cell proliferation, antitumor activity and memory profile. This new allogeneic NKG2D CAR-T therapy represents a promising universal treatment for a variety of cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8e4e75f43da33ddda8e85ac431c369c654f5ec0" target='_blank'>
              A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors
              </a>
            </td>
          <td>
            C. Aparicio, Mónica Queipo, Marina Belver, Francisco Espeso, Julia Serna-Pérez, Lucía Enríquez-Rodríguez, Carlos Acebal, Álvaro Martín-Muñoz, A. Valeri, A. Leivas, Paula Río, Daniel J. Powell, Rosa Lobo-Valentín, David Arrabal, Joaquín Martínez-López, Ana Sánchez, Miguel Á. de la Fuente, Margarita González-Vallinas
          </td>
          <td>2025-09-30</td>
          <td>Cancers</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ea81bcddaf13d081e97df3be63dd2c84368f07c4" target='_blank'>
              mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow.
              </a>
            </td>
          <td>
            Taylor Fulton-Ward, N. Gudgeon, Isaac Thirlwell, E. Bishop, Bryan Marzullo, Hannah Giles, Graham McIlroy, Paul Ferguson, B. Kishore, Kate Rogers, Nuri Nuri Alfasi, Timothy Wong, Satnam Aytain, Daniel A. Tennant, G. Pratt, Sarah Dimeloe
          </td>
          <td>2025-09-12</td>
          <td>Blood advances</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Abstract Background Dual immune checkpoint blockade (IO/IO) has significantly improved overall survival in renal cell carcinoma (RCC), but only ∼50% of patients initially respond to treatment. Understanding the mechanisms underlying primary response and resistance is critical to improving therapeutic outcomes. Methods We developed a novel mouse model of sarcomatoid RCC (sRCC) by targeting Vhl, Bap1, and Cdkn2a/b, recapitulating the genomic and histological features and tumor microenvironment of human sRCC. Mice were treated with anti-CTLA-4 antibody. Tumor-infiltrating immune populations were analyzed using single-cell RNA sequencing and flow cytometry to evaluate T cell subsets and cytotoxic function. Results Anti-CTLA-4 treatment led to Treg depletion and an increase in activated Th1 cells. Importantly, only responder mice exhibited a selective expansion of TCF1+ CD4+ T cells. This was accompanied by increased granzyme B and perforin expression in effector CD8+ T cells, indicating enhanced cytotoxic activity. In contrast, non-responder mice lacked this TCF1+ CD4+ population and associated cytotoxic CD8+ responses. Conclusions Our findings reveal that Treg-depleting anti-CTLA-4 therapy promotes anti-tumor immunity by expanding a TCF1+ CD4+ T cell population that orchestrates CD8+ T cell responses. This mechanism offers a novel insight into immune modulation in sRCC and identifies a potential target to improve immunotherapy efficacy in RCC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3aa635a80718bf4810ef5e37204ff599497c31dc" target='_blank'>
              47TCF1+ CD4+ T cells mediate response to anti-CTLA-4 therapy in a sarcomatoid RCC mouse model
              </a>
            </td>
          <td>
            Hui Jiang, Lynda Vuong, F. Kuo, Doris Zheng, Alex Penson, Jing Zhang, Shengyu Gao, Ankur Mascareno, Yingbei Chen, Yash S. Khandwala, Daniel Barbakoff, Andrea Lopez Sanmiguel, G. Luca Gusella, Ming Li, A. Hakimi
          </td>
          <td>2025-10-01</td>
          <td>The Oncologist</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Solid tumors often suppress antitumor immune responses by promoting various dysfunctional CD8+ T cell states, which limit the effectiveness of T-cell-based immunotherapy. However, the mechanisms that promote these states have not been fully characterized. It is demonstrated that spontaneous priming responses during tumor growth can produce memory T cell reservoirs that are conducive to poor proliferative responsiveness during boosting vaccination. Surprisingly, when type I interferon (IFN-I) signaling is impeded, boosting vaccination can elicit robust proliferative responses from tumor-primed memory T cells and promote tumor control. This is observed in multiple tumor types and target antigens. In contrast to conventional memory T cells, tumor-primed memory T cells are unique in their pre-encoded responsiveness to IFN-I and show enrichment of pathways pertaining to DNA repair and cell cycle arrest. Tumor-primed memory T cells up-regulate p21 expression and blockade of either p21 or IFN-I can alleviate this effect to improve their proliferative capacity during boosting vaccination. Characterization of tumor-primed memory T cells revealed transcriptional and phenotypic features of cellular senescence, where higher senescence severity correlated with higher responsiveness to IFNα/β receptor blockade. Overall, IFN-I hyperresponsiveness may be a unique feature of senescent tumor-primed memory T cells that can exacerbate their dysfunction during cancer vaccination.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb2455df0fef81e7cabdf5fd3952e0ae44f71bd" target='_blank'>
              Pre-Encoded IFN-I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors.
              </a>
            </td>
          <td>
            Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan
          </td>
          <td>2025-10-05</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Despite recent advances in triple-negative breast cancer (TNBC) biology and new therapies, this aggressive subtype remains difficult to treat. A key obstacle is the immunosuppressive tumor microenvironment (TME), often dominated by myeloid cells that impair anti-tumor immunity. Radiation therapy (RT), used as an in-situ vaccine, enhances tumor immunogenicity and has shown promise when combined with immune checkpoint blockade (ICB) in preclinical and clinical settings1-3. We previously found that combining RT with CTLA-4 blockade and a CD40 agonist antibody (CD40a), which activates myeloid cells, led to profound tumor regression and occasional complete responses in a rapidly metastasizing TNBC mouse model4. However, CD40a did not improve control of lung metastases beyond that achieved with RT and CTLA-4 blockade. In tumors, CD40a induced remodeling of dendritic cell and macrophage populations, along with enrichment in B cell–associated gene signatures. As CD40 signaling can promote either effector or regulatory B cell responses depending on context5, we hypothesized that triple therapy induces organ-specific B cell differentiation that may hinder systemic immune control. We first assessed systemic versus local effects of CD40a on B cells in naïve and tumor-bearing (4T1) mice. In both settings, CD40a expanded splenic B cells and increased MHC-II+ expression. In lungs, tumor implantation alone led to increased B cell infiltration, even without CD40a. However, these lung B cells showed reduced activation in untreated tumor-bearing mice, only partially restored by CD40a, suggesting a distinct, potentially immunosuppressive phenotype. To evaluate this in the context of RT + CTLA-4 blockade + CD40a, we analyzed B cells from lungs and tumors via multiparametric flow cytometry and observed that CD40a consistently shifted B cell profiles across compartments. Among B cells, we identified regulatory B cells (Breg) as expressing TIM1, CD138, CD5, CD39, and FasL. CD40a decreased Breg infiltration in tumors but significantly increased it in lungs. In both tissues, Breg marker expression correlated with tumor or lung burden. Given TIM1’s role in IL-10–producing Bregs—and its capacity to suppress T cells independently of IL-10—6-8 we tested a TIM1-blocking antibody in combination with RT + CTLA-4 blockade + CD40a. While TIM1 blockade did not enhance tumor control, it markedly reduced lung Bregs. Our data highlight organ-specific B cell responses following CD40a-based immunotherapy and suggest that lung-resident Bregs may limit systemic immune efficacy. Ongoing work focuses on defining mechanisms of Breg-mediated suppression and, in collaboration with bioengineers, on developing intra-tumoral delivery strategies to reduce systemic immunosuppressive effects of agents like CD40a. 1-PMID: 29180535 2-PMID: 33476307 3-PMID: 30397353 4-PMID: 37620372 5-PMID: 19265127 6-PMID: 25582854 7-PMID: 31511630 8-PMID: 31685302



 Maud Charpentier, David Sprott, Sandra Demaria. Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B007.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c36421ca4c9e00ab71754a147fca0a0213794c4" target='_blank'>
              Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy
              </a>
            </td>
          <td>
            M. Charpentier, David Sprott, Sandra Demaria
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Introduction and Aim Immunotherapies targeting tumor-associated macrophages (TAM) to improve antitumor immunity, are promising treatment strategies for many types of cancer. The signal-regulatory protein-α (Sirp-α)/CD47 axis is a key innate immune checkpoint target important in regulating phagocytosis in macrophages. We aimed to determine whether a Sirp-α monoclonal antibody (mAb) could prevent renal cell carcinoma (RCC) progression by acting on macrophages and modifying their phenotype. Methods We explored the gene expression signature of macrophages in the RCC microenvironment by analyzing transcriptome data of blood monocytes from patients with RCC vs healthy donors, and macrophages vs non-immune cells in RCC from public databases. We characterized the prevailing macrophage polarization phenotypes and the different ratios of Akt1 and Akt2 in RCC according to cell surface markers and expression profiles, prior to examining the effect of Sirp-α mAb on the M2 macrophage polarization in an in vitro co-culture model of RCC cells with macrophages. The co-culture model included human RCC cell lines and induced M2 macrophages, including a subset that had been transfected to overexpress phosphoinositide 3-kinase (PI3K). Results and Conclusion Treatment of RCC with Sirp-α mAb counteracted the enhanced migration and invasion of RCC as measured in wound healing and transwell assays and in vivo model. Collectively, our data showed that the different ratio of Akt1 and Akt2 of the PI3K/Akt pathway is involved in the RCC-induced M2 polarization of macrophages and that a new mechanism that the Sirp-α mAb inhibited M2 macrophage polarization by regulating components of the PI3K/Akt pathway. Elucidating the mechanism by which Sirp-α mAb inhibits the development of RCC allows us to provide a new theoretical basis for the study of the mAb in RCC immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4ca9b82ddc5e4792b0475ed0519f4c399be891e" target='_blank'>
              Sirp-α Antibody Inhibits Renal Cell Carcinoma Progression via Akt1/Akt2 Modulation in Tumor-Associated Macrophages
              </a>
            </td>
          <td>
            Junfeng Hao, Naiquan Liu, Xin Huang, Hanlei Zhou, Hanrong Li, Yizhou Zhang, Bing Yu, Ziqian Bi, Xinyuan Song, Shunan Li, Keyu Chen, Ning Li, Chao Zhu, Jiahe Wang
          </td>
          <td>2025-10-01</td>
          <td>Journal of Inflammation Research</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Age-related accumulation of somatic mutations in hematopoietic stem and progenitor cells (HSPCs), causing clonal hematopoiesis (CH), often precedes the development of hematologic malignancies. Chronic inflammation and aberrant cytokine expression that are common in aging, contribute to clonal expansion and genomic instability. Acute myeloid leukemia (AML) is an (epi)genetically and physiologically diverse malignancy, characterized by clonal proliferation and incomplete differentiation of HSPCs. The innate immune system, with pattern recognition receptors (PRRs), plays a pivotal role in maintaining hematopoietic homeostasis. Dysregulated signaling through PRRs disrupts hematopoiesis, fostering malignant cell proliferation. In addition, cytokines and interferons exert multifaceted effects on HSPCs, impacting their proliferation, differentiation, and survival. Therapeutic approaches targeting innate immune pathways, offer promising avenues for treating hematologic malignancies. Understanding the intricate crosstalk between innate immunity and hematopoiesis would provide insights into novel therapeutic strategies for combating hematologic malignancies, offering hope for improved patient outcomes and survival. In this review, we discuss about the malfunctioning innate immune-inflammatory axes in the context of abnormal hematopoiesis and the therapeutic approaches that are utilizing/targeting these pathways with efficacy. This review delves into the derangements of innate immune and inflammatory pathways implicated in the development of AML and myelodysplastic syndromes (MDS), shedding light on the therapeutic strategies targeting these pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde18cfb4c76b3db17292e304b00038b9b81709c" target='_blank'>
              Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies
              </a>
            </td>
          <td>
            Satyaki Bhowmik, A. Bose, A. Sengupta
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="The immunosuppressive tumor microenvironment (TME) remains a major barrier to effective immunotherapy in gastric cancer (GC). Here, we identified the E3 ubiquitin ligase BFAR as a critical regulator of neutrophil-mediated immune evasion through the S100A8/A9-BFAR-PRP19-YBX1 signaling axis. Multi-omics analyses revealed that BFAR is overexpressed in GC and correlates with poor prognosis. Functional studies demonstrated that BFAR knockdown suppressed tumor growth by reducing neutrophil infiltration and immunosuppressive reprogramming to restore CD8+ T cell function. Mechanistically, BFAR mediated K48-linked ubiquitination and degradation of PRP19, leading to stabilization of the oncoprotein YBX1, which transcriptionally upregulated neutrophil-recruiting chemokines CXCL1/CXCL3. Infiltrating neutrophils secreted S100A8/A9, which activated NF-κB to induce BFAR expression in tumor cells and created a feedforward loop that sustains an immunosuppressive TME. Furthermore, BFAR promoted neutrophil PD-L1 expression via GM-CSF, reinforcing T cell exhaustion. Clinically, BFAR expression correlated with neutrophil infiltration and poor response to anti-PD-1 therapy, while its inhibition synergizes with immune checkpoint blockade in preclinical models. Our work unveils BFAR as a central orchestrator of neutrophil-driven immunosuppression and proposes targeting this axis to enhance immunotherapy efficacy in GC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4b75e42e82094deca19a7308d335b7f0d55be42d" target='_blank'>
              BFAR promotes neutrophil infiltration and immunosuppressive reprogramming through the PRP19-YBX1 axis to induce immune evasion in gastric cancer.
              </a>
            </td>
          <td>
            Xin Ma, Yumei Liu, Yingying Chen, Juan Wang, Feiyue Zhang, Wei Liang, Pengbo Zhang, Yunlan Zhou, Bei Miao, Sujuan Fei, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Li Li, Jiajia Wang
          </td>
          <td>2025-09-18</td>
          <td>Cancer immunology research</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 Ovarian cancer remains the most lethal gynecologic malignancy and a leading cause of cancer-related deaths among women. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has shown success in melanoma and correlates with survival in ovarian cancer. However, its application remains limited, partly due to inefficient expansion of functional, tumor-specific T cells.



 We developed a novel ex vivo expansion platform for ovarian TILs, integrating metabolic and phenotypic reprogramming with selective enrichment for tumor-reactive populations. Tissue from nine patients with stage III/IV high-grade epithelial ovarian carcinoma was collected for banking, NGS, and TIL expansion. Four had matched TILs expanded pre- and post-neoadjuvant chemotherapy. The initial priming phase employed our published cytokine cocktail designed to induce Th1/17 and Th17/Tc17 polarization, to promote effector differentiation while preserving stemness. TILs were cultured for five days in this cocktail to enhance metabolic fitness and anti-tumor potential. CD137+ (4-1BB+) T cells were isolated based on activation-induced co-stimulatory expression and subjected to rapid expansion using a G-Rex-based bioreactor system with irradiated feeder cells, anti-CD3, and low-dose IL-2. Expanded TILs were characterized by multicolor flow cytometry, CD107a degranulation, IFN-γ ELISA, and single-cell RNA sequencing (scRNA-seq), and benchmarked against TILs expanded using the conventional protocol from NCI.



 Our approach reliably produced 15–20 billion viable TILs per patient within 30 days, achieving >95% viability and ∼2500-fold expansion. CD137+ enrichment enhanced tumor reactivity, as shown by increased IFN-γ secretion and degranulation with autologous tumor and high-grade serous ovarian cancer cell lines. scRNA-seq revealed enriched cytotoxic CD8+ T cells and mucosal-associated invariant T (MAIT) cells, with reduced FOXP3+ regulatory and non-cytotoxic CD4+ subsets, compared to TILs from matched blood, tumor, and those expanded with high-dose IL-2 in the NCI protocol. CD8+ proliferative and cytotoxic T cell subsets were enriched under the hybrid CD137-sorted protocol. Transcriptomic profiling showed that CD8+ proliferating T cells from the hybrid group downregulated key metabolic genes, including SLC7A5 and LDHB, suggesting a rewired metabolic state that may support persistence. Similarly, CD8+ cytotoxic T cells showed chromatin remodeling, with upregulation of histone demethylases KDM5A and KDM7A, and downregulation of CHD7 and JARID2, indicating transcriptional plasticity. MAIT cells also showed increased activation markers (IFNG, CCL20). Expanded TILs exhibited reduced expression of exhaustion markers PD-1 and CD38 at the protein level.



 Metabolic reprogramming combined with CD137-based enrichment enables robust expansion of metabolically reprogrammed, tumor-specific TILs from ovarian tumors. This strategy offers a promising foundation for advancing TIL-based ACT in ovarian cancer.



 Paramita Chakraborty, Stephanie Mills, Jadan Zavestoski, Satyajit Das, Suganya Subramanian, Nicolina Mascia, Jian Liu, Stefano Berto, Brian Orr, Shikhar Mehrotra, Stephanie Mills. Metabolic reprogramming of ovarian CD137+ TILs for treatment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr PR006.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2b37662ad71037e3dead97ad855c982dd8d046b2" target='_blank'>
              Abstract PR006: Metabolic reprogramming of ovarian CD137+ TILs for treatment
              </a>
            </td>
          <td>
            Paramita Chakraborty, Stephanie Mills, Jadan Zavestoski, Satyajit Das, S. Subramanian, Nicolina Mascia, Jian Liu, S. Berto, Brian Orr, Shikhar Mehrotra
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Although chimeric antigen receptor (CAR)-T cells have demonstrated remarkable efficacy against hematologic malignancies, their effectiveness in solid tumors is limited by poor tumor infiltration and severe cytokine release syndrome (CRS). CAR-macrophage (CAR-M) therapy has emerged as a promising alternative, leveraging the innate tumor-homing capacity of macrophages while enabling antigen-specific phagocytosis and immune activation without triggering CRS. Prostate-specific membrane antigen (PSMA) represents an ideal therapeutic target due to its high expression in prostate cancer cells. In this study, we engineered PSMA-specific CAR-M with potent anti-tumor activity against prostate cancer cells both in vitro and in vivo. PSMA-specific CAR-M exhibited strong antigen-dependent phagocytic capability and underwent polarization toward a pro-inflammatory, tumoricidal phenotype upon PSMA recognition. Mechanistically, interaction with PSMA-expressing prostate cancer cells induced metabolic reprogramming, characterized by enhanced glycolytic activity and suppressed oxidative phosphorylation, which reinforced the anti-tumor function of CAR-M. Our findings highlight PSMA-targeted CAR-M therapy as a promising immunotherapeutic approach for prostate cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b18be8ba7a38c7fcc049e00187fed5999372458" target='_blank'>
              PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy
              </a>
            </td>
          <td>
            Yangli Xu, Duoli Xie, Chunhao Cao, Zhuqian Wang, Yue Ju, Lili Guan, Xuelong Li, Shanshan Wu, Luo Zhang, Chao Liang, Xiushan Yin
          </td>
          <td>2025-10-29</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Cryptococcal meningitis is a fungal infection in patients with compromised CD4 T cell function. CD4 T cells provide killing signals to macrophages, principally IFNγ, to limit intracellular fungal replication. However, CD4 T cells may also drive inflammatory tissue damage. Yet, it is not fully understood how fungal-specific CD4 T cells infiltrate the brain and how they influence functional phenotypes of CNS-resident myeloid cells. In the current work, we develop a mouse model to track fungal-specific CD4 T cells and determine their influence on microglia. We found IFNγ+ fungal-specific CD4 T cells have limited TCR signalling and characterise a population of inflammatory microglia that upregulate MHCII and IFNγ-regulated genes during infection. Inflammatory microglia have poor fungicidal capacity and significantly expand during infection, a process that depends on CD4 T cell infiltration. Taken together, these data identify the early inflammatory consequences of fungal-specific CD4 T cell infiltration and identify proliferating microglia as important drivers of brain inflammation during infection. Cryptococcal meningitis is a common infection in patients with compromised CD4 T cell function. Using a CD4 T cell activation tracking mouse the authors show the localisation and activation of CD4 T cells in the brain after cryptococcus infection and how these cells interact with MHCII expressing microglia which may increase pathologic brain inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37f4633c141c3226368499b170bc53f8df43b779" target='_blank'>
              Brain-infiltrating CD4 T cells drive inflammatory microglia proliferation during cryptococcal meningitis in mice
              </a>
            </td>
          <td>
            Sofia Hain, Man Shun Fu, Lucy Wigg, Lorna S. George, D. Lecky, Alexander J Whitehead, Erin Clipston, Ko Sato, Masahiro Ono, Marcel Wuthrich, Bruce Klein, Kazuyoshi Kawakami, J. Rayes, D. Bending, Rebecca A. Drummond
          </td>
          <td>2025-10-09</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Background Despite the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC), patient outcomes vary even among those with identical EGFR mutations. This study investigates whether osimertinib, a third-generation EGFR-TKI, activates the nucleotide-binding oligomerization domain-like receptor protein-3 (NLRP3) inflammasome in macrophages to drive antitumor immunity and explores its mechanistic basis. Methods Using bone marrow-derived macrophages from wild-type and gene-deficient mice, human peripheral blood mononuclear cells, and a Lewis lung cancer murine model, we assessed osimertinib-induced NLRP3 inflammasome activation, interleukin (IL)-1β secretion, pyroptosis, and tumor microenvironment (TME) remodeling. Mechanistic studies evaluated lysosomal dysfunction, calcium overload, mitochondrial damage, and reactive oxygen species (ROS) production. Clinical correlations were analyzed in patients with NSCLC treated with EGFR-TKIs. Results Osimertinib triggered NLRP3 inflammasome activation in macrophages via lysosomal dysfunction-induced calcium overload, leading to mitochondrial damage and ROS production, which acted as damage-associated molecular patterns to activate NLRP3. This process promoted IL-1β release, pyroptosis, and CD8+ T-cell activation while suppressing regulatory T cells in the TME. In murine models, osimertinib’s antitumor effects were abrogated by NLRP3 inhibition (MCC950) and enhanced by recombinant IL-1β (rIL-1β) co-administration (p<0.01). Clinically, high NLRP3 and IL-1β expression in tumor-associated macrophages (TAMs) correlated with prolonged progression-free survival (p<0.01) and overall survival (p<0.01) in EGFR-TKI-treated patients with NSCLC. Conclusions Osimertinib exerts off-target immunomodulatory effects by activating the tumor-extrinsic NLRP3 inflammasome, linking mitochondrial-lysosomal crosstalk to antitumor immunity. NLRP3 and IL-1β in TAMs emerge as predictive biomarkers for EGFR-TKI efficacy, while rIL-1β combination therapy represents a novel strategy to enhance clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/863e1cef18a3ff1f96b29c912ef92adbf59c3495" target='_blank'>
              Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity
              </a>
            </td>
          <td>
            Haiyang Yu, Xin Sun, Yan Li, Jing Pan, Xuemei Liu, Hongbin He, Haibo Wu, Yubei Sun, Yueyin Pan, Xiaojun Qian
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Immunotherapy remains ineffective in many solid tumors due to poor T-cell infiltration and a metabolically suppressive tumor microenvironment. A dual strategy combining low-level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T-cell lymphoma (EL4) model. NanoSTING@Mn, composed of ADU-S100 complexed with Mn2⁺ and encapsulated in biomimetic liposomes, potently activates the cGAS-STING pathway, induces a type I interferon response, and promotes lymphocyte infiltration. These monocytes polarize into M1 macrophages, suppressing regulatory T cells. Simultaneously, LLL photo-biomodulation reprograms mitochondrial metabolism in tumor-infiltrating CD8⁺ T and natural killer cells, restoring their durability and leading to complete local tumor eradication. This combination expands a distinct CD8⁺ T-cell subset with Tcf-1⁺ progenitor-exhausted features and elevated memory/effector gene expression, enhancing proliferation and cytotoxicity, as shown by single-cell RNA sequencing. Intranasal nanoSTING@Mn delivery mobilizes these LLL-revived T cells to the lung, where they differentiate into resident memory T cells and establish systemic antitumor immunity. Upon intravenous rechallenge, disseminated tumor cells are eliminated, preventing metastasis and ensuring long-term protection. This synergistic approach offers a scalable platform to boost immunotherapy efficacy and redefines immune-based metastasis prevention strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e9ba5699caa736e818a9807d89458c43c8a2b62" target='_blank'>
              Light Metabolically Reprograms CD8+ T Cells to Potentiate STING-Driven Tumor Eradication and Prevent Metastasis.
              </a>
            </td>
          <td>
            Asmita Banstola, Shilin Gao, ZhengKun Zhang, Yan Dong, Prabhat Upadhyay, Quanwei Zhang, Yongli Li, Zuan-Tao Lin, Zhilong Wang, Mei X. Wu
          </td>
          <td>2025-10-23</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="The efficacy of CD19 CAR-T cells in B-cell lymphoma patients is not as good as that in B-cell acute lymphoblastic leukemia (B-ALL) patients. This might be attributed to the intricate tumor microenvironment of B-cell lymphoma, which leads to CAR-T cell exhaustion, inability to sustain function, and difficulty infiltrating into the tumor interior. We developed CD19 CAR structures that simultaneously produce membrane-bound IL-15 (mbIL-15) and CXCR5. This design aims to enhance the migration of CAR-T cells into CXCL13+ B-cell lymphomas and their long-term antitumor ability. Compared with CD19 CAR-T cells, CD19 mbIL15-CXCR5 CAR-T cells exhibited greater cytotoxicity against CD19+ tumor cell lines in vitro. In particular, when exposed to recurrent tumor antigen stimulation, CD19 mbIL15-CXCR5 CAR-T cells still exerted long-lasting antitumor effects. CD19 mbIL15-CXCR5 CAR-T cells had a greater proportion of central memory T (TCM) and effector memory T (TEM) cells, which allowed them to exhibit more long-lasting antitumor effects. Moreover, in Transwell assays and mouse models, compared with CD19 CAR-T cells, CD19 mbIL15-CXCR5-CAR-T cells exhibited significant chemotaxis toward CXCL13+ tumor cells and superior tumor infiltration ability. The Xenogram animal model demonstrated better and more persistent tumor suppression ability than did the CD19 CAR-T cells. We preliminarily demonstrated the safety of CD19 mbIL15-CXCR5-CAR-T cells in vivo by evaluating liver and kidney function and major organ morphology in mice. In summary, the use of CD19 mbIL15-CXCR5-CAR-T cells is a relatively safe and effective option for the treatment of B-cell malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/984da11ad30bb4c6e74e1f03fcaa2f86bdf7da61" target='_blank'>
              A novel fourth generation of CAR-T cells: CD19 CAR-T cells engineered to express membrane-bound interleukin-15 and CXCR5 for the treatment of lymphoma
              </a>
            </td>
          <td>
            Xinping Cao, Jile Liu, Mohan Zhao, Shujing Guo, Meng Zhang, Xiaomei Zhang, Rui Sun, Yifan Zhao, R. Guo, Yi Zhang, Mingfeng Zhao
          </td>
          <td>2025-10-25</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Cytotoxic T lymphocytes eliminate infected or malignant cells, safeguarding surrounding tissues. Although experimental and systems-immunology studies have cataloged many molecular and cellular actors involved in an immune response, the design principles governing how the speed and magnitude of T-cell responses emerge from cellular decision-making remain elusive. Here, we recast a T-cell response as a feedback-controlled program, wherein the rates of activation, proliferation, differentiation and death are regulated through antigenic, pro- and anti-inflammatory cues. We demonstrate how the speed and magnitude of T-cell responses emerge from optimizing signal-feedback to protect against diverse infection settings. We recover an inherent trade-off: infection clearance at the cost of immunopathology. We show how this trade-off is encoded into the logic of T-cell responses by hierarchical sensitivity to different immune signals. This model explains experimentally observed patterns of T-cell effector expansion regulation in mice. Extending our model to immune-based T-cell therapies for cancer tumors, we identify a trade-off between the affinity for tumor antigens (“quality”) and the abundance (“quantity”) of infused T-cells necessary for effective treatment. Finally, we show how therapeutic efficacy can be improved by targeted genetic perturbations to T-cells. Our findings offer a unified control-logic for cytotoxic T-cell responses and point to specific regulatory programs that can be engineered for more robust T-cell therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/54671a6a3aa477ee5cd8f17387b609ce783798c9" target='_blank'>
              Design principles of the cytotoxic CD8+ T-cell response
              </a>
            </td>
          <td>
            Obinna A. Ukogu, Zachary Montague, Grégoire Altan-Bonnet, Armita Nourmohammad
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Plasma cells (PCs) possess the unique capacity to produce antibodies (Abs), effectors of the humoral response against virtually all microbes and toxins, but also against self-antigens, participating in the development of autoimmune diseases (ADs). In recent years, it has become evident that PCs contribute in more ways than just secreting Abs, as their cytokine production, such as IL-10+LAG3+ PCs or IL-35+ PCs, partial complement activation, or their interaction with other cells are critical for immune homeostasis. Thus, PCs represent a heterogeneous immune compartment composed of several subsets with different functions in immunity and immunoregulation. These findings suggest that certain characteristics, such as surface markers of disease-specific PC subsets, allow targeting pathogenic PCs with high selectivity in various ADs. Selective targeting of pathogenic PCs is a fundamental part of precision medicine in ADs such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Long-lived PCs (LLPCs) that produce high-affinity antibodies and reside in the bone marrow are essential for protection against infections but are also generated during autoimmune responses and resist current therapies. A unique subset of CD19-lacking PCs (CD19- PCs) was found enriched in human bone marrow, while almost absent from blood, tonsils, and spleen. New therapies targeting pathogenic PCs while sparing protective and regulatory ones represent an unmet medical need in ADs, replacing current depletion strategies based on antibodies against pan-PC markers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a36e52815b5b81d3027a208581b718dcebb2a4d" target='_blank'>
              Targeting Plasma Cells in Autoimmune Diseases
              </a>
            </td>
          <td>
            Andreia C. Lino
          </td>
          <td>2025-09-17</td>
          <td>Crossover Science</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e39635bfd474baba915275af7f24159951e53105" target='_blank'>
              Detailed splenic single-cell biodistribution of phosphatidylglycerol-containing liposomes
              </a>
            </td>
          <td>
            Deja Porenta, E. Lozano-Andrés, E. Mastrobattista, F. Broere, N. Benne
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus affecting 10–20 million people worldwide. While many carriers remain asymptomatic, HTLV-1 infection can trigger intense inflammatory responses which are defined by the sustained release of pro-inflammatory cytokines and chemokines. Central to this process is the HTLV-1 encoded Tax oncoprotein, a viral regulator that drives uncontrolled inflammation by hijacking multiple cellular signaling pathways, such as the RelA/NF-κB signal transduction pathway. CD4 T-cells are the primary targets of Tax-mediated transformation, undergoing uncontrolled proliferation and significantly contributing to chronic immune activation seen in HTLV-1-associated diseases. However, highly activated CD4 T-cells are not alone in fueling this inflammatory “wildfire.” Other immune cells, including CD8 T-cells, monocytes, macrophages, dendritic cells, and neutrophils, also play critical roles in exacerbating the inflammatory milieu. These cells, in conjunction with CD4 T-cells, release a barrage of pro-inflammatory cytokines (IL-1α/β, IL-2, IL-6, IL-12, IL-17, TNF-α/β, and IFN-γ) and chemokines (MCP-1, MIP-1α/β, RANTES, MCP-3, IL-8, CXCL9, CXCL10, and CXCL11), all of which are perpetuating the cycle of immune activation and tissue damage. This hyper stimulated immune response contributes to HTLV-1 replication/dissemination and can lead to the development of adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM-TSP). Despite existing treatments aimed at controlling viral replication, the persistent inflammation in HTLV-1-infected individuals even in asymptomatic carriers (ACs) remains a major challenge, suggesting that targeting these pro-inflammatory responses may be another mandatory therapeutic strategy. In this context, this short-review focuses on the key immune responses that drive HTLV-1-associated inflammation and explores how these high pro-inflammatory responses contribute to the development of HTLV-1-related complications, including HAM-TSP, ATLL, and other associated inflammatory diseases during chronic viral infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b1c88ff613a1a2b03ab924aca7e3e186aff7d68" target='_blank'>
              Sustained inflammation during human T-lymphotropic virus type 1 infection: a wildfire contributing to disease progression
              </a>
            </td>
          <td>
            Saina Shegefti, Mahsa Alaei, Nazanin Ghahari, Roman Telittchenko, Shahin Bolori Hanafi, S. Isnard, J. Routy, D. Olagnier, J. van Grevenynghe
          </td>
          <td>2025-09-12</td>
          <td>Frontiers in Medicine</td>
          <td>0</td>
          <td>74</td>
        </tr>

        <tr id="
 Introduction:
 Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate immune cells against tumor cells but can cause immune related adverse events such as myocarditis, a serious side effect with up to 40% case fatality rate. We hypothesize that cardiac fibroblasts and cytotoxic T-Cells work in tandem to direct inflammation in the setting of ICI treatment, resulting in myocarditis.


 Methods:
 To study the role of CFBs in ICIM, we first examined fibroblast behavior
 in vivo
 through picrosirius red staining for cardiac fibrosis. We then cultured C57BL/6 murine CFBs and treated them with cardiac serum acquired from a genetic mouse model of ICIM and analyzed
 Cxcl9
 expression by qPCR. Additionally, we stimulated CFBs with media or IFNγ for 24 hours (uCFBs and sCFBs respectively) before co-culturing them with CD8 CXCR3hi T-Cells for 6 hours, after which we analyzed
 Cxcl9
 and
 Cxcl10
 CFB expression by qPCR (Fig 1C) and T-Cell cytotoxicity by flow cytometry (Fig 1D/E). We next examined CD8 T-Cells harvested from C57BL/6 mice treated with combination immunotherapy to induce ICIM via single-cell sequencing to investigate potential axes of T-Cell/CFB crosstalk
 in vivo
 .


 Results:
 Our picrosirius red staining revealed a significant increase in cardiac interstitial and perivascular fibrosis, suggesting that CFBs are inflammatorily active and fibrotic in the context of ICIM (Fig 1A). We demonstrated that treating CFBs with ICIM cardiac serum results in a significant upregulation of CXCL9 by qPCR (Fig 1B). Utilizing our co-culture system, we demonstrated that the presence of CD8 CXCR3hi cytotoxic T-cells significantly increases CXCL9/10 expression compared to both control and IFNγ stimulation, underscoring the importance of T-cell presence in CFB activation (Fig 1C). We also used flow cytometry to confirm the cytotoxic quality of the T-Cells used in our co-culture system (Fig 1D/E). Using single-cell sequencing, we identified a cluster of CXCR3hiVLA4hi CD8 T-Cells from ICI-treated myocarditis mice (Fig 1F.) which are highly cytotoxic compared to other clusters (Fig 1G.), demonstrating that VLA-4:VCAM-1 signaling between T-cells and CFBs may act as a critical driver of cytotoxicity in the heart.


 Conclusions:
 Our findings position cardiac fibroblasts as potentially critical drivers of T-Cell migration and increased cytotoxicity in the context of ICIM, rendering this crosstalk an important direction of study in future of understanding and treating ICIM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f55ccb863bc3d94fa9ccdf7c648353cb039d3ca" target='_blank'>
              Abstract 4369397:
 Uncovering the Role of T-Cell and Fibroblast Crosstalk in Immunotherapy-Induced Myocarditis
              </a>
            </td>
          <td>
            Noah Wagner, Maria Rosaria Vitale, Yin Sun, Maria Zambrano, Abraham L. Bayer, Pilar Alcaide, Javid Moslehi, Han Zhu
          </td>
          <td>2025-11-04</td>
          <td>Circulation</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Immune dysregulation presents a significant clinical challenge due to its rapid progression and complex interplay between hyperinflammatory and immunosuppressive responses. Different responses from the innate and adaptive immune systems can result in diseases such as immunoparalysis, cytokine storms, and secondary infections. Current diagnostic methods remain non-specific and time-consuming, delaying targeted interventions. A compartmentalized approach to immune monitoring, distinguishing innate and acquired immune response functional differentiation, is essential for distinguishing between hyperactivation and suppression. Key biomarkers, including cytokines, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and CD4/CD8 counts, as well as Programmed Death Ligand-1 (PDL-1) and V-type immunoglobulin domain-containing suppressor of T cell activation (VISTA) regulators, can guide personalized treatment strategies. Although they need more clinical validation, novel therapeutic methods such as cytokine inhibitors, immunological stimulants, and immunomodulators have demonstrated promise. Early diagnosis and precision medicine developments could lead to better patient outcomes. Advances in non-coding RNAs have led to specific diagnostic panels based on microRNA (MiRNA) levels. A deeper understanding of immune imbalance in sepsis is critical for optimizing treatment and reducing mortality rates. This review highlights emerging diagnostic and therapeutic strategies to address the multifaceted nature of sepsis-related immune dysregulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/897b72fe16a73b092550ba6bda38d228d2fdd4b1" target='_blank'>
              Immune Dysregulation in Sepsis. A Narrative Review for the Clinicians
              </a>
            </td>
          <td>
            Asimina Valsamaki, Vassileios Vazgiourakis, Konstantinos Mantzarlis, E. Manoulakas, Demosthenes Makris
          </td>
          <td>2025-09-29</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93139cf5b3596da1c668725b5c5f4c783d1133ae" target='_blank'>
              Targeting human M2 macrophages with antibodies in optimized 3D tumor spheroids
              </a>
            </td>
          <td>
            Chloé Bazile, F. Gava, Flavien Raynal, Marcin Domagala, J. Bordenave, Laetitia Ligat, Manon Farcé, Corinne Bousquet, Vera Pancaldi, Véronique Gigoux, M. Poupot
          </td>
          <td>2025-09-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>33</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025'],
    y: [12],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>